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ABSTRACT 
Oxytocin has established roles in parturition and lactation, but can also be released 
in response to non-reproductive stimuli, such as hyperosmolarity and stress. As a majority of 
appetite regulating peptides activate the hypothalamo-pituitary-adrenal stress axis, and 
oxytocin is also a stress hormone in the rat, it was hypothesized that the oxytocin system in 
the neurohypophysial axis could be a target for appetite-regulating peptides of central and 
peripheral origin. The effects of  central administration of neuropeptide Y (NPY; a central 
orexigenic peptide and a central and peripheral neurotransmitter co-released with 
noradrenaline; n=5 rats) and systemic administration of secretin (a peripheral gut peptide 
belonging to the family of brain-gut peptides; n=26) and leptin (a peripheral anorexigenic 
peptide from adipose tissue; n=23) on the electrical a tivity of SON oxytocin neurones in 
vivo were studied in urethane-anaesthetized female rats with extracellular recording. Effects 
were compared with the excitatory responses to chole ystokinin (CCK; a peripheral 
anorexigenic gut peptide; n=45). Influences of fasting and pregnancy and effects of these 
peptides on the activity of SON vasopressin neurones w re also studied. Results: (1) All the 
central and peripheral appetite peptides tested increased the electrical activity of SON 
oxytocin neurones. (a) NPY: Basal firing rate of 3.5 ± 1.05 (mean ± s.e.m) spikes/s was 
increased by 1 ± 0.45 spikes/s 1min after NPY (basal vs 0-10min post-NPY: P=0.03, paired 
t-test; n=5). (b) Secretin: Basal rate of 4.1 ± 0.4 spikes/s was increased by 1.7 ± 0.2 spikes/s 
2.5min after secretin (basal vs 0-10min post-secretin: P<0.001, paired t-test; n=26). (c) 
Leptin: Basal rate of 3.4 ± 0.4 spikes/s was increased by 0.4 ± 0.08 spikes/s 1.5min after 
leptin (basal vs 0-10min post-leptin: P=0.01, paired t-test; n=23).  (d) CCK: Basal rate of 3.6 
± 0.3 spikes/s was increased by 1.1 ± 0.15 spikes/s 1min after CCK (basal vs 0-10min post-
CCK: P<0.001, Wilcoxon signed rank test; n=45). (2) Secretin induced excitatory responses 
were greater than to other peptides (P<0.001, Kruskal-Wallis one-way ANOVA on ranks). 
(3) Secretin dose-dependently increased SON oxytocin neurone electrical activity and 
peripheral oxytocin release in anaesthetized rats. (4) Intracerebroventricular infusion and 
microdialysis studies with benoxathian (α1 adrenergic antagonist) revealed that secretin-
induced excitation of SON oxytocin and vasopressin neurones involves central excitatory 
noradrenergic pathways. (5) Fasting for 18h did not alter the excitation of SON oxytocin 
neurones induced by secretin, CCK and leptin. (6) The pathway leading to excitation of 
oxytocin neurones by CCK was not influenced by prior leptin administration. (7) SON 
oxytocin neurones were responsive to leptin during late pregnancy. (8) NPY-induced 
excitation of oxytocin neurones was intact in anaesthetised late pregnant rats, contrasting 
with attenuated oxytocin secretory responses observed previously in conscious rats. (9) 
Systemic NPY excited SON oxytocin neurones. (10) Systemic CCK administration either 
inhibited (77%) or did not affect (23%) SON vasopressin neurones, while leptin had no 
significant effect, and responses to secretin were predominantly excitatory (67%). Systemic 
NPY inhibited vasopressin neurones, but central NPY was ineffective. Conclusion: Appetite 
peptides target SON oxytocin neurones. Postprandially released secretin and leptin might, 
like CCK, induce peripheral oxytocin release, so as to regulate water and electrolyte 
homeostasis, which is inevitably disturbed during feeding. Any central release of oxytocin 
induced by these peptides, might regulate feeding behaviour and satiety. Oxytocin neurone 
excitation induced by NPY may be relevant during stress responses. 
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Appetite control encompasses the regulation of food intake, energy balance, 
adiposity and body weight. In recent years it has become clear that a range of peptide 
hormones or neuropeptides (together termed ‘appetite peptides’), in the circulation or 
released in the brain, are essential elements of the systems controlling appetite. They act in 
or on complex neural networks in the brain. This thesis addresses the question of the possible 
roles of oxytocin in these networks by investigating responsiveness of oxytocin neurones to 
peptides that are well-established or putative appetite regulators. 
1.1. Current obesity crisis necessitates understanding appetite regulation 
Despite day-to-day fluctuations in the amount of food consumed, the body weight 
remains almost constant in adults. When the energy xpenditure equals energy intake, the 
body is in a state of energy balance. There are short-term and long-term signals regulating 
this balance. However, if these signals are altered and the energy balance is disturbed, in 
such a way that intake exceeds expenditure, it results in weight gain potentially leading to 
obesity, or expenditure exceeds the intake resulting in cachexia.  
The Association for the Study of Obesity1 proclaims that the number of obese people 
is rising rapidly throughout the world, making obesity one of the most rapidly developing 
public health problems. The World Health Organisation (WHO)2 describes the problem of 
obesity as a "worldwide epidemic". According to WHO, around 1 billion people worldwide 
are overweight3, of which 300 million are clinically obese. The prevalence of obesity has 
increased by 75% worldwide since 1980 (Flegal, 2005).  
The USA has a particularly high prevalence of obesity. On average, over one third of 
the adult population are obese, rising to more than 50% in some ethnic subgroups in the 
USA. Although the UK lags behind the USA, the rate of change is very similar to the USA 
(Source: Association for the Study of Obesity4). Almost 1 in 4 adults in England are 
currently obese. More than 12 million adults and one million children in England will be 
                                                
1 http://www.aso.org.uk/mlw/files/scale%20of%20the%20problem.pdf 
2 http://www.who.int/dietphysicalactivity/publications/facts/obesity/en/ 
3 The WHO defines "overweight" as a body mass index (BMI) equal to or more than 25 and 
"obesity" as a BMI equal to or more than 30. BMI is defined as the weight in kilograms 
divided by the square of the height in meters (kg/m2). 
4 http://www.aso.org.uk/mlw/files/scale%20of%20the%20problem.pdf 
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obese by 2010, according to the figures published by the Department of Health5. If it is 
carried on, by 2050, 9 in 10 adults will be overweight or obese.  
Overweight and obese people cost the UK economy £7 billion in treatment, reduced 
productivity, loss of earnings and benefits. By 2050, this figure could be almost half the 
NHS's current yearly budget - £50 billion – as per Diabetes UK6. The Department of Health7, 
UK, reports that the cost of overweight and obese indiv duals to the NHS is estimated to be 
£4.2 billion annually and this is forecast to more than double by 2050. The British Heart 
Foundation estimates that of the total 270,000 heart attacks each year caused by the coronary 
heart disease causes in the UK, 28,000 (10.37%) are directly attributable to obesity8.  
The International Obesity Task Force9 r ports an irony in developing countries: the 
struggle to reduce hunger in the face of opposing problem of obesity. According to the 
Diabetes Foundation of India10 (DFI), 30-50% people in the urban areas are overweight or 
obese in India. Currently, 38% of the urban population suffer from diabetes and it is 
expected to rise to 60% by 2025. 
The current obesity crisis indicates that there is a pressing need to understand the 
pathways that control energy homeostasis and to determine the potential to which they can 
be exploited in the treatment of obesity. Promoting and prolonging satiety is one of the 
potentially important tactics to tackle obesity. Henc , understanding the physiology behind 
satiety is imperative in developing treatment strategies for obesity. With the aim of exploring 
and emphasizing the involvement of oxytocin, a satiety peptide, in appetite regulation (Leng 
et al., 2008), this study focuses on the effects of ome of the appetite regulating peptides on 
the neurones in the supraoptic nucleus (SON) that synthesize oxytocin.  
1.2. Appetite regulating peptides and hypothalamic ontrol 
Food is an essential commodity for survival. The storage of energy in the form of 
adipose tissue is important especially for mammals to maintain constant body temperature. 
In small mammals, with the exception of hibernators, energy is not adequately retained and 
thus life is all about procuring and consuming food. Hence, feeding continues as a cyclical 
process with fall in energy level resulting in initation of hunger alternating with rise in 
energy levels and satiety after feeding. The interplay of appetite peptides in signaling the 
energy status to the brain in these processes is the forerunner of appetite regulation.   










The short term meal-related behaviour determines th long term effects such as body 
weight regulation: short-term control of meal size, meal frequency and the feeling of satiety 
after a meal are the important determinants of the long-term regulation of body weight. The 
appetite peptides can be separated into short- and long-term mediators. Short-term mediators 
are meal related signals that participate in a meal-to-meal control system [e.g. 
cholecystokinin (CCK)], whereas long-term mediators have a sustained inhibitory effect on 
food intake and govern body weight and energy metabolism (e.g. leptin). In addition, 
appetite regulating peptides can be of central [i.e. produced in the hypothalamus/brainstem; 
e.g. neuropeptide Y (NPY)] or peripheral (i.e. produced in the gut or adipose tissue; e.g. 
CCK, leptin) origin; they can be orexigenic (e.g. NPY) or anorexigenic (e.g. CCK and 
leptin).   
The signals from the appetite peptides are integratd in the brain, mainly in the 
hypothalamic nuclei, from where the information is relayed onto higher centres of the brain 
involved in feeding behaviour. Expression of appetite seems to have been chemically coded 
in the hypothalamus (Kalra et al., 1999). The hypothalamic nuclei directly involved in 
appetite regulation are the arcuate nucleus (ARC), lateral hypothalamic area (LHA), 
dorsomedial nucleus (DMN), ventromedial nucleus (VMN) and paraventricular nucleus 
(PVN) (Broberger, 2005). The LHA is the hunger centr  or feeding centre where as the 
VMN is the satiety centre (Stellar, 1954; Bray et al., 1990; Flier and Maratos-Flier, 1998). 
The feeding centre is chronically active and its stimulation can be transiently inhibited after 
ingestion of food, bringing about satiety (Konturek et al., 2004).  
1.3. Oxytocin and vasopressin in homeostasis 
Feeding and prandial drinking alter body fluid and electrolyte homeostasis. Hence, 
intrinsic mechanisms to maintain dynamic equilibrium are essential during feeding to avoid 
the consequences of altered homeostasis. The best examples for such intrinsic mechanisms 
for fluid homeostasis are the oxytocin and vasopressin ystems (Leng et al., 1988).  
The supraoptic nucleus (SON) and the PVN are the two main nuclei where these 
hormones are synthesized (Fig. 1.1a and 1.1b). The PVN includes smaller parvocellular 
neurones (pPVN), the axons of which are short and project to other nuclei within the brain or 
project to the median eminence and secrete releasing hormones [e.g. corticotropin releasing 
hormone (CRH), thyrotropin releasing hormone (TRF)], and larger magnocellular neurones 
(mPVN) with longer axons that terminate in the posterior pituitary and secrete oxytocin or 
vasopressin (Zimmerman et al., 1984). The SON is composed entirely of magnocellular 
neurones. Nearly all SON and mPVN neurones project to the posterior pituitary. They  
release either oxytocin or vasopressin into the circulation; however, most of these neurones 
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express mRNA for both peptides but in very different amounts (Xi et al., 1999). Peripheral 
oxytocin has been known to be involved in the regulation of reproduction, parturition, milk 
ejection, fluid homeostasis, pancreatic secretion, cardiovascular control, and stress (Murphy, 
1952; Chan and Sawyer, 1962; Nakano and Fisher, 1963; Fendler et al., 1964; Kaneto and 
Kosaka, 1970; Wakerley et al., 1973). The importance of central oxytocin in the control of 
reproductive and social behaviours, learning, memory, anxiety and stress was realised more 
recently (Engelmann et al., 2000; Heinrichs and Domes, 2008; Savaskan et al., 2008) (Fig. 1. 
2).  
1.4. Central oxytocin and appetite 
The importance of oxytocin in appetite regulation as  satiety peptide was 
recognised from the 1980s when Verbalis et al (1986a) found that ingestion of food and 
CCK administration elevated plasma oxytocin levels. This led them to suggest that satiety 
might involve activation of hypothalamic oxytocinergic pathways that control the inhibition 
of ingestion (Verbalis et al., 1986a). Later, interruption of a PVN-hindbrain oxytocinergic 
projection was found to induce hyperphagia (Kirchgessner et al., 1988). Subsequently, 
Arletti et al (1989) reported that oxytocin influences feeding behaviour in rats (Arletti et al., 
1989). Central administration of oxytocin dose-dependently reduced the food intake and the 
time spent eating, and increased the latency to the first meal in fasted rats (Arletti et al., 
1989). Central pretreatment with an oxytocin antagonist prevented the inhibitory effect of 
central oxytocin on feeding, and increased food intake (Arletti et al., 1989). The inhibition of 
feeding and drinking after central oxytocin administration was observed in both sexes to 
about the same degree (Benelli et al., 1991). Later, th  anorectic effect of central oxytocin 
was confirmed by more studies from Olson et al (Olson et al., 1991a, b, c) and Verbalis et al 
(Verbalis et al., 1993). Central oxytocin has been found to inhibit salt appetite 
complementing the peripheral natriuretic actions of oxytocin (Blackburn et al., 1992; 
Blackburn et al., 1993; Stricker and Verbalis, 1996). Endogenous glucagon like peptide-1 
(GLP-1) receptor signaling was suggested to be an important downstream mediator of 
central oxytocin induced anorexia in rats (Rinaman and Rothe, 2002).  
CCK, a peripheral anorectic peptide, was found to ac iv te oxytocin neurones in the 
SON and PVN (Hamamura et al., 1991). CCK-activated nucleus tractus solitarii (NTS) 
neurones were shown to send noradrenergic projections t  the SON oxytocin neurones 
(Onaka et al., 1995a) and also to receive oxytocin axon innervation from the PVN oxytocin 
neurones (Blevins et al., 2003), though these neuronal subpopulations in the NTS may be 
different. CCK was found to be less effective in inhibiting food intake in the presence of 
central oxytocin receptor antagonist suggesting the involvement of central oxytocin in CCK-
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induced satiety (Blevins et al., 2003). Recently, i was observed by Takashi Higuchi (2009) 
that bilateral ablation of SON abolished CCK-induced satiety (Takashi Higuchi, personal 
communication). However, CCK-induced reduction in food consumption was not affected in 
oxytocin-deficient mice (Mantella et al., 2003).  
Central administration of an oxytocin receptor antagonist attenuated the effect of 
leptin on food intake (Blevins et al., 2004). An anorectic dose of leptin administered into the 
third ventricle increased the number of pPVN oxytocin neurones that expressed Fos, a subset 
of which projected to the NTS (Blevins et al., 2004). Oxytocin receptor antagonism resulted 
in a significant decrease in the potentiating effect of leptin on CCK activation of NTS 
neuronal Fos expression (Blevins et al., 2004). Studies on female oxytocin deficient mice 
suggested that central oxytocin may be an important inhibitor of sodium consumption 
(Amico et al., 2003). Genetic absence of oxytocin in male and female mice enhanced their 
daily consumption of caloric and noncaloric sweet solutions (Amico et al., 2005; Billings et 
al., 2006; Sclafani et al., 2007). The pattern of cnsumption suggested that the absence of 
oxytocin increased sweet and not sweet carbohydrate intake by attenuating or abolishing 
postingestive satiety-related processes (Sclafani et al., 2007).  
SON oxytocin neurones are strongly activated during feeding (Johnstone et al., 
2006). Centrally released oxytocin seems to antagonise the actions of ghrelin, a peripheral 
appetite stimulating hormone, because the orexigenic response to ghrelin was elevated by 
pretreatment with an oxytocin receptor antagonist (Olszewski et al., 2007). During mid-
pregnancy, central oxytocin release is attenuated (Douglas et al., 1995), which may 
contribute to the hyperphagia that prevails during pregnancy (Douglas et al., 2007), even in 
the face of increased oxytocin receptor binding andmRNA expression in the hypothalamus 
(Young et al., 1997; Bealer et al., 2006).  
1.5. Source of central oxytocin  
Until recently, oxytocin from the pPVN was considered to be the source of brain 
oxytocin. However, most of the oxytocin in the brain is not in the nerve terminals but in the 
dendrites of mPVN and SON neurones. The dendrites typically comprise about 80% of the 
volume of a neurone. SON neurones have 1-3 dendrites projecting to the ventral surface of 
the brain forming a dense plexus (Armstrong, 1995). At the plexus, the concentration of 
oxytocin is 100-1000 fold higher than that in blood (i.e. more than 1-10nM). The half life of 
oxytocin released in the brain is approximately 20min by which time oxytocin effectively 
spreads to distant brain areas (Mens et al., 1983). Interestingly, axonal and dendritic peptide 
release of oxytocin can occur independent of each other (Sabatier et al., 2003b; Sabatier and 
Leng, 2006).  While an increase in the electrical ativity of oxytocin neurones corresponds to 
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the peripheral release of oxytocin, dendritic release of oxytocin may or may not accompany 
an increase in the electrical activity and Fos exprssion. For example, CCK increases Fos 
expression and electrical activity of oxytocin neurones accompanied by peripheral 
(Hamamura et al., 1991) as well as central oxytocin (Neumann et al., 1994) release, but 
central administration of α-melanocyte stimulating hormone (α-MSH), a central anorectic 
peptide, inhibits electrical activity and peripheral release while inducing dendritic release of 
oxytocin and Fos expression (Sabatier et al., 2003b; Sa atier et al., 2003a). 
1.6. SON and appetite: peptides/receptors/pathways 
Because of the anatomical location of the SON in close proximity with other nuclei 
involved in appetite regulation (Berthoud, 2002), the concept of central oxytocin release 
seems even more relevant in the regulation of appetite (Fig. 1.3). Moreover, oxytocin 
receptors are expressed in the central nervous system (CNS) areas that are involved in 
appetite regulation, feeding behaviour, learning and memory such as the hypothalamus, 
brainstem and the limbic regions (Gimpl and Fahrenholz, 2001). 
The SON is an outstanding model for the understanding of neuronal function 
because of its homogeneity, yet it expresses almost every gene that is expressed in the brain 
(Mutsuga et al., 2004). For example, with regard to appetite regulating peptides, SON 
neurones are immunoreactive for several of them, including CCK (Vanderhaeghen et al., 
1981; Meister et al., 1990), CRH (Lightman and Young, 1987), TRH (Meister et al., 1990), 
orexin (Backberg et al., 2002) and cocaine amphetamine regulated transcript (CART) (Elias 
et al., 2001), galanin (Gaymann and Martin, 1989; Meister et al., 1990), dynorphin 
(Lightman and Young, 1987; Meister et al., 1990), enkephalins (Meister et al., 1990) and 
neuropeptide FF (Boersma et al., 1993), though the p ysiological significance of these 
peptides in the SON is not known. In turn, SON neurones express receptors for several 
appetite peptides such as leptin (Hakansson et al., 1998), secretin (Chu et al., 2006a, b), CCK 
(Day et al., 1989), NPY (Wolak et al., 2003), melanocortin-4 receptor (MC4-R) (Mountjoy 
et al., 1994), orexin (Backberg et al., 2002), CRH (Luo et al., 1994) and PACAP (Nomura et 
al., 1996). Moreover, the SON receives projections from nuclei that are involved in appetite 
regulation such as the medial preoptic area (mPOA) (Wilkin et al., 1989; Oldfield et al., 
1994), DMN (Honda and Higuchi, 2007), LHA (Stanzani et al., 1984), parabrachial nucleus 
(Jhamandas et al., 1991) and NTS (Day, 1989; Onaka et al., 1995a; Shioda and Nakai, 1996).  
The projections from the NTS, ARC and LHA to the SON and are important because 
of the significant involvement of these nuclei in appetite regulation:  
NTS: The NTS receives direct inputs from the visceral sensory and taste receptors 
via vagal, glosso-pharyngeal, facial and trigeminal afferents (Contreras et al., 1982). The 
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vagal afferents are particularly important through which several peripheral appetite peptides 
such as CCK signal the brain (Monnikes et al., 1997) (Fig. 1.4). The NTS receives strong 
projections from the area postrema (AP) (Cunningham et al., 1994) that detects peripheral 
signals via its deficient blood-brain barrier (Faraci et al., 1989). The NTS possesses a 
significant population of POMC neurones besides the ARC and is one of the nuclei with the 
highest concentration of MC4-R (Mountjoy et al., 1994). Direct NTS injection of 
melanocortin receptor agonist reduces and antagonist increases food intake (Williams et al., 
2000). The NTS has direct reciprocal connections with other hypothalamic nuclei involved 
in food intake regulation such as the PVN and LHA (Kannan and Yamashita, 1985; Williams 
et al., 2001; Buller, 2003). There are no direct projections to the cerebral cortex but there are 
projections via thalamus, hypothalamus, amygdala and p rabrachial cortex (Berthoud, 2002). 
In addition, the cerebral cortex receives information from the NTS via brainstem arousal 
systems such as the LC and raphe nucleus (Berthoud, 2002).  
 ARC:  The ARC integrates hormonal signals for energy home stasis (Cone et al., 
2001). The ARC-median eminence (ME) area is one of the circum-ventricular organs (CVO) 
where the blood-brain barrier is deficient, allowing entry of blood-borne chemicals and 
hormones such as leptin (Schwartz et al., 1992; Friedman and Halaas, 1998). The ARC 
contains mainly two populations of neurones: NPY-agouti related peptide (AgRP) and 
POMC-CART neurones. AgRP is the endogenous antagonist for MC4-R (Rossi et al., 1998). 
NPY-AgRP neurones promote food intake and inhibit the anorexigenic effect of α-
melanocortin stimulating hormone (α-MSH) from POMC neurones via MC4-R antagonism 
by AgRP. A subpopulation of ARC-NPY neurones expresses leptin receptors (Ob-Rb) 
(Mercer et al., 1996). Leptin reduces NPY mRNA (Wang et al., 1997) and increases POMC 
mRNA level (Schwartz et al., 1997; Mizuno et al., 1998) in ARC neurones. One of the 
derivatives from POMC is α-MSH (Bjorbaek and Hollenberg, 2002), in response to which 
the dendrites of SON neurones release oxytocin (Sabatier et al., 2003b).  
 LHA:  The LHA contains two distinct neuronal populations containing either orexins 
(orexin A and B) or melanin concentrating hormone (MCH) both of which stimulate food 
intake upon central administration (Qu et al., 1996; Dube et al., 1999) and their mRNA 
levels are increased by fasting (Herve and Fellmann, 1997; Cai et al., 1999). Orexins are 
involved in the regulation of arousal as well (Kohlmeier et al., 2004). 
 VMN:  The neuronal populations of the VMN are affected by many appetite peptides 
such as leptin, ghrelin, orexin-A and CCK (King, 2006). If feeding accompanies central 
oxytocin release, the primary target could be the VMN (Sabatier et al., 2007), the satiety 
centre, because the VMN is one of the most prominent sites of oxytocin receptor expression 
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(Bale et al., 1995a, b). α-MSH-induced central oxytocin from the SON diffuses to the VMN 
(Nancy Sabatier, Personal communication) and the electrical activity of VMN neurones is 
altered in response to central oxytocin (Sabatier e al., 2007). It is not known whether VMN 
neurones project to the SON. 
 The finding that the SON receives direct and/or indirect projections from these 
centres that are directly involved in appetite contr l signifies the potential importance of the 
SON in appetite control too. 
1.7. Oxytocin, satiety and reward 
The termination of a meal and the feeling of satiety do not depend on the nutritive or 
calorific value of the food (Anderson and Woodend, 2003). It seems that it is the presence of 
food and associated cascade of taste, stretch and hormonal signals following the food intake 
that mediate satiety. Lacking the sense of contentm after food intake or satiety could be 
one of the important causes of obesity (Moran et al., 1998). Satiety associated with food 
intake is a natural reward11 (Kelley and Berridge, 2002) that is essential for sustaining 
procurement processes, which otherwise will be terminated without a reward. Oxytocin is 
one peptide that is implicated in satiety, feeding behaviour and reward (Marazziti and Catena 
Dell'osso, 2008). In addition, SON oxytocin neurones are activated by oropharyngeal 
stimulation (Naimi et al., 1997), gastric distensio and peripheral post-prandial signals such 
as CCK (Renaud et al., 1987), all of which contribute to satiety. 
1.8. Oxytocin lacks attention as an anorectic peptide  
Despite the accumulating evidence for the involvement of oxytocin neurones in 
regulation of food intake, the primary hypothalamic sources of oxytocin, such as the mPVN 
and SON, are not generally considered as important ce tres involved in appetite regulation 
(Kalra et al., 1999; Schwartz, 2001; Berthoud, 2002; Grill and Kaplan, 2002; Saper et al., 
2002; Appleyard, 2003; Luckman and Lawrence, 2003; Jobst et al., 2004; Leibowitz and 
Wortley, 2004; Williams et al., 2004; Arora and Anubh ti, 2006; Morton et al., 2006), 
except for passing reference to a role of the mPVN in appetite regulation (Kalra et al., 1999; 
Berthoud, 2002). Furthermore, except for the recent r views by Douglas et al and Leng et al 
(Douglas et al., 2007; Leng et al., 2008), oxytocin is ot given much attention as an anorectic 
signal (Kalra et al., 1999; Berthoud, 2002; Grill and Kaplan, 2002; Saper et al., 2002; 
Appleyard, 2003; Leibowitz and Wortley, 2004; Williams et al., 2004; Arora and Anubhuti, 
2006; Morton et al., 2006).  
                                                
11 Definition of a reward: the willingness to engage in otherwise unrelated behaviours that quickly 
extinguish in the absence of the reward [Saper CB, Chou TC, Elmquist JK (2002) The need to feed: 
homeostatic and hedonic control of eating. Neuron 36:199-211.]. 
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 Recently, the presence of oxytocin and oxytocin receptors have been established in 
the enteric nervous system (Welch et al., 2009) the functional significance of which is yet to 
be explored. It has been well established that oxytocin neurones are activated in response to 
gut peptides such as CCK, secreted after food intake (Hamamura et al., 1991). However, 
oxytocin is not generally considered as a neurohormone integral to the brain-gut axis (Havel, 
2001; Konturek et al., 2004; Arora and Anubhuti, 2006; Naslund and Hellstrom, 2007; Wren 
and Bloom, 2007). 
1.9. Role of peripheral oxytocin and vasopressin in osmoregulation 
 Osmotic stimuli activate SON and PVN oxytocin neurones and increases peripheral 
release of oxytocin (Brimble et al., 1978; Verbalis et al., 1986a; Russell et al., 1988). 
Oxytocin administration results in a dose-dependent increase in urine flow (diuresis) and Na+ 
and Cl- excretion (natriuresis) in conscious and anaesthetized rats (Balment et al., 1980; 
Conrad et al., 1986; Verbalis et al., 1991; Windle and Forsling, 1991; Forsling et al., 1994; 
Huang et al., 1995; Windle et al., 1997). SON neurones in the rats are osmosensitive (Mason, 
1980) and osmoreceptor activation is involved in the stimulation of oxytocin and vasopressin 
release following osmotic stimulation (Negoro et al., 1988; Bourque et al., 1994).  
Oxytocin mediates its natriuretic and diuretic effects either by direct or by indirect 
means: 1. Oxytocin acts on its receptors in the nitric oxide (NO)-ergic cells of macula densa 
and proximal tubules and activates renal NO synthase leading to generation of NO that 
increases cGMP (at higher doses, oxytocin increases the release of ANP that in turn also 
increases cGMP). cGMP mediates decreased tubular Na+ re bsorption by closing Na+ 
channels and thus results in natriuresis (Soares et al., 1999). Regulation of renal kallikrien-
kinin system by oxytocin could be another direct mode of action. Urinary kallikrien and 
kinin levels are also increased during oxytocin-induced diuresis. Diuretic and natriuretic 
actions of oxytocin were significantly attenuated by administration of kallikrien inhibitor 
(Adachi et al., 1995). 2. Indirectly through ANP: Blood volume expansion and baroreceptor 
activation causes the release of ANP from ANPergic neurones in the hypothalamus that in 
turn stimulates release of oxytocin from the posterior pituitary. Oxytocin acts on the heart to 
release ANP from the right atrium. ANP has negative chronotropic and ionotropic effects on 
the heart and thus reduces cardiac output, thereby ducing effective circulating blood 
volume and also it promotes natriuresis in the kidneys (Haanwinckel et al., 1995; Antunes-
Rodrigues et al., 1997; Favaretto et al., 1997; McCann et al., 1997).  
Vasopressin is antidiuretic but synergistic with oxyt cin in natriuresis (Gross and 
Anderson, 1982; Balment et al., 1984; Balment et al., 1986; Brimble et al., 1988; Windle et 
al., 1995). Vasopressin neurones are inhibited when peripheral baroreceptors are activated 
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(Jhamandas and Renaud, 1986, 1987) and vasopressin release is stimulated during 
haemorrhage to preserve effective blood volume through its antidiuretic and hypertensive 
effects (Fyhrquist et al., 1981).  
As the fluid homeostasis is altered during and after food intake and oxytocin is 
released postprandially to regulate this alteration, the changes in the electrical activity of 
oxytocin and vasopressin neurones in response to appetite peptides will reflect the 
physiological fluid homeostatic changes taking place round feeding. 
1.10. Advantages of in vivo electrophysiology 
The technique of in vivo electrophysiology was chosen because of its technical and 
physiological advantages such as the ability in (1) showing the real-time activity of 
neurones, (2) showing clear cut excitation or inhibition unlike Fos expression which is not 
confirmatory of either excitation or inhibition, (3) showing the duration of excitation or 
inhibition of neurones in real-time upon administration of a drug, unlike Fos expression 
which begins long after initiation of an activation signal and in (4) providing single cell 
resolution unlike other real-time imaging studies which lack resolution, (5) permitting all the 
synaptic inputs and contacts to stay intact  (apart from anaesthetic effects) in vivo unlike in 
vitro electrophysiological studies where the system lacks synaptic inputs (6) reflecting 
peripheral release of the peptide and finally (7) the preparation allows physiological 
(systemic route) methods of administration of drugs nlike in vitro studies where only direct 
application is possible which may not be physiological. 
1.11. Summary 
Though independent studies indicate that oxytocin does play a significant role in 
appetite regulation and fluid homeostasis during and fter food intake, recent reviews in the 
literature ignore the role of oxytocin in energy and water homeostasis. Hence, more studies 
with a focus on SON oxytocin neurones are required to emphasize the relationship between 
oxytocin and appetite control. Therefore, this study was planned to explore the responses of 
SON neurones to four different appetite peptides of central and peripheral origin involved in 
stimulating or inhibiting appetite or in the signalling between the gut and the brain (Fig. 1.5):  
1. Neuropeptide Y - central orexigenic peptide. 
2. Leptin - peripheral anorexigenic peptide from adipose tissue. 
3. Secretin - a brain-gut peptide.  
4. CCK - peripheral anorexigenic peptide from the gut.
Detailed background information is given in the introductions to the respective 
chapters, however, the main objectives are stated below. Although the focus is on the SON 
oxytocin neurones, the effects of appetite peptides on SON vasopressin neurones were also 
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recorded and reported. Also, changes in oxytocin neurone responsiveness were investigated 
in response to some of the appetite peptides in states of extreme differences in food intake, 
such as late pregnancy and fasting. 
Neuropeptide Y: Central administration of NPY, the most potent orexig nic 
peptide, was found to elevate plasma oxytocin levels (Parker and Crowley, 1993). However, 
the plasma oxytocin response to central NPY is attenuated during pregnancy (Brunton et al., 
2006a), similar to the attenuation seen in the respon es to various other stimuli (Russell et 
al., 2008). To study whether NPY alters the electrical activity of SON oxytocin neurones and 
to study whether the increase in electrical activity is attenuated during late pregnancy, 
responses of SON oxytocin neurone to NPY were studied in virgin and late pregnant rats. 
 Leptin: The effect of systemic leptin on the electrical activity of SON oxytocin 
neurones is not known. As pregnancy is an interesting model to study the effects of leptin 
[i.e. a model of hyperleptinemia together with leptin resistance, a model of physiological 
hyperphagia despite high leptin levels (Ladyman and Grattan, 2004), a model of attenuated 
oxytocin response to various stimuli (Russell et al., 2008) and a model of altered fluid 
homeostasis (Brunton et al., 2008)], the effects of ystemic administration of leptin on SON 
oxytocin neurones was also studied in late pregnant rats. As it is reasonable to assume that 
reduction in circulating leptin levels by fasting (Ladyman and Grattan, 2004) would increase 
the sensitivity to exogenous leptin administration, the effects of leptin were studied in fasted 
virgin and late pregnant animals as well. 
Secretin: Recently, secretin, a brain-gut peptide, has been fou d to induce Fos 
expression in the SON (Goulet et al., 2003). Central administration of secretin in vivo 
elevated plasma oxytocin level and direct application of secretin increased oxytocin release 
from hypothalamic explants in vitro (Takayanagi and Onaka, 2007). However, the doses 
used in these studies were supraphysiological (40µg systemically or up to 1-10µg centrally). 
Hence, the effects of more physiological doses of secretin (less than 1µg; i.v) on the 
electrical activity of SON neurones were investigated. The secretin induced effects on SON 
neurones were expected to be similar to CCK induced effects as these peptides are 
physiologically similar. In addition, the neurochemical pathway involved in the secretin 
mediated SON neuronal responses was explored. The plasma oxytocin changes upon 
systemic administration of secretin were also studied in urethane-anaesthetized virgin rats to 
correlate with the electrical activity of SON oxytocin neurones.  
Interactions: As leptin and CCK are synergistic in reducing food intake and body 
weight (Barrachina et al., 1997; Matson et al., 1997; Matson and Ritter, 1999; Matson et al., 
2002), interaction between leptin and CCK on the CCK-induced excitation of SON oxytocin 
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neurones was sought. Also, the effect of reduction in the endogenous level of leptin by 
fasting on the excitation of SON oxytocin neurones induced by CCK and secretin was also 
studied. In addition, as fasting is a stressor and oxytocin is a stress hormone (Lang et al., 
1983), the basal activity of oxytocin neurones would be expected to be higher in the fasted 
rat model. On the other hand, as fasting also reduces fluid intake (Apostolou et al., 1976; 
Maejima and Nagase, 1991; Burlet et al., 1992; Youn and Buchanan, 1993) basal activity of 
oxytocin neurones would be expected to be lower to av id natriuretic effects of oxytocin. 
Hence, the effect of fasting on the basal and peptid -induced change in activity of oxytocin 
neurones was also observed. The SON oxytocin responses observed in fasted/unfasted rats 
upon administration of leptin and secretin were compared with the CCK-induced excitatory 
responses. 
1.12. Hypotheses 
1.12.1. Neuropeptide Y 
1. Central administration of NPY increases the electrical activity of SON oxytocin 
neurones in urethane-anaesthetized virgin rats and the response is attenuated in late-
pregnant rats. 
2. Systemic administration of NPY increases the electrical activity of SON oxytocin 
neurones in urethane-anaesthetized virgin rats in vivo. 
3. Central administration of NPY increases while systemic administration of NPY 
decreases the electrical activity of SON vasopressin neurones in urethane-
anaesthetized virgin rats in vivo. 
1.12.2. Leptin 
1. Systemic leptin, a long-term satiety signal, does not affect the electrical activity of 
SON oxytocin and vasopressin neurones in virgin rats.  
2. SON oxytocin neurones are resistant to the effects of ystemic leptin during late 
pregnancy.  
3. Leptin-induced effects in the SON oxytocin neurones are either positively (due to 
increased sensitivity) or negatively (to prevent nariuresis) altered by fasting in 
virgin and late-pregnant rats.  
4. Leptin-induced changes in the electrical activity of SON oxytocin neurones in fasted 
rats are dose dependent. 
1.12.3. Secretin 
1. Systemically administered secretin, at physiological doses, increases the electrical 
activity of SON oxytocin neurones and either inhibits or does not affect vasopressin 
neurones, similar to CCK. 
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2. Secretin dose-dependently excites SON oxytocin neurones and increases peripheral 
release of oxytocin in urethane anaesthetized female rats.  
3. Systemic secretin does not induce somato-dendritic oxytocin release from the SON. 
4. Similar to CCK, central noradrenergic pathways are involved in the secretin-induced 
excitation of SON oxytocin neurones. 
5. Basal activity and secretin-induced excitation of SON oxytocin neurones are 
attenuated in fasted state. 
1.12.4. Cholecystokinin 
1. CCK-induced excitation of SON oxytocin neurones arelt red during fasting in 
virgin and pregnant rats. 
2. Systemic leptin potentiates the CCK-induced excitatory responses of SON oxytocin 
neurones. 
1.13. Objectives 
1.13.1. Neuropeptide Y (NPY): 
1. To study the effect of central administration of NPY on the electrical activity of 
SON oxytocin neurones in urethane-anaesthetized virgin and late-pregnant rats in
vivo. 
2. To study the effect of systemic administration of NPY on the electrical activity of 
SON oxytocin neurones in urethane-anaesthetized virgin rats in vivo. 
3. To study the effect of central and systemic administration of NPY on the electrical 
activity of SON vasopressin neurones in urethane-anaesthetized virgin rats in vivo. 
1.13.2. Leptin 
1. To study the electrophysiological responses of SON oxytocin neurones to systemic 
administration of leptin in vivo in unfasted/fasted virgin/pregnant rats. 
2. To study whether leptin-induced changes in electrical activity of SON oxytocin 
neurones in fasted rats are dose dependent. 
3. To study the electrophysiological responses of SON vasopressin neurones to 
systemic administration of leptin vivo. 
1.13.3. Secretin 
1. To study the electrophysiological responses of SON oxytocin and vasopressin 
neurones to intravenous administration of secretin in urethane anaesthetized female 
rats in vivo. 
2. To evaluate whether secretin-induced effects on SON oxytocin neurones and plasma 
oxytocin concentration in urethane-anaesthetized femal  rats are dose dependent.  
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3. To study the systemic secretin-induced somato-dendritic oxytocin release from the 
SON. 
4. To study the involvement of adrenergic pathways in secretin-induced effects on 
SON oxytocin neurones in urethane anaesthetized female rats. 
5. To study the basal activity and secretin-induced change in the activity of SON 
oxytocin neurones in fasted rats. 
1.13.4. Cholecystokinin 
1. To study the electrophysiological responses of SON oxytocin neurones in vivo after 
systemic administration of CCK in fasted urethane-aaesthetized virgin and pregnant 
rats and to compare with unfasted virgin and pregnant rats. 
2. To study whether systemic administration of leptin potentiates the CCK-induced 
excitatory electrophysiological responses of SON oxyt cin neurones in unfasted 
virgin rats. 
3. To compare the electrophysiological responses of SON oxytocin and vasopressin 
neurones in unfasted/fasted virgin rats to systemic administration of secretin and 





Adult (≥10 weeks old) female Sprague-Dawley rats of 200-300g body weight were 
obtained from the colony maintained at Hugh Robson Building – Biomedical Research 
Resources, University of Edinburgh, UK. The rats, six per cage, were housed under 12h light 
and 12h dark cycle (lights on at 7 AM). Temperature was maintained at 19-23oC and the 
humidity at 55 ± 10%.  The rats had free access to feed and water except when they were 
fasted when they had access only to water.  
Random cycling female rats were used for the experiments as routine vaginal 
cytology was not feasible. The influence of altered steroidal status during different phases of 
cycle on the electrophysiological response of oxytocin neurones to the peptides studied was 
considered negligible as the responses in virgin rats h ve been observed to be consistent and 
homogeneous. 
The females were introduced into a male cage for mating.  The day a vaginal plug 
found was noted as day 0 with the expected day of parturition being day 22. Late pregnant 
rats of day 19-21 were used for experiments. All procedures were performed in accordance 
with current UK Home Office regulations under the Animals (Scientific Procedures) Act 
1986 and local ethical committee approval. 
2.2. Drugs 
2.2.1. Neuropeptide Y (NPY; Porcine)  
NPY was obtained from Tocris Bioscience (Bristol, UK) as a freeze-dried aliquot 
containing 200µg of NPY. This was resuspended in distilled water and stored at -20oC in 
20µg/4µl aliquots. For intracerebroventricular (i.c.v; lateral cerebral ventricle) use, 4 µl of 
2X aCSF (See Appendix) was added and NPY was administered at a dose of 5µg/2µl. NPY 
was used at a dose of 20µg/rat in 100µl saline for i.v. administration. 
2.2.2. Recombinant Rat Leptin 
Leptin was obtained from Peprotech (France) as a freeze-dried aliquot containing 
1mg of leptin. This was resuspended in normal saline (0.9% w/vol) and stored at 4oC. Leptin 
was administered i.v. at 1µg, 10µg, 100µg or 1mg per rat in 100µl saline. 
2.2.3. Secretin (Rat) 
Secretin was obtained from Tocris Bioscience (Bristol, UK) as a freeze-dried aliquot 
containing 1mg of secretin. This was resuspended in distilled water and stored at -20oC in 
1µg/10µl aliquots. Secretin was administered i.v. at 0.01µg, 0.1µg or 1µg per rat in 100µl 
saline. 
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2.2.4. Cholecystokinin (CCK) Octapeptide (Sulfated) 
CCK was obtained from Tocris Bioscience (Bristol, UK) as a freeze-dried aliquot 
containing 1mg of CCK. This was resuspended in distilled water and stored at -20oC as 
25µg/50µl aliquots. For use, 450µl saline was added to an aliquot. CCK was administered 
i.v. at a dose rate of 25µg/kg. 
2.2.5. Benoxathian hydrochloride  
Benoxathian was obtained from Sigma (Dorset, UK) as a freeze-dried aliquot 
containing 25mg of benoxathian. This was resuspended in distilled water and stored at -20oC 
as 2µmoles/50µl (800µg/50µl) aliquots. For microdialys s use, 950µl aCSF was added to 
make a 2mM solution. For i.c.v. use, 50µl of 2X aCSF was added and administered at a dose 
rate of 8µg/µl min-1.  
2.3. In-vivo electrophysiology 
2.3.1. Surgical procedure 
 Anaesthesia was induced by exposure to halothane (Halothane-VET, Merial Animal 
Health Ltd, Essex, UK) vapour in an anaesthetic chamber. The rats were then anaesthetized 
by intraperitoneal (i.p) injection of urethane (ethyl carbamate; 25% w/v; 1.25g/kg; Sigma). 
The left femoral vein was cannulated for intravenous drug administration and the cannula 
attached to a syringe (1ml) containing normal saline (0.15M; 0.9% NaCl). An endotracheal 
tube was inserted into the trachea to keep the airway patent.  
Using the ventral surgical approach (Leng and Dyball, 1991), the ventral surface of 
the SON and neural stalk were exposed (Fig. 2.1). The anaesthetised rat was fixed in a 
stereotaxic frame in the supine position. The ramii of the mandible were separated and the 
tongue was pulled between the lower incisors and hel  using a retractor. The lower incisors 
were parted and secured laterally with wires. Using thermal cautery, the soft palate and 
tissues covering the hard palate were cauterized. A ental drill was used to remove a 3mm 
diameter area of the hard palate. The lateral wing of the palatine bone covering the 
trigeminal nerve was also removed. The trigeminal nerve was severed to expose the 
ophthalmic vein which was blocked at both ends using bone wax and then severed. This 
exposed the meningeal covering of the ventral surface of the brain. The optic chiasma, seen 
as a white band, and a cerebral artery were visually discernible through the meninges. The 
SON is located lateral to the suture between the presphenoid and basi-sphenoid bones and it 
lies along the lateral border of the optic chiasma beneath the cerebral artery. A slit was made 
using a bent 26G needle close to the optic chiasma and adjacent to the cerebral artery to 
insert a recording electrode. 
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A shallow hole was drilled in the basi-sphenoid bone posterior to the suture between 
the presphenoid and basisphenoid bones. This required blocking the venous sinus that 
traverses the bone with bone wax. The median eminence, eural stalk and a part of the 
posterior pituitary were exposed once the thin bony sheet was removed.  
2.3.2. In-vivo electrophysiological recording 
SON neurones were antidromically driven by giving constant current biphasic 
rectangular pulses (1mA for duration of 1ms) via a tungsten bipolar stimulating electrode 
(Series 200, Model SNEX200; Pfeffer Science Products - Gmbh, Hofheim, Germany) placed 
in the neural stalk. A glass capillary (GC150F-10; .5mm outer diameter; 0.86mm inner 
diameter; Harvard Apparatus Limited, Kent, UK), pulled on a magnetic puller (Narishige 
Scientific Instrument Laboratory, Tokyo, Japan) into a recording microelectrode with a tip 
diameter of approximately 1µm and filled with 0.15M NaCl, was lowered into the SON. A 
Digitimer D130 spike processor was used to detect spikes. Signals were amplified and then 
filtered using a 50Hz noise eliminator (Hum Bug; Quest Scientific, Canada). The signal w s 
passed through an interface device (CED1401; Cambridge Electronic Design, Cambridge, 
UK) to a computer. For a single rat, a minimum of one to a maximum of three neurones were 
recorded. Hence, the ‘n’ number indicates the number of neurones recorded and not 
necessarily, but normally, the number of rats. The rats were killed by anaesthetic overdose 
(Pentobarbitone; 60mg/kg; i.v; Euthatal, Merial Animal Health Ltd, Essex, UK) at the end of 
the experiments. 
2.3.3. Identification of SON neurones  
SON neurones were identified by antidromic stimulation of the neural stalk with 
1mA current for duration of 1ms every 3s (Fig. 2.2). Each stimulation of the neural stalk 
evokes an action potential in the axon, which is propagated to the cell body (Yagi et al., 
1966). An antidromic spike occurring at a constant l tency confirmed the cell as a SON 
neurone. All SON neurones displayed positive-going spikes of prolonged and complex 
action potentials and most of them showed a distinct notch on the descending slope 
representing a prominent calcium component (Mason and Leng, 1984; Leng and Dyball, 
1991).  
2.3.4. Differentiation of SON oxytocin neurones from vasopressin neurones 
SON oxytocin neurones were differentiated from vasopressin neurones by their non-
phasic firing pattern, shape of the inter-spike interval histogram and hazard and by an 
excitatory response to i.v. cholecystokinin (CCK octapeptide, sulphated; Tocris; 25µg/kg). 
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2.3.4.1. Firing pattern 
 The typical firing pattern of vasopressin cells is known as ‘phasic firing’ (Fig. 2.4). 
Bursts of firing are separated by silent phases in between (Leng and Dyball, 1991). Oxytocin 
neurones fire in a continuous manner i.e. in a non-phasic pattern (Fig. 2.3). But some 
vasopressin neurones are also continuously active and these can be differentiated from the 
oxytocin neurones using other parameters described below. 
2.3.4.2. Interspike interval histogram 
 For oxytocin neurones, the descending tails of the int rspike interval distributions 
can be fitted well using a single negative exponential (Leng et al., 2001) (Fig. 2.5a – 2.6b). 
This shape of interval histogram suggests that spike  are generated randomly but subject to 
post-spike hyperpolarization (Sabatier et al., 2004).  
 For vasopressin neurones, the tails of the interval distributions cannot be fitted well 
using a single exponential (Leng et al., 2001) (Fig. 2.7a – 2.10b). The interspike interval 
histogram is highly skewed. This shows that the spike atterning is dominated by a sequence 
of post-spike refractoriness followed by hyperexcitability, consistent with a sequential 
hyperpolarization and depolarization (Sabatier et al., 2004).   
2.3.4.3. Hazard analysis 
 Hazard is the probability of occurrence of a spike immediately after a spike that has 
already occurred. Hazard functions use the same data as interval histograms, but, in each bin, 
plot the incidence of spikes as a proportion of the siz  of the subsequent tail of the histogram 
(Sabatier et al., 2004). A hazard function is calcul ted using the formula: 
h[i - 1, i] = n[i – 1,  1]/(N - n[0, i - 1]) 
where h [i – 1, i] is the hazard at interval i, n[i – 1, 1] is the number of spikes in interval i, n[0, i – 1] is 
the total number of spikes preceding the current interval and N is the total number of spikes 
in all intervals (Brown et al., 2008). This gives the inferred probability (as a decimal) of a 
cell firing a subsequent spike in any interval after a spike (at time 0), given that another spike 
has not occurred earlier (Brown et al., 2008). 
A constant hazard is produced by a completely random firing pattern. A positive 
shift in the hazard function (i.e. an increased hazard at any given time after the preceding 
spike without a change in the shape of the hazard plot) infers a step increase in the 
probability of a spike firing (i.e. of the neuron reaching threshold), which might result from 
increased (random) synaptic drive and/or a sustained d polarization upon which 
continued/increased (random) synaptic drive is superimposed. Divergence above or below a 
constant hazard reveals periods of increased and decreased post-spike excitability, 
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respectively, which might result from changes in intrinsic membrane properties following a 
spike (Brown et al., 2008). 
Ratios of peak early (<0.07s inter-spike interval) to mean late (0.2–0.3s inter-spike 
intervals) hazards (Brown et al 2008) were calculated before and after drug administration 
for each neuron to seek changes in the shape of thehazard plot. 
Hazard functions for oxytocin neurones show an initial refractory period, then a 
steady increase in hazard to a plateau after a post-s ike interval of about 50ms, implying that 
after about 50ms, there are no detectable excitatory effects of an individual spike upon 
neuronal excitability (Sabatier et al., 2004) (Fig. 2.11a). The seemingly increasing average 
hazard constructed for oxytocin neurones in the present study (Fig. 2.11b) is an artefact of 
truncation of interspike interval data to 0.5s. Hazard analysis of vasopressin neurones show a 
low probability of discharge immediately after a spike, indicating a refractory period, 
followed  by a peak of increased probability after each spike (from about 10 to 50 ms), 
which then decreases (Fig. 2.12a).  
The different hazard plots exhibited by SON oxytocin (Fig. 2.11a and b) and 
vasopressin neurones were used to aid identification of the neurones (Fig. 2.12a, b, c and d).  
2.3.4.4. Response to intravenous CCK 
 Oxytocin neurones are transiently excited (Fig. 2.13) and vasopressin neurones are 
transiently inhibited (Fig. 2.14), or not affected by intravenous administration of 
cholecystokinin (CCK; Tocris; 25µg/kg) (Renaud et al., 1987). This test was used to 
distinguish oxytocin and vasopressin neurones. 
2.3.5. Analysis of firing rate 
2.3.5.1. Oxytocin and non-phasic firing vasopressin cells 
Firing rates were recorded and analysed using Spike 2 software (Cambridge 
Electronic Design) and averaged in 30 second bins. The mean change in firing rate (spikes 
per second) was calculated for the basal activity (over 10 min) and the periods following 
each injection. 
2.3.5.2. Phasic firing vasopressin cells 
Firing rates were recorded and analysed using the W-BURSTS script of the Spike 2 
software (Cambridge Electronic Design). The settings were adjusted appropriately to the 
duration of phasic firing of a particular neurone. The settings defined for most of the 
analyses were as follows: Maximum interval to identify start of the burst: 1s; Maximum 
interval between spikes in any one burst: 1s; Minimum interval between the bursts: 5s; 
Minimum burst duration: 5s; Minimum number of spikes per burst: 20. The number of bursts 
found, the percentage of spikes in bursts, mean number of spikes per burst, mean burst 
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length (ms), mean interburst interval (ms) and mean cycle time (ms) were calculated using 
this analytical software.  
 Three criteria were employed to evaluate changes in the firing of a phasic firing 
vasopressin neurone before and after administration of a drug: 
1. Activity Quotient (AQ): The ratio of active period to total period.  
Activity Quotient = Mean burst length (s)/ Total period of observation (s) 
2. Frequency within bursts (spikes/s): Mean intraburst frequency of spikes. 
Frequency within bursts (spikes/s) = Mean number of spikes per burst/ Mean burst length (s) 
3. Mean interburst interval (s): Average period of silence between the bursts. 
2.4. Microdialysis 
As for the in vivo electrophysiology recording, rats were anaesthetized and the 
ventral surgical procedure was carried out. An in-house designed U-shaped microdialysis 
probe was prepared (total membrane length 2.0mm; inner diameter 200µm; mean pore 
diameter: 4-6nm; Cuprophan® RC55, Membrana, GmBH, Germany). The loop of the probe 
was positioned on the ventral surface of SON after op ning the meninges. In the experiments 
combining in vivo electrophysiology and microdialysis, the recording electrode was 
positioned within the loop while recording from SON neurones (Fig. 2.15). The SON was 
dialysed with artificial cerebrospinal fluid (aCSF) or benoxathian hydrochloride (2mM; 
Sigma, Dorset, UK) dissolved in aCSF, at a flow rate of 3µl/min using a mini-pump. For 
experiments involving collection of microdialysate, 90µl samples were collected once every 
30min. The rats were killed by anaesthetic overdose (P ntobarbitone; 60 mg/kg; i.v; 
Euthatal, Merial Animal Health Ltd, Essex, UK) at the end of the experiments. 
2.5. Intracerebroventricular (i.c.v) cannulation 
 A urethane-anaesthetized (1.25g/kg; i.p) rat was positioned in a stereotaxic frame in 
the prone position. A midline skin incision was made on the skull from the level of ears to 
the forehead exposing bregma and lambda. A guide cannul  (22G with a ventral projection 
of 3.5mm; Bilaney Consultants Ltd, Kent, UK) was positi ned 1.6mm lateral and 0.6mm 
caudal to the bregma and held in place by dental cement supported by two stainless screws 
inserted into the skull. A dummy cannula (Bilaney Consultants Ltd, Kent, UK) was inserted 
to keep the guide cannula closed until use. A 28G internal cannula (Bilaney Consultants Ltd, 
Kent, UK) which projected 1mm below the tip of the guide cannula was used for i.c.v. 
administration of vehicle or a drug. At the end of the experiment, in some rats, dye was 
injected to make sure that the tip of the cannula was in the correct location, i.e. in the 
cerebral ventricle. 
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2.6. Blood sampling (with Dr. Paula J Brunton) 
Rats were anaesthetised with urethane (25%; 1.25g/kg; i.p). The left femoral vein 
was cannulated with Silastic cannula (0.5 mm internal diameter; 0.25 mm wall) connected to 
a syringe filled with heparinised (Heparin Injection B.P., Leo Laboratories, Dublin; 50U/ml) 
0.9% sterile saline. A minimum of 2h of stabilization period was allowed before taking any 
sample. 0.3ml of blood was collected for each sample in a syringe containing 0.03ml 
heparinised saline. Blood was centrifuged immediately; plasma was separated and stored at -
20oC until assayed. At the end of the experiments, rat were killed by anaesthetic overdose 
(Pentobarbitone; 60mg/kg; i.v; Euthatal, Merial Animal Health Ltd, Essex, UK). 
2.7. Oxytocin radioimmunoassay (RIA): for plasma oxytocin (with Dr. Paula J 
Brunton)  
This method was adapted from that described by Higuchi et al (Higuchi et al., 1985). 
The first rabbit antioxytocin antibody THF-3, kindly supplied by Prof. Takashi Higuchi 
(University of Fukui, Japan), diluted to a final con entration of 1: 200,000 in RIA buffer, 
was added to tubes containing standard oxytocin (Nation l Institute for Biological Standards 
and Control, Hertfordshire, UK; range 2.4–2500pg/ml; in triplicate) or test samples (in 
duplicate). After 24h incubation at 4oC, radioiodinated oxytocin (125I, 3.7KBq/ml, 50µl; 
Perkin Elmer, Life and Analytical Sciences, Buckinghamshire, UK) was added to all of the 
tubes. After 48h incubation at 4oC, a second donkey anti-rabbit antibody (IDS Ltd, Boldon, 
UK) at a dilution of 1:25 in assay buffer was added and tubes were kept at 4oC for 24h 
incubation. At the end of that incubation period, the antigen-antibody complex was 
precipitated by adding standardized Pansorbin cells (Calbiochem Ltd, Nottingham, UK) 
diluted to 1:25 in assay buffer. Radioactivity of the precipitate was measured with a -
counter (WizardTM 1470 Automatic Gamma Counter, Perkin Elmer) and unknown oxytocin 
concentrations were read directly from the standard curve constructed automatically by the 
Ultraterm 2 software package (Wallac Oy, Turku, Finland) (Fig. 2.16). The sensitivity of the 
assay was 2.4pg/ml and the intraassay variation was less than 14%. All samples from an 
experiment were assayed in a single assay to avoid interassay variation. [Refer to Appendix 
for details on reagents] 
2.8. Oxytocin radioimmunoassay (RIA): for somato-dendritic oxytocin release from the 
SON (Done at Prof. Rainer Landgraf’s Lab, Germany) 
The microdialysate (90µl/tube) samples were sent in dry ice (-79 oC) to Prof. Rainer 
Landgraf’s Lab (Max Planck Institute of Psychiatry, Germany) for oxytocin RIA. The RIA 
was done as per the procedure in Landgraf et l (Landgraf et al., 1995). The assay sensitivity 
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was 0.1pg/tube. The intra-assay coefficient of variation was 5-8% and inter-assay coefficient 
of variation was 8-12%.  
2.9. Statistical analysis 
Data are represented as mean ± standard error of the mean (s.e.m). Statistical tests 
were performed on the SigmaStat® software version 3.10 (Systat Software Inc., London, 
UK). While comparing, the average responses from indiv dual cells of a group were 
compared with that of another group. Statistical data were analyzed by paired t-test, one-way 
or two-way ANOVA and one-way repeated measures (RM) ANOVA where appropriate. The 





 Neuropeptide Y (NPY) (Tatemoto, 1982; Tatemoto et al., 1982) is a ubiquitous 
hormone that has both central and peripheral effects (Kuo et al., 2007). It is a 36-amino acid 
peptide belonging to the pancreatic polypeptide family (Tatemoto, 1982). It is the most 
potent appetite stimulant known (Kalra et al., 1991; Flynn et al., 1999). NPY is one of the 
most conserved peptides during evolution (Larhammar, 1996) suggesting that it is important 
for the regulation of essential physiological functions. It reacts with a family of G-protein-
coupled receptors (GPCR) named from Y1 to Y6 (Michel, 1991).  
Normally, the orexigenic peptides such as NPY, orexin and ghrelin activate the 
hypothalamo-pituitary-adrenal (HPA) axis (Haas and George, 1987, 1989; Suda et al., 1993; 
Johnstone et al., 2005; Spinazzi et al., 2006). The resulting glucocorticoid secretion enhances 
glucose availability (Munck and Koritz, 1962) ensuring energy homeostasis during periods 
of reduced availability of food. However, during late pregnancy, the HPA and oxytocin 
responses to central administration of the orexigenic peptides orexin A (Brunton and Russell, 
2003), NPY (Brunton et al., 2006a) and ghrelin (Bales et al., 2006a) are suppressed. The 
HPA and oxytocin secretory responses to NPY and orexin are absent in late pregnant rats, 
although the ingestive behavioural responses remain unaltered (Brunton and Russell, 2003; 
Brunton et al., 2006a). The oxytocin secretory respon es to central administration of NPY 
are reduced during late pregnancy, which may contribute to minimizing the risk of preterm 
labour and preserve the accumulated neurohypophysial stores of oxytocin for requirement 
during parturition (Brunton et al., 2006a). 
The electrophysiological responses of oxytocin neurones to physically stressful 
stimuli such as intravenous injection of IL-1β are also attenuated during late pregnancy in 
urethane-anaesthetized rats (Brunton et al., 2006b). A tonic endogenous µ-opioid inhibition 
of oxytocin neurone activity emerges centrally towards the end of pregnancy and is exerted 
at the presynaptic opioid receptors on the NA-ergic nerve terminals in the SON (Brown et 
al., 2000a). This opioid tone attenuates the IL-1β-induced OT neuronal (secretory and 
electrophysiological) responses during pregnancy, and administration of naloxone reverses 
this attenuation (Brunton et al., 2006b). It is notknown whether central NPY influences the 
electrical activity of SON oxytocin neurones and whether NPY-induced responses are 
attenuated during pregnancy.  
Injection of NPY into the SON increases the firing rate of SON vasopressin 
neurones (Khanna et al., 1993) and NPY injected into the PVN increases peripheral 
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vasopressin release (Leibowitz et al., 1988). However, the response of SON vasopressin 
neurones to i.c.v. administration of NPY is not know .  
As NPY is co-released at sympathetic nerve terminals along with noradrenaline 
(NA) during sympathetic activation (Donoso et al., 1997), peripheral NPY concentration is 
increased by stressors (Krukoff et al., 1999). NPY from the periphery can readily enter the 
brain by diffusion across the blood-brain barrier (Kastin and Akerstrom, 1999).  As oxytocin 
is a stress hormone in the rat (Lang et al., 1983), it can be hypothesized that stress-induced 
elevation of peripheral NPY may enhance activation of SON oxytocin neurones as a 
feedforward mechanism during stress. As NPY is a vasoconstrictor peripherally (Michel and 
Rascher, 1995), systemic administration of NPY may be expected to inhibit vasopressin 
neuronal activity. Hence, the effect of systemic administration of NPY on the electrical 
activity of SON oxytocin and vasopressin neurones wa also studied.  
3.2. Hypotheses 
1. Central administration of NPY increases the electrical activity of SON oxytocin 
neurones in urethane-anaesthetized virgin rats and the response is attenuated in 
late-pregnant rats. 
2. Systemic administration of NPY increases the electrical activity of SON 
oxytocin neurones in urethane-anaesthetized virgin rats in vivo. 
3. Central administration of NPY increases while systemic administration of NPY 
decreases the electrical activity of SON vasopressin neurones in urethane-
anaesthetized virgin rats in vivo. 
3.2.1. Objectives 
1. To study the effect of central administration of NPY on the electrical activity of 
SON oxytocin neurones in urethane-anaesthetized virgin and late-pregnant rats 
in vivo. 
2. To study the effect of systemic administration of NPY on the electrical activity 
of SON oxytocin neurones in urethane-anaesthetized virgin rats in vivo. 
3. To study the effect of central and systemic administration of NPY on the 
electrical activity of SON vasopressin neurones in urethane-anaesthetized virgin 
rats in vivo. 
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3.3. Background 
The drive to obtain energy to sustain physiological well-being and the drive to 
reproduce successfully are the two instinctive urges essential for the survival of a species 
(Kalra and Kalra 2003). Neuropeptide Y (NPY) is one of the important neurochemical 
signals relaying information regarding these instincts (Kalra and Kalra 2003).  
Neuropeptide Y was so-named because it is produced exclusively in neural tissue 
and has tyrosine (Y) residues at both ends (Kalra and Kalra 2003). It is considered to be the 
most abundant and widely distributed neuropeptide present in the mammalian central and 
peripheral nervous systems (Balasubramaniam, 1997).  
NPY is a pleotrophic neuroendocrine signal (Horvath e  al., 1997). As well as 
stimulating food intake (Clark et al., 1984), it is involved in the release of hypophysiotropic 
hormones (Kalra and Crowley, 1992; Kalra et al., 1992), inhibition of sexual behaviour 
(Clark et al., 1984) and a variety of autonomic activities (Gray and Morley, 1986). Central 
NPY markedly stimulates both nocturnal and diurnal feeding and drinking (Levine and 
Morley, 1984). NPY-induced food intake is suppressed by the opiate antagonist naloxone, 
and by the dopamine antagonist haloperidol (Levine a d Morley, 1984). Based on the 
maximum quantity of food ingested following central administration of NPY, this peptide 
represents one of the most potent stimulators of feeding (Levine and Morley, 1984). 
However, NPY is not the only peptide involved in the upregulation of food intake because 
NPY knockout mice have a normal feeding phenotype and respond normally to fasting and 
refeeding (Erickson et al., 1996).  
3.3.1. Hypothalamic source and distribution of NPY 
 The hypothalamic sources of NPY include the ARC NPY/AgRP neurones (Bai et al., 
1985; Grove and Smith, 2003), NA neurones in the A1 and A2 cell group of the brainstem 
(Everitt et al., 1984; Sawchenko et al., 1985; Simonian and Herbison, 1997), amygdala, 
hippocampus (Allen et al., 1984; de Quidt and Emson, 1986), BNST, septum, LH, POA, 
peri- and paraventricular nuclei, DMN (Li et al., 1998a, b; Grove et al., 2003), mPVN and 
SON (Larsen et al., 1992a, b; Fetissov and Nicolaidis, 1998). However, the most abundant 
NPY innervation, reaching virtually the entire hypothalamus, arises from the ARC (Bai et 
al., 1985; Grove and Smith, 2003). 
NPY neurones in the ARC co-express GABA (Horvath et al., 1997). NPY and 
GABA co-producing neurones are located in the dorsomedial ARC and non-GABAergic 
NPY neurones are located in the ventral ARC (Horvath et al., 1997). POMC neurones in the 
ARC express CART, a potent inhibitor of food intake (Elias et al., 1998; Kristensen et al., 
1998; Lambert et al., 1998; Thim et al., 1998; Vrang et al., 1999). NPY and POMC 
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containing neurones in the ARC make synaptic contacts with each other (Csiffary et al., 
1990). Many POMC neurones express Y1R mRNA and protein (Broberger et al., 1997) and 
many NPY neurones in the ARC co-express AgRP, an endogenous MC4-R antagonist (Lu et 
al., 1994; Fong et al., 1997). Activation of AgRP-NY neurones promotes feeding by 
activating NPY receptors and antagonizing MC4-R (Hahn et al., 1998). Activation of MC4-
R decreases food intake, increases energy expenditure and decreases body weight (Vergoni 
et al., 2000; Wirth and Giraudo, 2001). Leptin decreases hypothalamic NPY mRNA 
expression (Stephens et al., 1995; Schwartz et al., 1996; Sahu, 1998a, b) and opposes 
orexigenic effects of NPY (Smith et al., 1996; Sahu, 1998a). NPY in turn antagonizes the 
anorectic effect of leptin (Erickson et al., 1996; Baskin et al., 1998). Leptin also decreases 
AgRP mRNA expression (Ebihara et al., 1999; Mizuno and Mobbs, 1999; Korner et al., 
2001) and increases ARC POMC (Mizuno et al., 1998) and CART (Kristensen et al., 1998) 
mRNA expression enhancing its anorectic effect.  
ARC-NPY neurones regulate the synthesis and release of many neurohormones such 
as GnRH, GHRH, somatostatin, CRH, TRH, vasopressin, oxytocin and dopamine (Kalra and 
Kalra 2003). They also innervate other hypothalamic nu lei that regulate appetite, sexual 
behaviour and energy expenditure (Kalra and Kalra 2003). As the ventromedial region of the 
ARC lacks an intact blood-brain barrier (Norsted et al., 2008), the ARC NPY neurones 
receive hormonal afferent messages from peripheral ndocrine glands, leptin from 
adipocytes, ghrelin from stomach, steroids from gonads and adrenal cortex and cytokines 
from immune cells (Kalra and Kalra 2003). They also receive input signals from ascending 
neural pathways via brainstem catecholaminergic neurones and MCH neurones of the LH 
(Kalra and Kalra 2003). 
3.3.2. Extra hypothalamic source of NPY: The brainstem  
In the brain, 40% of NPY is synthesized in the ARC while the remainder is 
synthesized in the dorsovagal complex of the medulla (Bai et al., 1985; Chronwall, 1985; de 
Quidt and Emson, 1986). These brainstem NPY neurones project to other hypothalamic 
regions (Hokfelt et al., 1983b; Hokfelt et al., 1983a; Everitt et al., 1984). Especially, the C1 
and A1 cell groups contain abundant NPY-ir (Sawchenko et al., 1985) and these neurones 
project to the SON (Shioda et al., 1992). NPY co-loca izes with NA and adrenaline also in 
the LC (Everitt et al., 1984); however, the presence of NPY with NA in the A2 cell group is 
controversial (Harfstrand et al., 1987; Simonian and Herbison, 1997). NPY, indeed, is 
closely associated with NA and adrenaline in both the central and peripheral nervous system 
(Lundberg et al., 1985; Allen and Bloom, 1986; Gray and Morley, 1986; Morris et al., 1986). 
Under certain conditions, co-release of NPY and NA is important in amplifying or 
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restraining the postsynaptic response of hypothalamic target neurones (Kalra and Kalra 
2003). 
3.3.3. NPY receptors 
NPY activates a heterogeneous population of at leassix receptor subtypes, Y1 - Y6, 
all of which have been cloned except for the putative Y3R (Inui, 1999; Fetissov et al., 2004). 
Y1R mRNA is expressed in virtually all hypothalamic regions in the rat with the highest 
levels in the ARC and SON (Parker and Herzog, 1999). In the ARC, Y1R-ip neurones are 
predominantly POMC neurones (Broberger et al., 1997; Fuxe et al., 1997).  
Y2R is an inhibitory autoreceptor in the presynaptic terminal where its activation 
inhibits the endogenous release of NPY (Zhang et al., 1997). Hence, central administration 
of Y2R agonists decreases food intake (Leibowitz and Alexander, 1991). The presence of 
Y2R has been established in many hypothalamic nuclei such as the ARC, mPOA, DMH, 
VMH, PVN, LHA and intensely in the SON (Gustafson et al., 1997; Parker and Herzog, 
1999; Dumont et al., 2000). PYY3-36 is the agonist for Y2R mediating satiety signal from the 
gut to the brain (Ueno et al., 2008). 
Pancreatic polypeptide (PP), a peripheral appetite regulating peptide, is the natural 
ligand for the Y4R (Bard et al., 1995; Lundell et al., 1995). However, high levels of Y4R 
binding sites have been found in the mPOA, PVN, ARC and SON (Parker and Herzog, 1999; 
Dumont et al., 2000). 
Y5R mRNA has been localized in most of the hypothalamic sites including the PVN, 
LHA, ARC and SON (Gerald et al., 1996; Parker and Herzog, 1999). The highest level of 
Y5R-ir was found in the magnocellular oxytocin and vasopressin neurones in the SON 
(Campbell et al., 2001; Wolak et al., 2003) and hence it is possible that NPY may have direct 
actions on the SON neurones to stimulate oxytocin and vasopressin release through the 
activation of Y5R (Campbell et al., 2001).  
The putative Y3R has been characterized only in the NTS in the CNS (Lee and 
Miller, 1998) while the putative Y6R is absent in rats, non-functional in the pig, guinea pig 
and humans and functional only in mouse and rabbit (Inui, 1999; Starback et al., 2000). 
Y1R and Y5R subtypes have been implicated in the regulation of fo d intake 
(Criscione et al., 1998; Kalra et al., 1998) and they are widely distributed throughout the 
brain (Wolak et al., 2003). Surprisingly, Y1 and Y5 receptor knockout animals are not lean 
but develop late onset obesity (Kushi et al., 1998; Marsh et al., 1998; Pedrazzini et al., 1998; 
Kanatani et al., 2000). This could be attributed to redundancy of systems that control 
different functions, such as energy homeostasis, which could lead to compensatory changes 
during development (Eva et al., 2006).  
 51 
I.c.v. administration of Y1R and Y5R antagonists suppresses NPY-induced feeding 
(48% and 40-50% reduction, respectively) and Fos-like immunoreactivity only in the mPVN 
(46% and 47% reduction, respectively) (Yokosuka et al., 1999; Yokosuka et al., 2001). 
Hence, it is likely that NPY receptor sites concerned with feeding behaviour reside 
selectively in the mPVN and Y1R and Y5R are either coexpressed or expressed separately in 
those target neurones that promote appetitive drive (Yokosuka et al., 2001). 
3.3.4. NPY receptor signalling and downstream effects 
 NPY receptors belong to the GPCR superfamily. The YR gene family represents the 
largest and the most complex family of the GPCR superfamily for any known peptide 
(Blomqvist and Herzog, 1997). Binding of NPY to itsreceptors results in the inhibition of 
adenylate cyclase and activation of the phospholipase C/protein kinase C pathway 
(PLC/PKC) (Selbie et al., 1995; Parker et al., 1998; Leupen and Levine, 1999). Compounds 
that stimulate adenyl cyclase activity inhibit feeding while inhibition of cAMP synthesis 
tends to facilitate food intake (Chance et al., 2000). In accordance with this, 
intrahypothalamic administration of NPY inhibits hypothalamic adenyl cyclase activity and 
stimulates food intake in rats (Chance et al., 1989). 
  The perifornical hypothalamus (PFH) at the level of the caudal PVN is the most 
sensitive hypothalamic site for NPY-induced feeding (Stanley et al., 1993). In addition, NPY 
action on the PVN regulates feeding, thermogenesis and energy metabolism (Currie and 
Coscina, 1995). The CRH, CART and TRH neurones of the PVN have been shown to be 
downstream targets of NPY neurones (Heinrichs et al., 1998; Broberger, 1999; Kalra et al., 
1999). 
3.3.5. Mechanism of appetite regulation by ARC NPY neurones 
 A three-pronged interplay under the direction of NPY in the ARC-PVN axis initiates 
and extinguishes feeding behaviour (Kalra and Kalra 2003): 1. An increase in NPY and 
GABA release from the ARC NPY neurones sends information to higher brain centres to 
evoke feeding, while AgRP release from the ARC NPY neurones counteracts the tonic 
restraint from MC4 receptors to amplify appetite. 2. Increased NPY and GABA release 
within the ARC itself restrains POMC neurones causing a decreased release of alpha-MSH 
to diminish the tonic restraint on feeding. 3. After food intake, a gradual decrease in the 
release of NPY, GABA and AgRP in the PVN evoked by auto-feedback through Y2R on 
NPY neurones in the ARC inhibits feeding.  
 During the time when a meal is anticipated, diminished leptin restraint from adipose 
tissue stimulates ghrelin pulses from the stomach. This results in activation of NPY, AgRP 
and GABA secretion, resulting in hunger. Consumption of a meal reverses this chain of 
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neural and hormonal events. Steady increase in leptin secretion reinstates tonic restraint on 
NPY ARC neurones, and along with decrease in ghrelin secretion, it results in appetite 
suppression (Kalra and Kalra 2003). 
3.3.6. NPY and HPA axis 
Central NPY activates the HPA axis in rats (Haas and George, 1987; Harfstrand et 
al., 1987; Wahlestedt et al., 1987; Suda et al., 1993). Central NPY stimulates CRH release in 
the median eminence (Haas and George, 1987, 1989), increases CRH mRNA expression in 
the pPVN (Suda et al., 1993) and increases plasma ACTH (Haas and George, 1989) and 
corticosterone (Harfstrand et al., 1987). NPY-induced increase in the circulating level of 
corticosterone might enhance glucose availability to ensure energy homeostasis during 
stress. Also, stress activates 36% of NPY neurones in the ARC, 33% in the NTS and 75% in 
the VLM (Krukoff et al., 1999). 
3.3.7. Effect of NPY on SON neurones 
Central NPY induces Fos in the SON (Niimi et al., 2001). Injection of NPY into the 
SON increases the firing rate of SON vasopressin neurones (Khanna et al., 1993) and NPY 
injected into the PVN increases peripheral vasopressin release (Leibowitz et al., 1988). NPY 
potentiates phenylephrine (α-1 adrenergic agonist) induced oxytocin and vasopressin release 
from perifused explants of the hypothalamo-neurohypphysial system (Kapoor and Sladek, 
2001).  
NPY excites only a small proportion (23%) of SON vasopressin neurones in 
pentobarbitone-anesthetized male rats (Day et al., 1985). Direct application of NPY onto the 
SON in pentobarbitone-anaesthetized male rats shows that NPY acts on Y1R to excite 
vasopressin neurones but can also act on the presynaptic Y2R to depress A1-vasopressin 
synaptic transmission (Khanna et al., 1993). Bath application of NPY excites SON neurones 
in hypothalamic slices (Sibbald et al., 1989). Application of NPY at a dose having virtually 
no direct effects produces a 5-fold increase in SON neurone responsiveness to NA, showing 
that NPY itself is only weakly excitatory to SON neurones but it markedly potentiates the 
excitatory effects of low concentrations of NA (Sibbald et al., 1989). It appears that NPY 
either directly activates SON neurones and/or modulates the response of these neurones to α-
1 adrenergic stimulation (Willoughby and Blessing, 1987; Sibbald et al., 1989; Parker and 
Crowley, 1993; Kapoor and Sladek, 2001). The stimulatory effects of NPY on oxytocin and 
vasopressin release are mediated via activation of Y1R and/or Y5R, whereas activation of 
Y2R may cause suppression of activity (Willoughby andBlessing, 1987; Khanna et al., 1993; 
Kapoor and Sladek, 2001). 
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3.3.8. Changes in NPY and NPY receptor expression i the CNS during pregnancy 
During pregnancy, development of central leptin resistance around mid-gestation 
results in physiological hyperphagia despite high circulating levels of leptin (Grattan et al., 
2007). Food intake increases by up to ca. 50% during pregnancy and it happens only during 
the dark phase (Cripps and Williams, 1975). Changes in NPY and its receptors expression 
during pregnancy have not yet been studied in the rats. However, in pregnant Y1R/LacZ 
transgenic mice, NPY-ir is significantly increased in the PVN, decreased in the VMN and 
there is no change in the ARC (Oberto et al., 2003). In-situ hybridization study of specific 
hypothalamic areas shows that NPY mRNA content in the ARC significantly increases 
during pregnancy and lactation which might be partly esponsible for the hyperphagia 
observed during these periods of increased energy demand (Garcia et al., 2003). However, 
studies that analysed total hypothalamic NPY mRNA by Northern blotting report that 
hypothalamic NPY mRNA does not change during mid- (Wilding et al., 1997) or late 
gestation (Ajala et al., 2001). 
In pregnant Y1R/LacZ transgenic mice, Y1R gene expression is significantly 
increased in the PVN, ARC and medial amygdala and is reduced in the VMN (Oberto et al., 
2002; Oberto et al., 2003). Administration of finasteride from day 12-17 of pregnancy 
prevented the increase in Y1R/LacZ gene expression in the amygdala (Oberto et al., 2002). In 
virgin Y1R/LacZ transgenic mice, long term treatment with progesteron  or its 3α-reduced 
metabolite allopregnanalone increases Y1R gene expression in the medial amygdala (Ferrara 
et al., 2001). These results suggest that neurosteroids that accumulate in the brain during 
pregnancy contribute significantly to alterations i NPY signalling in the CNS (Ferrara et al., 
2001).  
HPA and oxytocin responses to NPY are suppressed during pregnancy in the rat 
(Brunton et al., 2006a). Administration of naloxone, an opioid antagonist, restored the HPA 
response to central administration of NPY in late pr gnancy (Bales et al., 2006b). In 
addition, suppression of NPY-induced oxytocin release and HPA activation in late 
pregnancy could be a result of increased effectiveness of GABAergic inhibitory input 
(Brunton et al., 2006a).  
3.3.9. Peripheral effects of NPY  
 NPY and NA are co-released at the sympathetic neuro- ffector junction (Pernow, 
1988). However, acute stress and tonic sympathetic activation preferentially release NA, 
while NPY is released during prolonged and/or intense stress (Kuo et al., 2007). Cold water 
stress increases mean arterial pressure, heart rate, decreases mesenteric blood flow and 
increases mesenteric vascular resistance and a Y1R antagonist inhibits up to 80% of the 
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vasoconstrictive effects of cold stress (Zukowska-Grojec et al., 1996). NPY has also been 
found in nonsympathetic neurones in several organs including the gastrointestinal tract, 
salivary glands, thyroid gland, pancreas, urinogenital system, airways and heart 
(Balasubramaniam, 1997). Peipheral actions of NPY include vasoconstriction, vascular 
remodelling, stimulating monocyte migration and activation, activation of platelets, 
angiogenesis and adipogenesis (Kuo et al., 2007). Peripheral NPY has also been implicated 
in stress-induced augmentation of diet-induced obesity by increasing angiogenesis and 
adipogenesis and reducing lipolysis (Kuo et al., 2007). 
3.4. Methods 
3.4.1. Experiment 1: Effect of central administration of NPY on the electrical activity of 
SON oxytocin and vasopressin neurones in urethane-an esthetised virgin and pregnant 
rats in vivo. 
Urethane-anaesthetized virgin and pregnant (19-21d of pregnancy) rats were fixed 
with an i.c.v. cannula and an i.v. cannula on the day of the experiment. The SON and neural 
stalk were exposed via the ventral transpharyngeal surgery. Stimulating and recording 
electrodes were placed in position. Once SON neurones were identified and oxytocin 
neurones and vasopressin neurones were differentiatd, 2µl aCSF or 5µg/2µl of NPY was 
administered i.c.v. after an initial basal recording of firing rate for 10min. 
Groups: 
a. Oxytocin neurones 
i. Virgin aCSF: n = 5 
ii. Pregnant aCSF: n = 4 
iii.  Virgin NPY: n = 5 
iv. Pregnant NPY: n = 6 
b. Vasopressin neurones:  
i. Virgin NPY: Non-phasic: n = 4 
3.4.2. Experiment 2: Effect of systemic administration (20µg per rat in 100µl saline; i.v) 
of NPY on the electrical activity of SON oxytocin and vasopressin neurones in 
urethane-anaesthetised virgin rats in vivo. 
Groups: 
a. Oxytocin neurones: n = 5 
b. Vasopressin neurones: 
i. Phasic: n = 3 
ii. Non-phasic: n = 6 
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3.5. Results 
3.5.1. Body weight 
As expected, the pregnant groups had significantly higher body weight than the 
virgin groups (Fig. 3.1).  
3.5.2. Basal firing rate of SON oxytocin neurones 
The basal firing rate did not differ within virgin and pregnant groups. However, the 
basal firing rate of oxytocin neurones in the pregnant groups was significantly higher than 
the respective virgin groups (Fig. 3.2). 
3.5.3. Effect of central administration of NPY on the electrical activity of SON oxytocin 
neurones in virgin rats 
Central administration of NPY (5µg/2µl aCSF; i.c.v) excited all five SON oxytocin 
neurones tested (Fig. 3.3) while a vehicle injection did not alter the basal firing rate (Fig. 
3.4). In the virgin NPY group (n=5 cells/rats), the basal rate of 3.5 ± 1.1 spikes/s was  
increased by 1 ± 0.45 spikes/s 1min after NPY. It remained elevated and returned to basal by 
40min on average. The average change in firing in rate 0-30min after NPY was significantly 
higher than that during the basal period (Fig. 3.5). In the virgin aCSF group (n=4), there was 
no change in the firing rate after aCSF administration. The mean increase in firing rate 0-
30min after NPY in the virgin NPY group was significantly higher than the change in firing 
rate 0-30min after aCSF in the virgin aCSF group (Fig. 3.6). 
After NPY there was an overall increase in the number of spikes occurring within 0-
0.5s of the preceding spike compared to the basal period as shown by the interspike interval 
histogram before and after NPY administration (Fig. 3.7a). The descending slope of the 
histograms fitted well with exponential curves (Fig. 3.7b). There was no apparent change in 
the shape in the hazard plots for 10min before and after NPY (Fig. 3.8). The ratio of peak 
early (<0.07s) to mean late (0.2 – 0.3s) hazard before and after NPY did not differ from each 
other (Fig. 3.9).  
3.5.4. Effect of central administration of NPY on the electrical activity of SON oxytocin 
neurones in pregnant rats 
In the pregnant aCSF group (n=4), the average basal firing rate was 6.6 ± 0.6 
spikes/s and the vehicle injection (2µl aCSF; i.c.v) did not alter the firing rate significantly 
(e.g. Fig. 3.10). Central administration of NPY (5µg/2µl aCSF; i.c.v) excited all six SON 
oxytocin neurones tested in late pregnant rats (e.g. Fig. 3.11).  On average, the basal firing 
rate of 6.5 ± 0.8 spikes/s was increased by 1.2 ± 0.3 spikes/s 9min after NPY injection. The 
rate remained elevated until returning to basal again by 25min. The mean increase in firing 
rate 0-30min after NPY compared to the change in fir g rate during the basal period was 
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significantly greater. The average firing rate 0-30min after NPY in the pregnant NPY group 
was significantly higher than the rate 0-30min after aCSF injection in the pregnant aCSF 
group (Fig. 3.12) but it was not different from the firing rate observed in the virgin NPY 
group (Fig. 3.13). 
3.5.5. Effect of systemic administration of NPY on firing rate of SON oxytocin neurones 
in virgin rats 
Systemic administration of NPY (20µg; i.v) excited four of five SON oxytocin 
neurones tested (E.g. Fig. 3.14) while one neurone did not respond. On average, the basal 
firing rate of 2.5 ± 0.95 spikes/s was increased by 1.4 ± 0.6 spikes/s 30s after NPY (n=5). 
The mean increase in firing rate 0-5min after NPY was significantly higher than that during 
the basal period (Fig. 3.15). 
3.5.6. Effect of central administration of NPY on the firing rate of SON vasopressin 
neurones in virgin rats 
The effect of central administration of NPY was observed in four non-phasic and 
one phasically firing SON vasopressin neurones. Among the four non-phasic vasopressin 
neurones, 2 were excited, 1 was inhibited and 1 did not respond. On average, the basal firing 
rate was 6.6 ± 1.2 spikes/s and it was not altered by central NPY administration (Fig. 3.16). 
There was also little alteration (a slight inhibition) in the firing of the phasic vasopressin 
neurone after central NPY. The activity quotient (0.06) was unaltered by NPY; frequency 
within bursts was slightly reduced from 4.2 spikes/s to 4.04 spikes/s 0-5min after NPY; 
mean interburst interval increased from 3.9s to 5.7s 0-5min after NPY. There was no change 
in the interspike intervals before and after NPY (Fig. 3.17a). The distal tails of the histogram 
fitted well with exponential curves leaving the intervals before 0.2s which is a characteristic 
for vasopressin neurones (Fig. 3.17b). NPY administrat on did not alter the shape of the 
hazard plot (Fig. 3.18). 
3.5.7. Effect of systemic administration of NPY on the firing rate of SON vasopressin 
neurones in virgin rats 
The effects of systemic administration of NPY were observed in eight non-phasic 
and three phasically firing SON vasopressin neurones. Among the eight non-phasic 
vasopressin neurones, 7 were inhibited (e.g. Fig. 3.19) and 1 did not respond. On average, 
the basal firing rate of 7 ± 0.99 spikes/s was reduc  by 2.4 ± 1.8 spikes/s 1min after NPY 
(n=6). The firing rate 0-5min after NPY was not different from the basal period (Fig. 3.20).  
Systemic NPY administration transiently inhibited all three phasic vasopressin 
neurones tested (e.g. Fig. 3.21). However, the formal easures of activity of the 3 cells did 
not show significant effects (Fig. 3.22, 3.23 and 3.24).    
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3.6. Discussion 
3.6.1. Central NPY-induced excitation of SON oxytocin neurones 
 This study reports for the first time that central administration of NPY increases the 
electrical activity of SON oxytocin neurones in female rats in vivo. There are other 
electrophysiological studies reporting activation of only SON vasopressin neurones by direct 
application of NPY in male rats in vivo (Day et al., 1985; Willoughby and Blessing, 1987) or 
in vitro (Sibbald et al., 1989).  
Central administration of NPY did not alter the shape of the hazard plot and this is 
supported by the lack of change in the ratios of peak arly to mean late hazard before and 
after NPY. Hence, central NPY administration evidently did not alter the intrinsic properties 
[such as resting membrane potential, input resistance, depolarizing afterpotential (Stern and 
Armstrong, 1996)] of the SON oxytocin neurones. The positive shift in the hazard function 
without a change in the shape of the hazard plot indicates an increase in the synaptic drive 
and/or a sustained depolarization upon which continued/increased synaptic drive is 
superimposed (Brown et al., 2008). It is possible that central NPY potentiates the effects of 
excitatory noradrenergic inputs from the brainstem onto the SON as shown in studies n vitro  
(Sibbald et al., 1989). 
As central administration of NPY induces Fos activation in SON oxytocin neurones 
and increases peripheral oxytocin release (Brunton e  al., 2006a), this study reinforces the 
point that Fos activation most often accompanies an increase in neuronal electrical activity 
which in turn, in neurosecretory cells, is accompanied by the release of the neuropeptides.   
3.6.2. Physiological importance of central NPY-induced excitation of SON oxytocin 
neurones 
NPY-induced excitation of oxytocin neurones and theaccompanying peripheral 
release of oxytocin might be physiologically important for at least three reasons.  
1. Stress-induced activation of oxytocin neurones via NPY neurones: Stressors 
activate NPY neurones in the ARC and brainstem (Krukoff et al., 1999) and oxytocin is also 
a stress hormone in the rat (Lang et al., 1983). Hence, stress-induced activation of NPY 
neurones might potentiate stress-induced activation of oxytocin neurones. These 
physiological modulations of oxytocin neurones by NPY might be possible because the ARC 
and the brainstem neurones, where NPY is expressed in abundance (Chronwall, 1985), 
project directly to the SON (Leng et al., 1988; Shioda et al., 1992) (though it is not known 
whether ARC-NPY neurones particularly project to the SON) and SON neurones strongly 
express NPY receptors (Parker and Herzog, 1999; Campbell et al., 2001; Wolak et al., 2003).  
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As the function of neuropeptides such as NPY is often to amplify and reinforce the 
actions of other neurotransmitters regulating important physiological processes (Urban et al., 
2006), in addition to other neuropeptides/pathways, NPY might also increase oxytocin 
neuronal activity and peripheral oxytocin release to nsure homeostasis during stress. 
As peripheral oxytocin in itself increases glucose availability and uptake by 
increasing glucagon and insulin release, respectively (Altszuler et al., 1992; Lee et al., 2008), 
NPY-induced oxytocin release might be a valuable mechanism to enhance glucose 
availability during increased energy demand.  
2. Activation of SON oxytocin neurones by NPY during/after food intake: NA/NPY 
neurones in the A1 and A2 cell groups are activated by food intake and associated stimuli 
such as gastric distension, vagal stimulation, gut peptides (e.g. CCK) (Monnikes et al., 1997; 
Willing and Berthoud, 1997; Rinaman et al., 1998; Conde et al., 1999; Krukoff et al., 1999; 
Ohiwa et al., 2006; Appleyard et al., 2007). Activation of NA neurones in the A2 cell group 
results in the excitation of SON oxytocin neurones via excitatory NA projections (Raby and 
Renaud, 1989; Onaka et al., 1995a; Buller and Day, 1996). Hence, central NPY 
administration might presumably resemble NA/NPY discharge from the axon terminals at 
the SON in response to stimuli such as food intake and associated CCK release. 
3. Activation of SON oxytocin neurones by NPY during food anticipation: NPY is a 
orexigenic neuropeptide and anticipation for food upregulates NPY in the ARC (Drazen et 
al., 2005). However, ARC-NPY neuronal projections to the SON have not been established. 
In addition, SON oxytocin neurones are not activated during food anticipation (Johnstone et 
al., 2006). Activation of SON oxytocin neurones by NPY during food anticipation appears 
irrelevant because, physiologically, oxytocin as a promoter of natriuresis needs to be 
released after food intake not during food anticipation.  
4. Activation of SON oxytocin neurones by NPY during food deprivation: Oxytocin 
from the magnocellular neurones can enter the hypotalamo-hypophysial portal blood to 
potentiate basal or CRH/AVP (Arginine vasopressin)-induced ACTH and subsequent 
corticosterone secretion (Makara et al., 1982; Lang et al., 1983; Gibbs, 1985, 1986; 
Engelmann et al., 2004). Food deprivation-induced upregulation of ARC NPY (Kalra and 
Kalra, 2003) might activate oxytocin neurones and icrease oxytocin release so as to 
potentiate CRH-induced ACTH secretion. The resulting increase in endogenous 
glucocorticoids will ensure mobilization of glucose to meet the energy demand until food is 
available (Olefsky and Kimmerling, 1976). However, it is not known whether ARC-NPY 
neurones project to the SON. 
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3.6.3. Physiological effects of central NPY and oxytocin 
 1. Anxiolysis: The drive for energy is an absolute essential for the survival of a 
species. However, procuring food during a meal time could be an arduous task for animals in 
the wild, resulting in anxiety. Food restriction increases anxiolytic-like behaviour (Inoue et 
al., 2004) suggesting that anxiety associated with anticipation/absence of food is alleviated 
naturally. It is likely that an endogenous mechanism for anxiolysis is in place through NPY 
upregulation during meal time because central NPY acts as an anxiolytic (Heilig and 
Murison, 1987a, b; Heilig et al., 1989; Heilig et al., 1992; Baraban et al., 1997; Bannon et 
al., 2000; Stogner and Holmes, 2000; Thorsell et al., 2000; Kask et al., 2001a; Kask et al., 
2001b; Redrobe et al., 2002). GABA and its receptor agonists increase feeding and induce 
anxiolysis in animal models of anxiety (Lopes et al., 2007). As NPY is co-localized with 
GABA in several limbic structures (Horvath et al., 1997; Pu et al., 1999), some of the central 
actions of NPY, like anxiolysis, might involve interaction with GABAergic transmission (Pu 
et al., 1999).  
Central oxytocin also is anxiolytic (Mantella et al., 2003; Amico et al., 2004; Ring et 
al., 2006). NPY potentiates NA-induced oxytocin release from hypothalamo-hypophysial 
explants (Kapoor and Sladek, 2001). If NPY-induced excitation of oxytocin neurones is 
accompanied by dendritic release of oxytocin, oxytocin and NPY might complement each 
other in their anxiolytic effects. Anxiolysis during the postprandial period might also 
enhance the feeling of satiety. Hence, anxiolytic effects of NPY and oxytocin could be 
beneficial not only during stress but also around the meal time making the entire process of 
feeding pleasurable.  
2. Appetite regulation: As NPY is one of the most potent appetite stimulants k own, 
check-points like oxytocin, through its central anorectic actions (Olson et al., 1991a, b, c), 
might be needed even during normal feeding to balance the potent orexigenic effect of NPY 
so as to regulate appetite and meal size, and consequently body weight. 
It is interesting that Y1, Y2 and Y5 receptor knockout mice are not lean but develop 
late onset obesity (Kushi et al., 1998; Marsh et al., 1998; Pedrazzini et al., 1998; Kanatani et 
al., 2000) similar to oxytocin receptor deficient mice (Takayanagi et al., 2008). However, it 
is not known whether NPY and oxytocin receptor modulation depend on each other in this 
context. 
3. Regulation of behaviour: In addition to appetite regulation and anxiety alleviation, 
central actions of NPY and oxytocin have been implicated in diverse social behaviours (van 
Wimersma Greidanus et al., 1986; Carter et al., 2008; Karl et al., 2008; Veenema and 
Neumann, 2008), behavioural adaptation to stress (Thorsell et al., 1999; Ebner et al., 2005), 
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learning (Argiolas and Gessa, 1991; de Wied et al., 1993; Gulpinar and Yegen, 2004; Eaton 
et al., 2007), memory (Argiolas and Gessa, 1991; de Wied et al., 1993; Cleary et al., 1994; 
Gulpinar and Yegen, 2004; Fang et al., 2008) and reward processes (Argiolas and Gessa, 
1991; de Wied et al., 1993; Brown et al., 2000b; Marazziti and Catena Dell'osso, 2008). 
Central oxytocin might also enhance the memory related to food and feeding behaviour 
(Neumann, 2008).  NPY plays a role in the motivation t  eat and in food anticipatory 
responses (Flood and Morley, 1991; Drazen et al., 2005). Hence it is likely that central NPY 
and oxytocin interact with each other to modulate complex behavioural patterns. 
3.6.4. Central NPY-induced excitation of SON oxytocin neurones in pregnant rats: 
Discrepancy in the basal activity 
The basal activity of SON oxytocin neurones during late gestation is expected to be 
low to prevent the risk of preterm labour and to preserve the oxytocin stores that are required 
for impending parturition. However, the basal firing rate of SON oxytocin neurones in 
pregnant rats observed in this study was higher than t reported earlier (Douglas et al., 
1995; Brunton et al., 2006b). This might be the result of influence of the day of gestation of 
the rats used (19-21d in this study vs. 20-21d and 21d by the other studies) (Douglas et al., 
1995; Brunton et al., 2006b). However, it is also possible that the present measurement 
reflects the small sample of cells (n=5).  
3.6.5. Central NPY-induced excitation of SON oxytocin neurones in pregnant rats: 
Discrepancy in NPY-induced increase in activity 
Surprisingly, the SON oxytocin neurone electrical activity in response to central 
NPY was not attenuated in urethane anaesthetized lat -pregnant rats. This conflicts with the 
attenuated Fos induction and oxytocin secretory respon e previously observed in conscious 
late-pregnant rats following central NPY (Brunton et al., 2006a).  
3.6.5.1. Discrepancy: Due to anaesthesia and surgery? 
As autonomic and neuroendocrine responses are influenced by surgery and 
anaesthetics, different results may be obtained when comparing studies in conscious and 
anesthetized animals (Watanabe et al., 2004). For example, electrical stimulation of the PVN 
produces excitatory responses in renal sympathetic n rve activity in unanaesthetized rats but 
not in anaesthetized rats (Kannan et al., 1989). Hence, the opposing results for the effects of 
i.c.v. NPY observed in conscious and anaesthetized lat -pregnant rats might be due to the 
effect of anaesthetic and the complex surgical procedure followed to expose the SON in the 
present study. 
Urethane preserves the physiological functioning of SON oxytocin neurones as it 
does not affect the milk ejection reflex (Leng and Dyball, 1991). However, intraperitoneal 
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injection of urethane results in the movement of water from the circulation into the 
peritoneal fluid resulting in plasma hyperosmolality (Van Der Meer et al., 1975). SON 
oxytocin neurones are osmosensitive (Mason, 1980) and hyperosmotic stimuli increase their 
activity (Leng et al., 2001). Although plasma osmolality is reduced during pregnancy 
(Brunton et al., 2008), urethane, and hence the hyperosmolality-induced increase in firing 
rate in anaesthetised pregnant rats might be the cause of lack of attenuation of oxytocin 
neurone activity upon central NPY.  
However, in a similar study of urethane anaesthetized virgin and late-pregnant rats, 
the electrophysiological response of the electrical activity of SON oxytocin neurones to 
systemic administration of IL-1β was attenuated in the pregnant rats (Brunton et al., 2006b). 
Lack of attenuation following NPY in the present study indicates that the immune challenge 
and orexigenic stimuli might be processed differently by the inputs to the oxytocin system. 
3.6.5.2. Discrepancy: Due to lack of feeding? 
The differences observed between conscious and anaesthetized rats in SON oxytocin 
neurone responses upon central administration of NPY could also be attributed to absence of 
food and water intake after central NPY and absence of food/consciousness-related sensory 
inputs as a result of anaesthesia. 
Following central administration of NPY, food and water intake significantly 
increased in conscious virgin and late pregnant rats (Brunton et al., 2006a). However, 
absence of availability of food and water in anaesth tized rats following NPY might alter the 
peripheral input signals to the oxytocin system. For example, the stimulatory effect of NPY 
on the HPA axis in rats with free access to food after NPY was stronger than the effect 
observed in rats that were fasted after NPY treatmen  (Hanson and Dallman, 1995). Fos 
expression in PVN and SON neurones after central NPY followed by food intake was much 
greater than that after NPY without food (Li et al., 1994). In addition, oropharyngeal 
stimulation during food intake and gastric distensio  during/after food intake activates, 
through vagal afferents, brainstem neurones (Rinama et al., 1998; Liu et al., 2004; 
Sabbatini et al., 2004; van de Wall et al., 2005; Huo et al., 2007) and the SON receives a 
substantial excitatory noradrenergic innervation from the brainstem (Alonso and 
Assenmacher, 1984). Absence of these peripheral feeding-related signals in anaesthetized 
rats might alter the oxytocin electrophysiological response. 
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3.6.5.3. Discrepancy: Due to lack of inputs? 
In addition, the SON oxytocin system is well connected to limbic structures 
(Oldfield et al., 1985; Oldfield and Silverman, 1985) and central oxytocin modulates social 
and feeding behaviours (Olszewski et al., 2007; Amico et al., 2008). Hence, lack of 
consciousness during anaesthesia resulting in diminished sensory inputs to the oxytocin 
system might also contribute to the differences in oxytocin neurone responses observed in 
conscious and anaesthetized animals. 
3.6.5.4. Discrepancy: Due to enhanced endogenous NPY activity? 
The number of neurones expressing NPY Y1R and the amount of Y1R within the 
magnocellular neurones are increased with hypertonic saline ingestion or water deprivation 
(Urban et al., 2006). In euhydrated animals, 30 and36% of oxytocin and vasopressin 
neurones, respectively, coexpressed Y1R whereas these values were increased to 52 and 
63%, respectively, in salt-loaded animals (Urban et al., 2006). Under normotensive 
conditions, the expression of NPY-ir within the magnocellular divisions of the hypothalamus 
is primarily within the fibres in the PVN and SON and there are few NPY-ir neurones within 
the magnocellular system (Urban et al., 2006). Subjecting animals to osmotic stressors, 
either water deprivation or replacing the drinking water with hypertonic saline, significantly 
increases NPY mRNA and peptide expression within the PVN and SON (Larsen et al., 
1992b; Larsen et al., 1993). In addition, haemorrhage increases NPY gene expression within 
the C1 and A1 groups in the medulla (Chan and Sawchenko, 1998). Hence, the NPY 
neurones projecting to, and within, the hypothalamus are activated under conditions of 
hyperosmolarity, haemorrhage or decreased blood pressu  (Urban et al., 2006). All these 
conditions prevail in the animal model used in thisstudy: urethane results in hyperosmolarity 
and the ventral transpharyngeal surgery to expose the SON results in a certain degree of 
haemorrhage and decreased blood pressure. This is again compounded by the lack of water 
intake under anaesthesia. These conditions of altered water homeostasis and increased 
endogenous NPY activity might also contribute to the unattenuated oxytocin neurone 
response observed in anaesthetized pregnant rats upon acute central NPY administration in 
this study.  
3.6.6. Systemic NPY-induced excitation of SON oxytocin neurones 
Systemic administration of NPY also increased the electrical activity of SON 
oxytocin neurones in this study. The mode of action of peripheral NPY on oxytocin neurones 
is not known; however, NPY can enter the brain by diffusion across the blood-brain barrier 
(Kastin and Akerstrom, 1999).  
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3.6.7. Regulation of physiological processes by systemic NPY and oxytocin 
1. Stress: Stressors increase peripheral NPY levels (Krukoff et al., 1999). In 
addition, NPY is co-released at sympathetic nerve terminals along with NA during 
sympathetic activation (Donoso et al., 1997). Hence, physiologically, peripheral stress-
induced NPY release might potentiate oxytocin secretion during the stress response.  
2. Adiposity: Chronic increase in peripheral levels of NPY results in adiposity (Kuo 
et al., 2007), on the contrary, oxytocin negatively modulates adipogenesis (Elabd et al., 
2008). Hence, peripheral oxytocin might be important to neutralise the adipogenic effect of 
peripheral NPY to ensure constancy of body weight even during adverse stressful conditions.  
3. Cardiovascular regulation: Peripheral NPY and oxytocin are also opposite in their 
effects in cardiovascular regulation. Peripheral oxyt cin results in a dose-related biphasic 
change in mean arterial pressure which consists of an initial pressor effect accompanied by 
bradycardia and a decrease in cardiac output, followed by a more prolonged fall in mean 
arterial pressure accompanied by an increase in cardiac output (Petty et al., 1985). Overall, 
oxytocin causes a long-term decrease of blood pressu  in rats (Petersson et al., 1996). On 
the other hand, NPY has a vasopressor effect by direct vasoconstriction of blood vessels and 
by potentiating NA-evoked responses (Grundemar and Hakanson, 1993). Hence, oxytocin 
release might be essential to neutralise or reduce vasopressor effects of NPY during stress or 
sympathetic activation. It is noteworthy that oxytocin is capable of inducing the release of 
ANP from the heart (Haanwinckel et al., 1995; Gutkowska et al., 1997) which exerts a 
relaxing effect on vasculature and antagonizes the contractions induced by norepinephrine 
(Waeber et al., 1990). These effects of ANP are also opposite to the effects of NPY on the 
vasculature (Grundemar and Hakanson, 1993). The opposing roles of these peptides may 
have important implications in cardiovascular physiology. 
4. Natriuresis: Peripheral oxytocin is natriuretic either directly or indirectly through 
ANP (Conrad et al., 1993; Haanwinckel et al., 1995). Similarly, peripheral NPY is also 
natriuretic (Allen et al., 1985; Bischoff et al., 1996; Bischoff et al., 1998a, b; Bischoff and 
Michel, 1998). In addition, NPY significantly increases plasma ANP in a dose-related 
manner in normally-hydrated rats as well as in water-loaded rats, indicating that an increase 
of ANP release may be responsible for NPY-induced natriuresis (Baranowska et al., 1987). 
Hence, peripheral NPY and oxytocin interaction might also be important for water and 
electrolyte homeostasis.  
3.6.8. NPY-induced changes in the electrical activity of SON vasopressin neurones 
Central NPY did not have much effect on the activity of SON vasopressin neurones 
in this study. Injection of NPY into the SON increas d the firing rate of SON vasopressin 
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neurones (Khanna et al., 1993). A conclusive result might have been obtained had the 
response to central NPY been studied in more vasopre sin neurones. However, the responses 
of vasopressin neurones to various stimuli, such as secretin, CCK and leptin, have always 
been mixed with a percentage of neurones being excited or inhibited and some other not 
responding (See secretin/CCK/leptin chapters). 
Systemic administration of NPY inhibited the three SON vasopressin neurones 
tested. Systemic NPY is a vasoconstrictor through its postsynaptic activation of NA receptor 
mechanisms in the sympathetic nerve terminals (Lundberg et al., 1990). Hence, the acute 
inhibition of vasopressin neurones could be possibly due to increase in the blood pressure 
following NPY-induced vasoconstriction. As vasopressin is also a vasoconstrictor, inhibition 
of vasopressin neuronal activation by systemic NPY could possibly be a feedback 
mechanism preventing excessive vasoconstriction.  
As NPY rapidly diffuses across the blood-brain barrier, systemic NPY might also 
alter the electrical activity of SON vasopressin neurones either by direct action on the NPY 
receptors in the neurones or indirectly via presynaptic regulation of NA release on to the 
SON. Direct application of NPY onto the SON in pentobarbitone-anaesthetized male rats 
showed that NPY acts on Y1R to excite vasopressin neurones, but can also act on the 
presynaptic Y2R to depress A1 to vasopressin neurone synaptic transmission (Khanna et al., 
1993). The inhibitory effect of systemic NPY on vasopressin neurones observed in this study 
suggests the second possibility.  
3.7. Conclusion 
Centrally administered NPY increases the electrical activity of SON oxytocin 
neurones in urethane-anaesthetized virgin rats, with similar effects in late pregnant rats. 
These findings contrast with studies in conscious rat in which i.c.v NPY activated oxytocin 
neurones in virgin, but not late pregnant rats. Systemic administration of NPY also increased 
the firing rate of SON oxytocin neurones in virgin rats (pregnant rats were not tested). 
Oxytocin neurone excitation induced by NPY may be rel vant during stress responses. In 
addition, it is likely that peripheral/central NPY and oxytocin interact with each other to 
regulate complex physiological processes such as appetite, stress regulation, anxiety, 





Leptin, synthesised in adipose tissue, is a centrally-acting anorexigenic hormone. 
Leptin acts in the hypothalamus to reduce food intake nd increase energy expenditure 
(Campfield et al., 1995; Pelleymounter et al., 1995).  
Most supraoptic nucleus (SON) neurones are strongly immunoreactive for short and 
long isoforms of leptin receptor (Hakansson et al., 1998). Oxytocin and vasopressin mRNA 
expression in the PVN were down-regulated by 48h fasting in mice and were restored by 
leptin (Tung et al., 2008). The effect of bath application of leptin was predominantly 
inhibitory on SON neurones in vitro (Honda et al., 2002) and intracerebroventricular (i.c.v) 
administration of leptin did not induce STAT3 activation in the SON in rats (Hubschle et al., 
2001) and did not induce Fos expression in the mPVN and SON (Yokosuka et al., 1998).  
Systemic leptin administration increases Fos expression in the pPVN, but not in 
oxytocin neurones (Elias et al., 2000). Systemic leptin did not induce pSTAT3 or Fos (Celine 
Caquineau, personal communication) but increases nuclear STAT5 in the SON (Mutze et al., 
2007). As the activation of STAT pathway by leptin may indicate either excitation or 
inhibition of SON neurones, it is not clear whether systemic leptin excites or inhibits the 
electrical activity of SON oxytocin and vasopressin neurones in vivo. However, leptin, a 
long-term satiety signal, may not have an immediate effect on SON neurones. 
Pregnant females do not show suppression of food intake in response to exogenous 
leptin (Mounzih et al., 1998; Johnstone and Higuchi, 2001; Ladyman and Grattan, 2004; 
Lecklin et al., 2005). Moreover, an increase in plasm  leptin levels was observed especially 
during the latter half of pregnancy, when maternal and food consumption markedly increased 
(Kawai et al., 1997). This paradoxical increase in leptin suggests that pregnancy is a 
physiological state of leptin resistance. As oxytocin neurone responses to various stimuli are 
attenuated during pregnancy (Douglas et al., 2007), it was hypothesized that leptin-induced 
effects on SON oxytocin neurones are suppressed in pregnant rats (Fig. 4.1). However, it is 
not known whether the leptin-induced effects in SON oxytocin neurones are modified by 
pregnancy, which might contribute to resistance to an rectic effects of leptin.    
Fasting reduces circulating leptin concentration (Maffei et al., 1995). Fasting for 24h 
decreases plasma leptin level significantly in both pregnant and non-pregnant rats (Ladyman 
and Grattan, 2004) and fasting for 3 days significantly decreases leptin transport across the 
blood-brain barrier in mice (Kastin and Akerstrom, 2000). It may be hypothesized that 
leptin-induced excitatory effects will be more pronou ced after fasting as fasting-induced 
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reduction in endogenous levels of leptin will increas  hypothalamic sensitivity to exogenous 
leptin. On the other hand, fasting may reduce the activity of SON neurones, so that 
natriuresis could be avoided by reducing peripheral release of oxytocin to any stimuli 
including leptin as fasting reduces sodium and water intake. In addition, if increased firing 
rate of SON oxytocin neurones in unfasted rats in response to leptin infusion leads to central 
release of oxytocin, this is expected to reduce food intake and salt appetite in rats fed a  
libitum (Blackburn et al., 1993). In fasted rats, suppressed central release of oxytocin in 
response to leptin is expected to permit increased ppetite.  
4.2. Hypothesis 
1. Systemic leptin, a long-term satiety signal, does not affect the electrical activity of 
SON oxytocin and vasopressin neurones in virgin rats.  
2. SON oxytocin neurones are resistant to the effects of ystemic leptin during late 
pregnancy.  
3. Leptin-induced effects in the SON oxytocin neurones are either positively (due to 
increased sensitivity) or negatively (to prevent nariuresis) altered by fasting in 
virgin and late-pregnant rats.  
4. Leptin-induced changes in the electrical activity of SON oxytocin neurones in fasted 
rats are dose dependent. 
4.2.1. Objectives  
1. To study the electrophysiological responses of SON oxytocin neurones to systemic 
administration of leptin in vivo in unfasted/fasted virgin/pregnant rats. 
2. To study whether leptin-induced changes in electrical activity of SON oxytocin 
neurones in fasted rats are dose dependent. 
3. To study the electrophysiological responses of SON vasopressin neurones to 
systemic administration of leptin vivo. 
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4.3. Background 
4.3.1. Leptin and its receptors 
Leptin is a hormone derived from adipose tissue that primarily acts in the 
hypothalamus to control body fat levels by regulating appetite and energy metabolism 
(Campfield et al., 1995; Halaas et al., 1995; Pelleymounter et al., 1995). Leptin secretion 
correlates with the amount of fat in the body, therefore the circulating level of leptin 
indicates the current body fat store (Maffei et al., 1995; Considine et al., 1996). Plasma 
leptin concentration follows a circadian rhythm. In rats, it rises to maximal values during the 
night after they start eating (Merino et al., 2008).  
Leptin mediates its effects through its receptors. Five leptin receptor subtypes (Ob-
Ra to Ob-Re) have been identified (Lee et al., 1996; Fei et al., 1997; Leibel et al., 1997; 
Friedman, 1998). Ob-Ra, a predominant short form of leptin receptor is capable of leptin-
mediated signalling but much less effectively than the full-length receptor, Ob-Rb 
(Murakami et al., 1997). Short forms of leptin receptors could function as specific transport 
systems for leptin, as they are present in high amounts in the choroid plexus and brain 
microvessels (Tartaglia et al., 1995; Lee et al., 1996; Guan et al., 1997; Bjorbaek et al., 
1998). The long form, Ob-Rb, is the functional receptor through which leptin mediates its 
effects and is widely distributed in the brain including the ARC, VMH, PVN, DMH, SON, 
lateral POA, mPOA and SCN (Hakansson et al., 1996; Mercer et al., 1996; Fei et al., 1997; 
Zamorano et al., 1997; Bjorbaek et al., 1998; Elmquist et al., 1998; Mercer et al., 1998; 
Shioda et al., 1998; Yarnell et al., 1998). The secretory form, Ob-Re, which is spliced in 
ahead of the transmembrane domain, might be a soluble binding protein for leptin (Lee et al., 
1996). The other short forms could behave as functio al antagonists by sequestering leptin 
and preventing its binding to the Ob-Rb subtype (White et al., 1997). Plasma leptin crosses 
the blood-brain barrier via a receptor mediated transport system (Banks et al., 1996; Golden 
et al., 1997; Hileman et al., 2002). 
4.3.2. Leptin action in hypothalamus 
 The binding of leptin to its receptor results in a rapid activation of intracellular 
JAK2. JAK2 tyrosine phosphorylates STAT3 proteins. pSTAT3 then dissociates and forms 
dimers in the cytoplasm, finally translocating to the nucleus to regulate gene transcription. 
STAT3 activation is likely a crucial component in regulation of body weight by leptin 
(Bjorbaek and Kahn, 2004). Studying pSTAT3 activation to monitor leptin-induced effects is 
more appropriate than Fos studies because Fos immunoreactivity colocalizes only in a subset 
of all leptin-responsive STAT3 nuclei (Hubschle et al., 2001). However, Fos almost always 
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indicates neuronal excitation [there are exceptions; (Sabatier et al., 2003a)] while pSTAT3 
activation indicates either leptin-induced excitation or inhibition (Hubschle et al., 2001). 
Systemic leptin induces Fos expression in the hypothalamus (Woods and Stock, 
1996; Elmquist et al., 1997) including in the PVN, DMH, VMH and ARC (Elias et al., 
2000). In the ARC, leptin-induced Fos is expressed in CART, dynorphin and neurotensin 
expressing neurones, while in the VMH Fos is seen in dynorphin neurones. Fos and Ob-Rb 
mRNA double-labelled neurones are found in the ARC, VMH and DMH (Elias et al., 2000). 
Leptin decreases food intake more potently when microinjected directly into the 
ARC and hence the ARC is a primary hypothalamic site of the satiety effect of leptin (Satoh 
et al., 1997a). About 40% of ARC neurones in Wistar rats are inhibited by bath application 
of leptin at 10-8 to 10-6 M (Rauch et al., 2000). Leptin decreased input resistance and 
inhibited evoked excitatory postsynaptic currents in ARC neurones (Glaum et al., 1996). 
Bath application of 10-10 M leptin inhibited about 60% and excited only 4% of the 
ventromedial ARC (vmARC) neurones where leptin receptors are co-localized with NPY 
(Nagamori et al., 2003). On direct bath application of 10-11 – 10-10 M leptin, glucose sensitive 
neurones of the ARC showed a marked dose-dependent decrease in activity after long 
latency (Shiraishi et al., 1999). In contrast, leptin increases the frequency of action potentials 
in the anorexigenic POMC neurones (Cowley et al., 2001). 
The satiety effect of leptin is also mediated via the VMH (Satoh et al., 1997b). 
VMH-lesioned rats overproduce leptin but cannot respond to it (Satoh et al., 1997b). 
Glucose-receptive neurones in the VMH were hyperpolarized by bath application of leptin 
(4-50nM) through activation of ATP-sensitive potassium channels (Spanswick et al., 1997). 
However, in an in-vivo study, microiontophoretic administration of leptin i creased the 
activity of glucose responsive and non-glucose respon ive neurones in the VMH (Shiraishi et 
al., 2000).  
4.3.3. Effect of leptin on HPA axis 
Levels of AVP mRNA in the PVN and the SON are increas d by i.c.v. leptin 
(Yamamoto et al., 1999). I.c.v. leptin (100 pmol/rat) induces significant increases in the 
expression of CRH mRNA in the PVN and POMC mRNA in the pituitary and also increases 
plasma ACTH and corticosterone levels dose-dependently (peak occurred at 15 min) 
(Morimoto et al., 2000). This activation of the HPA axis was attenuated by i.c.v. 
pretreatment with a V1a or V1a/1b receptor antagonist but not with a V2 receptor antagonist. 
Hence, central leptin activates the HPA axis through AVP which in turn activates CRH 
neurones to drive ACTH and corticosterone (Morimoto et al., 2000). 
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4.3.4. Effect of leptin on magnocellular oxytocin and vasopressin neurones 
Intracerebroventricular leptin treatment induces a time-dependent nuclear 
translocation of STAT3 immunoreactivity in hypothalamic nuclei, with strong nuclear 
STAT3 signals detectable in the ARC, LH and DMH, and less strong STAT3 
immunoreactivity in the DHA, LHA, PHA, mPOA, vmPOA, PVN and SCN, but none in the 
SON (Hubschle et al., 2001). Central leptin administration increases AVP mRNA levels in 
the SON increases plasma AVP concentration in a dose- ependent manner (Yamamoto et 
al., 1999). The maximal effect is seen 15min after th  administration of leptin (Yamamoto et 
al., 1999). However, i.c.v. leptin had no effects on plasma oxytocin secretion and gene 
expression in the SON (Yamamoto et al., 1999) and did not increase Fos expression in SON 
oxytocin neurones (Blevins et al., 2004). Central leptin administration increases the 
percentage of oxytocin neurones that show Fos activation in the pPVN, although the actual 
numbers are relatively small (Blevins et al., 2004). Interestingly, oxytocin receptor 
antagonist administered i.c.v. to 6h fasted rats 30-45min before i.c.v. leptin prevented leptin-
induced attenuation of cumulative food intake (Blevins et al., 2004). Recently, it has been 
found that oxytocin and vasopressin mRNA expression were down-regulated during 24h 
fasting in mice and were restored by leptin administration (Tung et al., 2008). 
Systemic leptin administration increases Fos expression in the pPVN, but not in 
oxytocin neurones (Elias et al., 2000). Systemic leptin did not induce pSTAT3 or Fos in the 
SON (Celine Caquineau, personal communication). However, systemic leptin treatment 
increases nuclear STAT5 in the SON (Mutze et al., 2007). STAT5 activation is seen only 
after a prolonged time interval (120-150min after lptin). Hence, leptin might induce the 
formation or release of a secondary mediator in the brain, which in turn, could account for 
nuclear STAT5 activation (Mutze et al., 2007). As SON neurones express leptin receptors 
(Hakansson et al., 1998) and systemic leptin activates vagal afferents (Wang et al., 1997) and 
brainstem neurones (Grill et al., 2002), it is possible that leptin either acts directly or 
indirectly on the SON neurones. As the activation of STAT5 does not indicate whether the 
neurones are excited or inhibited by leptin, electrophysiological studies become very 
important to determine the effects of leptin administration.  
In an in vitro study, bath application of leptin (10-8 – 10-12 M) induces mainly 
inhibitory response in SON neurones of Wistar rats, lthough a minority showed excitation 
(Honda et al., 2002). Tolbutamide (a K+ channel blocker) did not reverse the inhibitory 
actions of leptin in the SON indicating that this effect is not by activation of ATP-sensitive 
K+ channels (Honda et al., 2002). The inhibitory effect persisted with blockade of synaptic 
transmission by the perfusion of low Ca2+ and high Mg2+ medium, indicating that the 
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inhibitory effect of leptin on SON neurones is due to its direct action (Honda et al., 2002). 
However, the effect of leptin in vivo and the effect when leptin is administered via the 
systemic route on SON neurones, which is physiological, are not known. 
4.3.5. Leptin action on the brainstem 
Leptin receptor mRNA has been localized in rat brainstem (Elmquist et al., 1998; 
Mercer et al., 1998). Leptin receptor immunoreactivity colocalizes with TH (Tyrosine 
hydroxylase) and serotonin in the NTS and raphe nuclei (Hay-Schmidt et al., 2001). 
Systemic leptin induces Fos in the superior lateral and external lateral subdivisions of the 
parabrachial nucleus and the NTS of the brainstem (Elias et al., 2000), and STAT3 
phosphorylation in the dorsal motor nucleus of the vagus nerve (DMNV), lateral 
parabrachial nucleus (PBel) and the NTS of the brainstem increases 30min after leptin 
administration (5 mg/kg; i.v.) (Hosoi et al., 2002b). These findings indicate that circulating 
leptin may directly act in the brainstem to elicit physiological responses, or that leptin 
administration might activate a neurotransmitter system that subsequently activates STAT3 
signaling system in the brainstem (Hosoi et al., 2002b). On the contrary, although Ob-Rb 
leptin receptor expression was found in the AP  region (Mercer et al., 1998), leptin-induced 
pSTAT3 immunoreactivity was not detected in that nucle s (Hosoi et al., 2002b). Hence the 
brain regions where Ob-Rb receptors exist do not always respond to physiologically 
circulating leptin (Hosoi et al., 2002a). 
Leptin receptor is expressed in a variety of peripheral tissues (Tartaglia et al., 1995; 
Takaya et al., 1996). Leptin receptor is expressed in the vagas nerve (Buyse et al., 2001) and 
leptin has been shown to activate vagal afferent nerves (Wang et al., 1997; Yuan et al., 
1999). Leptin-induced reduction in food intake is not abolished by vagotomy in rats and 
hence vagal afferents do not constitute a major route for mediating the regulatory effect of 
leptin on food intake, over a period of several hours (Sachot et al., 2007). 
4.3.6. Leptin during fasting 
Fasting reduces circulating leptin concentration (Maffei et al., 1995). With 3d of 
fasting in rats, leptin mRNA in fat fell dramatically; fasting levels of leptin mRNA were 
reduced to 12% of fed control levels (Frederich et al., 1995). Depriving male mice of food 
for 48h caused a 16% fall in weight and reduced circulating leptin from 3.87 ± 0.35 to 1.5 ± 
0.11 ng/ml (Ahima et al., 1996). A 24h fast decreased plasma leptin significantly in both 
pregnant and non-pregnant rats compared with pre-fasting levels (Ladyman and Grattan, 
2004). Leptin levels fall rapidly with the onset of starvation, disproportionate to changes in 
adipose tissue mass (Ahima et al., 1996). Fasting for 48h reduces SOCS3 mRNA in ARC 
and DMH compared to fed rats (Baskin et al., 2000). Fasting (for 3d) induced reduction in 
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circulating levels of leptin increases NPY and AgRP expression and decreases POMC and 
CART expression in the ARC, and decreases TRH mRNA in the PVN (Fekete et al., 2006). 
Central leptin administration reverses these changes (F kete et al., 2006).  
Starvation markedly activates the HPA axis (Chowers t al., 1969). Leptin 
administration in mice blunted the fasting-mediated surge in plasma ACTH and 
corticosterone (Ahima et al., 1996). In hypothalamic perifusion studies, hypoglycaemic 
stimulus-induced CRH release was inhibited by leptin in a dose-dependent manner (Heiman 
et al., 1997). Leptin does not directly alter pituitary release of ACTH (Heiman et al., 1997). 
Hence, this attenuation of the stress induced HPA axis response by leptin is exerted at the 
hypothalamic level to inhibit CRH release (Heiman et al., 1997). 
4.3.7. Leptin resistance during pregnancy 
4.3.7.1. Gestational profile of leptin 
Pregnancy is a hypermetabolic state associated with a great increase in maternal 
body fat and weight. Positive energy balance is maintained during pregnancy by increase in 
food intake to prevent the depletion of maternal energy sources (Richard and Trayhurn, 
1985). During pregnancy, despite the presence of elevated plasma leptin, food intake 
increases by up to 50% in rats (Cripps and Williams, 1975; Shirley, 1984; Ladyman and 
Grattan, 2004). Hence, pregnancy, a state of physiological hyperphagia, is an example of 
transient leptin resistance (Augustine et al., 2008). 
Abdominal fat mass increases during pregnancy and is significantly higher than non-
pregnant levels on day 14 to 21 of pregnancy (Ladyman and Grattan, 2004). Total abdominal 
fat mass on day 21 of pregnancy is almost double the amount in non-pregnant rats (Ladyman 
and Grattan, 2004). Leptin content in adipose tissue  also increases during pregnancy 
compared with the non-pregnant state. It sharply declines to less than non-pregnant levels on 
day 21 (Kawai et al., 1997). An increase in leptin mRNA in fat was observed as pregnancy 
advances (Kawai et al., 1997; Garcia et al., 2000). Therefore, the rise in plasma leptin levels 
during pregnancy results not only from increase in fat mass but also from increased gene 
expression and protein production of leptin in adipose tissues (Kawai et al., 1997). 
 Whether the placenta is a source of leptin during pregnancy in rodents is 
controversial. It has been reported that placental (on day 12 and 19) and decidual (on day 12) 
tissues obtained from pregnant rats do not show any leptin mRNA expression (Kawai et al., 
1997). Similar observations in placenta have been rported (Gavrilova et al., 1997). On the 
contrary, an increase in leptin mRNA level in rat placenta has been observed as pregnancy 
advances (Garcia et al., 2000). Also, placental leptin receptor expression, Ob-Rb in 
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particular, increases during pregnancy (Chien et al., 1997; Kawai et al., 1997; 
Szczepankiewicz et al., 2006).  
4.3.7.2. Mechanisms of leptin resistance 
 Central leptin resistance may involve several mechanisms (Augustine et al., 2008) as 
described below.   
4.3.7.2.1. Resistance – by receptor gene down regulation 
 Seeber et al reported that hypothalamic Ob-Rb mRNA expression is elevated in 
early pregnancy (Day 7) in rats but returned to pre-pregnancy levels by mid-gestation and 
remained thereafter (Seeber et al., 2002). Hence, changes in the absolute levels of Ob-Rb 
mRNA expression do not account for leptin resistance during pregnancy, but the increase in 
hypothalamic Ob-Rb in early pregnancy could potentially reset the sensitivity of the 
hypothalamus to leptin, such that the subsequent decline in Ob-Rb expression could 
contribute to leptin resistance (Seeber et al., 2002). 
Hypothalamic Ob-Rb mRNA levels have been found to be significantly lower in 
pregnant (day 18) than in nonpregnant rats, but no changes were found in the content of the 
mRNAs encoding short forms of the leptin receptor (Ob-Ra, Ob-Rc, Ob-Re and Ob-Rf) 
(Garcia et al., 2000). These authors opined that this specific down regulation of the Ob-Rb at 
the hypothalamic level would explain, at least partially, the state of leptin resistance during 
pregnancy. Ob-Rb mRNA levels in the VMH decrease during pregnancy while they 
remained relatively constant in the ARC (Ladyman and Grattan, 2005). Thus, leptin 
resistance occurs at the hypothalamic level with a region-specific loss of hypothalamic Ob-R 
mRNA (Ladyman and Grattan, 2005). 
4.3.7.2.2. Resistance – by reduced leptin transport across BBB 
In contrast to the lack of change in pregnancy of the mRNA expression of short 
forms of the leptin receptors in the hypothalamus repo ted by Garcia et al (Garcia et al., 
2000), Szczepankiewicz et al reported that both long and short forms of leptin receptor 
mRNA expression significantly decreased in the hypothalamus during pregnancy 
(Szczepankiewicz et al., 2006). The decrease in short forms of the receptors might mean that 
less amount of leptin cross the blood-brain barrier during pregnancy contributing to leptin 
resistance (Szczepankiewicz et al., 2006).  
4.3.7.2.3. Resistance – by increase in plasma leptin binding activity 
 The increase in plasma leptin level during pregnancy could possibly be due to 
gradual and marked increase in plasma leptin-binding activity between dioestrus and late 
pregnancy (Seeber et al., 2002). The placenta produces large amounts of the OB-Re isoform 
of leptin receptor mRNA, which encodes a soluble binding protein  (Gavrilova et al., 1997). 
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Plasma binding proteins are thought to restrict exiof leptin into extravascular tissues, thus 
reducing the metabolic clearance rate of leptin (Cumin et al., 1997a, b) and its access to 
target cells (Huang et al., 2001). Hence, the presence of leptin-binding proteins in the plasma 
during pregnancy may impair leptin action by restricting leptin access to the brain 
(Augustine et al., 2008). 
4.3.7.2.4. Resistance – by alteration in leptin receptor signaling 
In the ARC, NPY mRNA level is either unchanged (Rocha et al., 2003) or increased 
during pregnancy (Garcia et al., 2003) and levels of POMC mRNA also remain unchanged 
(Garcia et al., 2003; Rocha et al., 2003) or increased (Douglas et al., 2002). Similarly, ARC 
AgRP mRNA level is either unchanged (Ladyman, unpublished results; as cited in Augustine 
et al., 2008) or increased (Rocha et al., 2003) during prenancy. Either no change or elevated 
NPY and AgRP mRNA in the face of elevated leptin during pregnancy is further evidence 
for leptin resistance at the level of the ARC (Augustine et al., 2008). Though the overall 
level of pSTAT3 activation in the ARC after leptin administration in pregnant rats is reduced 
(Ladyman and Grattan, 2004), the number of leptin-responsive cells, measured by leptin-
induced phosphorylation of STAT3 is not altered in the ARC in pregnant rats (Ladyman and 
Grattan, 2005). Hence, some signalling pathways other than those involving pSTAT3 might 
be altered during pregnancy (Augustine et al., 2008). Indeed, leptin action on NPY and 
AgRP neurones may be independent of STAT3 (Bates et al., 2003). 
4.3.7.2.5. Resistance – induced by hormonal mechanisms 
(1) By leptin 
 Chronic high leptin level has been shown to induce leptin resistance (Sahu, 2002), 
and prolonged infusions of high levels of leptin for more than 14d are required to induce 
resistance (Sahu, 2002; Zhang and Scarpace, 2006). However, nonpregnant ob/ob mice 
(genetically lacking leptin) can be treated with leptin for up to 6 months with no observed 
resistance to leptin, whereas pregnant ob/ob mice treated with leptin throughout pregnancy 
become leptin resistant at mid-pregnancy (Mounzih et al., 1998). In addition, levels of leptin 
rise slowly during pregnancy and are only elevated 2-3 fold for a few days prior to 
development of leptin resistance (Ladyman and Grattan, 2004). Hence, from these lines of 
evidence it is unlikely that leptin resistance during pregnancy is leptin-induced (Augustine et 
al., 2008). 
(2) By 17β-oestradiol 
 17β-Oestradiol is anorectic as it reduces meal size (Eckel and Geary, 2001; Asarian 
and Geary, 2002) and increases energy utilization (Wade and Gray, 1979). It increases leptin 
 74 
sensitivity in the brain (Clegg et al., 2006). Henc, low 17β-oestradiol levels during 
pregnancy might reduce leptin responsiveness (Augustine et al., 2008). 
(3) By progesterone 
  Administration of progesterone and its metabolites increases food intake in rats 
(Hervey and Hervey, 1967; Wade and Gray, 1979; Chen et al., 1996). Progesterone treated 
rats show increased food intake and body weight but maintain normal plasma and CSF leptin 
levels (Grueso et al., 2001), which indicates that progesterone might inhibit CNS actions of 
leptin (Augustine et al., 2008).  
(4) By prolactin and placental lactogen 
 Prolactin receptors are expressed in the hypothalamic regions containing orexigenic 
neurones (Augustine et al., 2003; Kokay and Grattan, 2005). Prolactin infusion induces 
hyperphagia in a dose-dependent manner in virgin rats (Gerardo-Gettens et al., 1989; Sauve 
and Woodside, 1996). This was found to be a central effect with direct actions of prolactin in 
the hypothalamus (Sauve and Woodside, 1996). During pre nancy, levels of prolactin and its 
closely related hormone, placental lactogen, are elevated (Grattan, 2001), which might 
contribute to pregnancy induced hyperphagia (Augustine et al., 2008). Leptin resistance 
develops between day 7 and 14 of pregnancy coincidet with the development of the 
placenta and the onset of secretion of placental lactogen (Ladyman and Grattan, 2004). Early 
pregnant and pseudopregnant rats show pulsatile proactin secretion and hyperphagia, but 
continue to have a relatively small response to leptin (Ladyman and Grattan, 2004; 
Augustine and Grattan, 2008). In contrast, during the second half of pregnancy, when 
placental lactogen production is chronically elevatd, animals show a loss of response to 
leptin (Ladyman and Grattan, 2004). Augustine and Grattan (2007) induced leptin resistance 
in pseudopregnant rats by giving chronic i.c.v. prolactin infusions to mimic the pattern of 
placental lactogen secretion during the second half of pregnancy. Hence, chronically high 
lactogen levels, secreted by the placenta during the second half of pregnancy may be 
responsible for central leptin resistance and hyperphagia possibly through DMH NPY 
neurones that possess prolactin receptors (Ladyman and Grattan, 2004; Augustine and 
Grattan, 2008).  
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4.4. Methods 
4.4.1. Experiment: Effect of systemic administration of leptin on the electrical activity 
of SON oxytocin and vasopressin neurones in urethane-anaesthetised fasted/unfasted 
virgin/pregnant rats. 
Urethane-anaesthetized virgin and pregnant (19-20d of pregnancy) rats were fixed 
with an i.v. cannula on the day of the experiment. The SON and neural stalk were exposed 
via the ventral transpharyngeal surgery. After identifyi g SON neurones, oxytocin neurones 
were differentiated from vasopressin neurones. After an initial basal recording of firing rate 
in SON oxytocin neurones for 10min, leptin was administered i.v. in 100µl normal saline 
and the response was recorded. Both unfasted virgin and pregnant groups were treated with a 
same dose of leptin (100µg) irrespective of the body weight. Fasted virgin and pregnant rats 
were treated with 1µg, 10µg, 100µg or 1mg leptin to study the dose response. Vasopressin 
neurones were studied only with 100µg dose of leptin. The groups studied are: 
 For oxytocin neurones: 
o Unfasted Virgin: n = 23 (100µg) 
o Unfasted Pregnant: n = 5 (100µg) 
o Fasted Virgin:  
 1µg leptin: n = 6  
 10µg leptin: n = 6  
 100µg leptin: n = 8  
o Fasted Pregnant:  
 1µg leptin: n = 3  
 10µg leptin: n = 6  
 100µg leptin: n = 8  
 1mg leptin: n = 6 
 For vasopressin neurones: 
o Phasic: n = 8 (100µg) 
o Non-phasic: n = 13 (100µg) 
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4.5. Results 
4.5.1. Body weight 
The pregnant rats had significantly higher body weight than the virgin rats whether 
they were fasted or unfasted while fasting did not alter the body weight significantly both in 
virgin and pregnant rats (Fig. 4.2).  
4.5.2. SON oxytocin neurone basal firing rates 
The basal firing rate of SON oxytocin neurones in unfasted pregnant rats was 
significantly higher than that of unfasted virgin rats (Fig. 4.3). The basal rates did not differ 
significantly between other groups.  
4.5.3. Effect of systemic leptin administration on electrical activity of SON oxytocin 
neurones in fasted/unfasted virgin and pregnant rats 
4.5.3.1. Unfasted virgin rats (n=23): 
Leptin administration (100µg; i.v) excited 16/23 SON oxytocin neurones (e.g. Fig. 
4.4), inhibited 4/23 neurones and had no effect on 3/23 neurones. On average, the basal rate 
of 3.4 ± 0.4 spikes/s was increased by 0.4 ± 0.08 spike /s 1.5min after leptin injection (n=23, 
Fig. 4.5). The rate returned to basal firing rate by 10min. The mean firing rate during 0-
10min after leptin was significantly higher than during the basal period (P=0.01, paired t-
test). The incidence of a spike occurring within 0-0.5s after a spike was significantly 
increased 0-10min after leptin compared to that during the basal 10min period (P=0.004, 
paired t-test, Fig. 4.6a). The descending slopes of the histograms fit well with exponential 
curves which is a characteristic of oxytocin neurones (Fig. 4.6b). There was no change in the 
shape of the hazard plot (Fig. 4.7) or in the ratio of peak early (<0.07s) to mean late (0.2-
0.3s) hazard before and after leptin injection (Fig. 4.8).  
4.5.3.2. Unfasted virgin rats (n=23) vs.unfasted pregnant rats (n=5): 
Leptin excited all five SON oxytocin neurones tested in unfasted pregnant rats (e.g. 
Fig. 4.9); this compares with excitation of 16/23 SON oxytocin neurones in unfasted virgin 
rats. The basal rate of 3.4 ± 0.4 spikes/s was increased by 0.4 ± 0.08 spikes/s at 1.5min after 
leptin in unfasted virgin rats while the basal rate of 6.65 ± 0.4 spikes/s was increased by 0.8 
± 0.2 spikes/s at 17min after leptin in unfasted pregnant rats. The rates returned to basal by 
10min in unfasted virgin rats and by 30min in unfasted pregnant rats. Overall, the effect of 
leptin was greater and more prolonged in unfasted late pregnant rats than in unfasted virgin 
rats (Fig. 4.10).  
4.5.3.3. Fasted virgin rats (n=8) vs.fasted pregnant rats (n=8): 
In fasted virgin rats, 5/8 SON oxytocin neurones were xcited, 2/8 were inhibited 
and 1/8 did not respond. In fasted pregnant rats, 2/8 neurones were excited, 2/8 were 
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inhibited and 4/8 did not respond. In fasted virgin rats, overall, the basal rate of 4.45 ± 0.75 
spikes/s was increased by 1 ± 0.5 spikes/s, on average, 25.5min after leptin and it returned to 
basal by 1h (Fig. 4.11a and 4.11b). This apparent increase (including cells that were excited, 
inhibited or not affected) during the entire period of observation after leptin injection was not 
statistically significant compared to the average basal rate. However, the excitation observed 
0-10min after leptin was nearly significant (P=0.051, paired t-test; Fig. 4.11a and 4.11b). 
In fasted pregnant rats, the basal rate was 4.6 ± 0. 5 spikes/s and, on average, there 
was no change in the firing rate after leptin treatment compared to the basal rate. The 
response after leptin did not differ significantly between fasted virgin and pregnant rats (Fig. 
4.11a and 4.11b). Hence, the excitation of SON oxytocin neurones by i.v. leptin in fasted 
virgins was evidently increased by fasting (see below and Fig.  4.12a and 4.12b). In contrast, 
the excitatory response of SON oxytocin neurones to i.v. leptin in late pregnant rats was 
reduced by fasting, and essentially suppressed (see below and Fig. 4.13).  
4.5.3.4. Unfasted virgin rats (n=23) vs.fasted virgin rats (n=8): 
In unfasted virgin rats 70% of SON oxytocin neurones were excited (16/23 excited, 
4/23 inhibited and 3/23 did not respond) and in fasted virgin rats 62.5% of oxytocin neurones 
were excited (5/8 excited, 2/8 inhibited and 1/8 did not respond). The basal rate of 3.4 ± 0.4 
spikes/s was increased by 0.4 ± 0.08 spikes/s by 1.5min after leptin in unfasted virgin rats 
while the basal rate of 4.45 ± 0.75 spikes/s was increased by 1 ± 0.5 spikes/s 25.5min after 
leptin in fasted virgin rats (Fig. 4.12a, b). The rates returned to basal firing rate by 10min and 
1h in unfasted and fasted virgin rats, respectively. In unfasted virgin rats, the mean change in 
firing rate 0-10min after leptin was significantly higher than basal (P=0.01, paired t-test) 
while in fasted virgin rats, the excitation was nearly significant (basal vs. 0-10min after 
leptin: P=0.051; basal vs. 20-30min after leptin: P=0.2; paired t-test). The response after 
leptin did not differ significantly between the two groups (Fig. 4.12a, b).  
4.5.3.5. Unfasted pregnant rats (n=5) vs. fasted pregnant rats (n=8): 
All the SON oxytocin neurones were excited by leptin in unfasted pregnant rats 
(n=5) while overall there was no response in fasted pregnant rats (2/8 excited, 2/8 inhibited 
and 4/8 did not respond). In unfasted pregnant rats, the basal rate of 6.65 ± 0.4 spikes/s was 
increased by 0.8 ± 0.2 spikes/s 17min after leptin and it returned to basal by 30min. The 
excitatory response after leptin was significantly higher than the basal firing rate (P=0.006, 
paired t-test). The basal firing rate in fasted pregnant rats was 4.6 ± 0.65 spikes/s and there 
was no response, on average, to leptin injection. However, the changes in firing rate after 
leptin did not differ significantly between these groups (Fig. 4.13). 
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4.5.4. Dose dependent effects of leptin on electrical activity of SON oxytocin neurones in 
fasted virgin and pregnant rats 
4.5.4.1. Fasted virgin rats: 
As the dose of leptin was increased, the number of SON oxytocin neurones excited 
increased: 2/6 neurones were excited when 1µg leptin was injected (4/6 did not respond), 3/6 
neurones were excited when 10µg leptin was injected (3/6 were inhibited) and 5/8 neurones 
were excited when 100µg leptin was injected (2/8 inhibited and 1/8 did not respond). The 
leptin-induced change in firing rate was not significantly different from the basal rate in the 
1µg and 10µg leptin groups (P>0.05) while in the 100µg group, there was a mild excitatory 
response after leptin which was nearly significant (P=0.051, paired t-test). However, the 
mean change in firing rate 0-10 and 0-20min after leptin was not significantly different 
between the groups (Fig. 4.14). 
4.5.4.2. Fasted pregnant rats: 
Overall, there was no response of SON oxytocin neurones in fasted pregnant rats to 
leptin injected at the various doses. None of the thr e neurones tested responded to 1µg 
leptin; a few were excited after 10µg (2/6 excited, 3/6 inhibited and 1/6 did not respond), 
100µg (2/8 excited, 2/8 inhibited and 4/8 did not respond) and 1mg (2/6 excited, 2/6 
inhibited and 2/6 did not respond) leptin. On averag , there was no significant change in 
firing rate within and between different dose groups after administration of leptin (Fig. 4.15). 
Comparing the dose response in fasted virgin/pregnant rats, there was no influence 
of physiological status (virgin/pregnant) on the response to different doses of leptin 
(1/10/100µg) administered (F2, 29= 0.5, P=0.6, two-way ANOVA). The responses of oxytcin 
neurones were not different between virgin and pregnant rats (F1, 29=2.7, P=0.1, two-way 
ANOVA) or between different doses of leptin (F2, 29=0.17, P=0.8, two-way ANOVA; Fig. 
4.16a, b and 4.11b). 
4.5.5. Effect of systemic administration of leptin on electrical activity of SON 
vasopressin neurones in unfasted virgin rats  
4.5.5.1. Non-phasic vasopressin neurones (n=13) 
The response to leptin (100µg; i.v) was predominantly inhibitory in non-phasic 
vasopressin neurones [6/13 inhibited (e.g. Fig. 4.17), 4/13 excited and 3/13 did not respond]. 
On average, the basal rate of 8.4 ± 1.2 spikes/s was decreased by 0.6 ± 0.45 spikes/s 1min 
after leptin (n=13). The rate returned to basal level by 2min. This transient inhibitory 
response was not significantly different from the basal (Fig. 4.18). 
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4.5.5.2. Phasic vasopressin neurones (n=8) 
Overall, phasic vasopressin neurones were little aff cted by leptin, however, a few 
neurones were inhibited (e.g. Fig. 4.19). During 0-5min after leptin administration the 
activity quotient decreased in 6/8 neurones and increased in 2/8 neurones, frequency within 
bursts decreased in 4/8 neurones and increased in 4/8 neurones and mean interburst interval 
increased in 4/8 neurones and decreased in 4/8 neuro es. Overall, activity quotient, 
frequency within bursts and mean interburst interval of phasic vasopressin neurones were not 
altered by leptin (Fig. 4.20, 4.21 and 4.22).  
4.5.5.3. Interspike interval histogram and hazard (n=19) 
There was no change in the interspike interval histogram after leptin administration 
(Fig. 4.23a). The distal tail of the histograms fitted well with the exponential curves while 
the proximal slope of the histogram of less than 0.2s intervals were left unfit, characterising 
vasopressin neurones (Fig. 4.23b). There was no change in the shape of the hazard plot after 
leptin administration (Fig. 24).  
4.6. Discussion   
4.6.1. Leptin-induced excitation of SON oxytocin neurones 
 Systemic leptin administration resulted in a signif cant excitatory effect on SON 
oxytocin neurones in unfasted virgin rats. Direct action of leptin on SON neurones results in 
inhibition of electrical activity in vitro (Honda et al., 2002) and i.c.v. leptin has no effect on 
oxytocin mRNA expression in the SON or on plasma oxyt cin level (Yamamoto et al., 
1999). Hence, the excitatory effects observed in this study might involve indirect actions of 
leptin.  
4.6.2. Rapid effects of leptin 
Leptin is a long term satiety signal. Leptin-induced r duction in food intake had a 
delayed onset (4-5h) and lower potency when injected systemically compared with central 
administration (30min onset) (Cusin et al., 1996; Barrachina et al., 1997; Thiele et al., 1997). 
However, it is interesting that the leptin induced xcitation of SON oxytocin neurones 
observed in this study were rapid.  The peak excitation was seen within 2min after injection 
and the effect lasted only for 10min. Systemic leptin activates STAT5 in SON neurones 
120min after injection (Mutze et al., 2007). However, systemic leptin activates STAT3 in 
mouse hypothalamus within 15min and it shows a peak r sponse at 30min (Vaisse et al., 
1996). I.c.v. leptin increases plasma corticosteron with the peak occurring at 15 min 
(Morimoto et al., 2000). Leptin inhibits both releas  (Stephens et al., 1995) and synthesis of  
NPY (Stephens et al., 1995; Schwartz et al., 1996). Similar rapid responses to leptin have 
also been observed in other studies (Spanswick et al., 1997; Powis et al., 1998; Honda et al., 
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2002). The change in neuronal responses observed in some studies is too rapid to be 
accounted for by genomic mechanisms (Honda et al., 2002). The acute regulation of 
orexigenic ARC neurones by leptin does not require STAT3 mediated transcription 
(Munzberg et al., 2007), but it is likely to be the r sult of inhibition of excitatory 
postsynaptic membrane potentials in NPY neurones (Glaum et al., 1996). Leptin inhibits 
hippocampal neurones by increasing K+ conductance (Shanley et al., 2002a; Shanley et al., 
2002b). Similarly, as the electrical activation of SON oxytocin neurones observed in the 
present study was too rapid to be accounted for by leptin receptor signalling involving 
STAT3 or STAT5 or any other signalling mechanisms involving gene transcription, these 
rapid actions of leptin could be possibly through non-genomic mechanisms either directly 
involving SON neurones or indirectly via modification of excitatory inputs to SON neurones.  
Indirect action of systemically administered leptin o  SON neurones could be 
possibly via ARC, VMH and/or brainstem neurones as these nuclei express leptin receptors 
(Hakansson et al., 1998; Grill et al., 2002) and are di ect targets for leptin (Elias et al., 2000).  
In addition, ARC and NTS neurones project to the SON (Alonso and Assenmacher, 1984; 
Leng et al., 1988). Indirect actions of leptin on the SON could also be via activation of the 
vagal afferents that express leptin receptors (Buyse et al., 2001; Burdyga et al., 2002) which 
in turn activates brainstem neurones resulting in activ tion of SON oxytocin neurones. 
4.6.3. Leptin-induced excitation of SON oxytocin neurones: Physiological implications 
Natriuretic peptides such as atrial natriuretic peptide (ANP) regulate postprandial 
natriuresis to establish normal plasma sodium and volume after food intake (McCann et al., 
2003). Oxytocin is released postprandially and it mediates the release of ANP (Haanwinckel 
et al., 1995). The natriuretic effect of peripheral oxytocin is also via direct binding of 
oxytocin to its receptors on NOergic cells in the macula densa and renal proximal tubules to 
release cGMP that closes Na+ channels, and also via generation of NO leading to increased 
cGMP (Soares et al., 1999).  
Similar to oxytocin, leptin also is an important renal sodium-regulating factor under 
conditions of mild sodium and volume expansion (Villarreal et al., 2006). Leptin receptors 
are expressed in the kidney and systemic administration of leptin induces a significant and 
rapid diuretic and natriuretic effect in conscious and anaesthetized rats (Jackson and Li, 
1997; Serradeil-Le Gal et al., 1997; Beltowski et al., 2004). Leptin-induced natriuresis is 
through direct binding of leptin to its receptors in renal tubules and is mediated by NO 
(Villarreal et al., 2004). Leptin antibody significantly decreases urinary sodium excretion 
and urinary flow by 30% compared to control rats (Villarreal et al., 2006). It is possible that, 
physiologically, in addition to its direct effects on renal tubules, leptin might act indirectly 
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through oxytocin promoting natriuresis. Transient increase in leptin mRNA expression seen 
in adipose tissue after food intake (Saladin et al., 1995) supports the possibility that 
postprandial natriuresis could be partly mediated by leptin through oxytocin.  
The increase in firing rate of SON oxytocin neurones in response to leptin observed 
in this study might accompany dendritic release of oxytocin through which leptin, at least in 
part, might mediate its anorectic effects. This is upported by the report that leptin-induced 
reduction in food intake was reduced by central administration of oxytocin receptor 
antagonist (Blevins et al., 2004). 
4.6.4. Leptin-induced excitation of SON oxytocin neurones in pregnant rats 
As pregnancy is a physiological state of leptin resistance (Augustine et al., 2008) and 
oxytocin neurone responses to various stimuli are attenuated during pregnancy (Douglas et 
al., 2007), leptin-induced excitation of SON oxytocin neurones observed in virgin rats was 
expected to be absent or less in late pregnant rats. Surprisingly, however, in unfasted 
pregnant rats, leptin had similar excitatory, but more prolonged effects on SON oxytocin 
neurones than in virgin rats, indicating that these neurones are not resistant to systemic leptin 
during pregnancy.  
Leptin resistance occurs at the hypothalamic level with a region-specific loss of 
hypothalamic Ob-R mRNA (Ladyman and Grattan, 2005). It is not known whether Ob-R 
expression in the SON is altered during pregnancy, a lack of such alteration might be 
responsible for this persistent excitatory response observed in pregnant rats. As leptin excites 
oxytocin neurones both during the non-pregnant and pregnant state and Ob-Rb mRNA levels 
remain relatively constant in the ARC in pregnancy (Ladyman and Grattan, 2005), it is 
possible that systemic leptin acts on SON neurones via the ARC. 
As the pregnant rats were given the same dose as virgin rats, dose per 100 gram BW 
would have been less as the body weight is significantly increased during late-pregnancy. 
Pregnant rats with higher body weight have higher circulating leptin levels, but also higher 
circulating leptin binding proteins (Augustine et al., 2008). Hence, the actual effective 
concentration of leptin in the pregnant rats was unknown. However, the oxytocin neurones in 
pregnant rats responded similarly to the dose as virgin rats. Though these responses in virgin 
and pregnant rats may not be directly comparable due to the discrepancy in the dose per 
gram BW given and due to the physiological changes during pregnancy altering the effective 
circulating concentration of leptin, this study showed that oxytocin neurones are not resistant 
to leptin during pregnancy. 
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4.6.5. Leptin-induced excitation of SON oxytocin neurones in pregnant rats: 
Physiological implications 
Total circulating blood volume and sodium are increased during pregnancy (Brunton 
et al., 2008). Oxytocin neurone responses are contained in pregnancy, which should maintain 
this altered physiological status so as to enable sufficient blood supply to the gravid uterus 
(Brunton et al., 2008). Hence, it is surprising that acute leptin activates SON oxytocin 
neurones and hence presumably increases oxytocin seretion even during pregnancy. As 
leptin receptor signalling is similar to  signalling by other cytokines, an acute bolus injection 
of leptin might be perceived as a strong cytokine signal to activate SON oxytocin neurones 
in pregnant rats, which otherwise are under control by several inhibitory mechanisms during 
pregnancy (Brunton et al., 2008).  
4.6.6. Effect of fasting on leptin-induced excitation of SON oxytocin neurones: Lack of 
dose-dependent response  
 Fasting was expected to either increase (due to increase in the sensitivity to leptin 
after reduction in the circulating leptin level by fasting) or decrease (to avoid natriuresis so 
as to conserve sodium and water during fasting) leptin-induced excitation of SON oxytocin 
neurones. The results show that fasting did not potentiate the acute effects of leptin in virgin 
and pregnant rats. In addition, though leptin-induced hange in firing rate was not different 
from basal rate both in fasted virgin and pregnant r ts and though this reduced response was 
not significantly lesser than the unfasted virgin and pregnant rats, fasting seems to have 
attenuated the response in pregnant rats as they did not respond to leptin. Lack of food intake 
also reduces water intake in rats, but does not alter the plasma osmolality (Bruno et al., 
1985). However, reduced circulating sodium level and plasma volume might attenuate the 
excitatory responses of oxytocin neurones to leptin so as to preserve the available sodium by 
avoiding oxytocin-induced natriuresis.  
 The response to 100µg leptin was almost significant (P=0.051) in fasted virgin rats 
compared to basal but there was no response to lesser do es. The fasted pregnant rats did not 
respond to any of the doses, even to the maximal 1mg dose. Fasting-induced homeostatic 
mechanisms might tightly regulate oxytocin neurone responses to preserve sodium level. On 
the other hand, oxytocin neurones in fasted rats might dose-dependently respond to leptin 
had the doses been higher. In addition, as this model f bolus injection of leptin does not 
resemble the slow physiological release, perhaps letin did not reveal its physiological 
effect. 
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4.6.7. Leptin perceived as inflammatory stimuli in unfasted animals and compensates 
for reduced levels in fasted animals? 
Leptin levels are acutely increased by inflammatory stimuli such as LPS and hence 
leptin induction is part of the acute phase response to inflammation (Grunfeld et al., 1996; 
Sarraf et al., 1997; Faggioni et al., 1998). The acute bolus injection of leptin might be 
perceived as an inflammatory stimulus exciting the oxytocin neurones as oxytocin is a stress 
hormone in the rat (Lang et al., 1983). During fasting, acute injection of leptin might just 
compensate for the reduced circulating levels and might not be perceived as an inflammatory 
stimulus and hence the oxytocin neurone responses are not altered in fasted rats. However, 
this concept does not explain why leptin excites oxyt cin neurones in unfasted pregnant rats 
in which oxytocin neurone responses to inflammatory stimuli such as IL-1β are suppressed 
during pregnancy (Brunton et al., 2006). 
4.6.8. Leptin-induced oxytocin secretion: trigger for parturition? 
Withdrawal of leptin from pregnant ob/ob mice result  in delay in parturition, with a 
prolongation of gestation for over 2 days (Mounzih et al., 1998) suggesting that an 
adequately higher circulating level of leptin is mand tory for a normal gestation period. This 
study found that fasting, which results in reduced l ptin level and reduced availability of 
energy sources, attenuated leptin-induced excitation of oxytocin neurones and thus oxytocin 
secretion in fasted pregnant rats. This may have the effect of delaying parturition, whereas an 
acute increase in leptin level, above the high leptin level in unfasted pregnant rats, might 
signal availability of surplus energy sources, and hence trigger parturition through oxytocin 
secretion.  
4.6.9. Leptin-induced effects on the electrical activity of SON vasopressin neurones 
Systemic leptin either inhibited or did not affect SON vasopressin neurone activity 
in this in vivo study. As direct action of leptin on SON neurones r ults in inhibition of 
electrical activity in vitro (Honda et al., 2002), leptin-induced effects on vasopressin 
neurones observed in this in vivo study could be due to direct/indirect effects of leptin on 
SON vasopressin neurones.  
The effect of systemic leptin on SON oxytocin neurones (excitatory) and vasopressin 
neurones (inhibitory or no effect) is similar to tha  of systemically administered CCK. 
Hence, it is possible that leptin-induced effects on SON neurones are mediated through CCK 
possibly involving abdominal vagal afferents and brainstem noradrenergic neurones. An 
interaction between CCK and leptin at the level of gastric vagal afferents (Yuan et al., 2000) 
support this hypothesis. 
 84 
4.7. Conclusion 
Systemic administration of leptin predominantly increases the electrical activity of 
SON oxytocin neurones and either inhibits or does not affect vasopressin neurones. SON 
oxytocin neurones are not resistant to leptin during pregnancy. Fasting did not alter leptin-
induced excitatory responses in SON oxytocin neurones in virgin and pregnant rats. 






Secretin is a twenty seven amino acid peptide from the S-cells of the duodenum. It is 
released in response to acidic contents entering the duodenum from the stomach (Bayliss and 
Starling, 1902). Suppression of gastric acid secretion with a H2 blocker completely arrests 
release of secretin after a meal in dogs (Kim et al., 1979). Pancreatic exocrine secretion after 
a meal is mainly stimulated by synergistic interaction between secretin and cholecystokinin 
(Chey et al., 1984). 
Peripheral injections of secretin result in Fos expr ssion in the brain including the 
hypothalamus and brainstem (Goulet et al., 2003; Yang et al., 2004b). Intravenous (i.v) 
injection of secretin (40µg/kg) increases Fos expression in the supraoptic nucleus (SON) 
significantly (Yang et al., 2004b). Intracerebroventricular (i.c.v) administration of secretin 
(1µg) increased Fos expression in SON oxytocin and vasopressin neurones and also 
increased peripheral release of oxytocin and vasopre sin dose dependently (0.1 - 10µg; 
Takayanaki and Onaka, 2007). Bath application of secretin (2-50µM) increased the release 
of oxytocin and vasopressin from hypothalamic explants (Takayanaki and Onaka, 2007). 
Secretin and its receptor are found in the SON and the magnocellular area of the 
paraventricular nucleus (mPVN) (Chu et al., 2006a), and these hypothalamic regions also 
contain secretinergic neurones (Welch et al., 2004). Secretin is also released from 
hypothalamic explants (Chu et al., 2006a). Hence, secretin is considered as a neuropeptide 
though its physiological role in the CNS is not established yet (Ng et al., 2002).  
As the gut is the primary source of secretin and as the role of peripheral secretin is 
well established, systemic administration of secretin for experiments on central actions seem 
more physiological than central administration. Though Fos studies show that SON neurones 
are activated by systemic administration of secretin, hey do not allow ‘real-time’ 
measurement of neuronal activity. In addition, as there are no double immunohistochemical 
studies of Fos and oxytocin/vasopressin available, whether SON oxytocin or vasopressin 
neurones are activated by peripheral secretin inject on is not known. Moreover, the duration 
and intensity of activation of individual oxytocin or vasopressin neurones in response to 
systemic secretin administration is not known. Dose dependent (0.4 – 40 µg/kg; i.v) 
increases in the number of cells expressing Fos in the CeA and AP have been reported 
(Goulet et al., 2003). Similarly, dose dependent (40 and 100µg/kg; i.p) increases in the 
number of Fos expressing cells in the CeA have been r ported (Yang et al., 2004b). 
However, it is not known whether the neuronal activity of individual cells is dose dependent. 
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Hence the present study was aimed at studying the in vivo electrophysiological responses of 
SON oxytocin neurones to intravenous administration of secretin. The plasma oxytocin 
release following systemic secretin was also studied. In addition, as there is no evidence that 
secretin decreases food intake in rats, systemic secretin-induced somato-dendritic oxytocin 
release from the SON was also studied, with the hypothesis that secretin does not induce 
dendritic release of oxytocin. 
Central administration of secretin increased the Fos expression in SON vasopressin 
neurones and peripheral release of vasopressin (Takayanagi and Onaka, 2007). Bath 
application induced vasopressin release from hypothalamic explants (Takayanagi and Onaka, 
2007). However, the response of SON vasopressin neuro s to systemic administration of 
secretin was not known. Hence, experiments were aimd to study whether secretin-induced 
responses in SON vasopressin neurones are similar to those induced by CCK, a functionally 
similar peptide (Chey and Chang, 2001), which when administered intravenously, either 
inhibits or does not affect the firing rate of SON vasopressin neurones (Verbalis et al., 
1986a; Verbalis et al., 1986b; Renaud et al., 1987). 
Electrophysiological studies on nodose ganglia in the rat suggest that secretin 
activates vagal primary afferent neurones (Li et al., 2005). Secretin induces Fos expression 
in the NTS, AP and LC regions of the brainstem (Yang et al., 2004b). Moreover, in vitro 
studies found that secretin depolarizes neurones in the nucleus tractus solitarius (NTS) 
through activation of a nonselective cationic conductance (Yang et al., 2004a). The SON 
receives noradrenergic excitatory inputs from the NTS (Onaka et al., 1995a). In addition, α-1 
adrenergic receptor activation induces release of oxytocin and vasopressin from 
hypothalamic explants (Randle et al., 1986). To investigate the possible involvement of 
excitatory adrenergic pathways in mediating secretin-induced responses in SON neurones, 
the effect on responses to secretin of administering benoxathian hydrochloride (a competitive 
α-1 adrenergic antagonist) by microdialysis onto the SON or by i.c.v. infusion was also 
studied. 
Oxytocin release during feeding might prevent the disturbances in water and 
electrolyte homeostasis which would otherwise occur as a result of food intake (Johnstone et 
al., 2006). However, in the unfed state, the activation of SON oxytocin neurones might be 
suppressed to avoid natriuresis and diuresis. Hence, the basal activity of SON neurones was 
expected to be less in fasted rats. However, though the entry of acidic contents from the 
stomach to duodenum is the signal for physiological release of secretin (Bayliss and Starling, 
1902), fasting also increases plasma secretin concentration in humans and dogs (Mason et 
al., 1979; Manabe et al., 1987). If it is also true in rats, the fasting-induced increase in the 
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circulating levels of secretin might actually increas  the basal rate of oxytocin neurones. In 
such a case, exogenous secretin injection might not exci e SON oxytocin neurones. To test 
these hypotheses, the effect of fasting on basal activity and secretin-induced increase in the 
activity of the SON neurones was also studied.  
5.2. Hypotheses 
1. Systemically administered secretin, at physiological doses, increases the 
electrical activity of SON oxytocin neurones and eith r inhibits or does not 
affect vasopressin neurones, similar to CCK. 
2. Secretin dose-dependently excites SON oxytocin neurones and increases 
peripheral release of oxytocin in urethane anaesthetized female rats.  
3. Systemic secretin does not induce somato-dendritic oxytocin release from the 
SON. 
4. Similar to CCK, central noradrenergic pathways are involved in the secretin-
induced excitation of SON oxytocin neurones. 
5. Basal activity and secretin-induced excitation of SON oxytocin neurones are 
attenuated in fasted state. 
5.3. Objectives 
1. To study the electrophysiological responses of SON oxytocin and vasopressin 
neurones to intravenous administration of secretin in urethane anaesthetized 
female rats in vivo. 
2. To evaluate whether secretin-induced effects on SON oxytocin neurones and 
plasma oxytocin concentration in urethane-anaesthetized female rats are dose 
dependent.  
3. To study the systemic secretin-induced somato-dendritic oxytocin release from 
the SON. 
4. To study the involvement of adrenergic pathways in ecretin-induced effects on 
SON oxytocin neurones in urethane anaesthetized female rats. 
5. To study the basal activity and secretin-induced change in the activity of SON 
oxytocin neurones in fasted rats. 
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5.4. Background 
5.4.1. Secretin and its peripheral actions 
Secretin was discovered more than 100 years ago (Bayliss and Starling, 1902).  It 
was the first hormone to be discovered and the concept of a ‘hormone’ began from its 
discovery. It belongs to the family of brain-gut peptides: the secretin/glucagon/VIP 
superfamily that includes pituitary adenyl cyclase activating peptide (PACAP), growth 
hormone releasing hormone (GHRH), peptide histidine isoleucine (PHI), peptide histidine 
methionine (PHM), glucagon-like peptide 1 and 2 (GLP-1 and GLP-2) and gastric inhibitory 
polypeptide (GIP) (Sherwood et al., 2000).  
Secretin functions via a cell surface receptor, the secretin receptor. The secretin 
receptor and the receptors for the secretin/glucagon/VIP superfamily are grouped under the 
B1 subclass in the G protein-coupled receptor (GPCR) superfamily (Siu et al., 2006). 
Secretin plays a key role in the physiology of the gastro-intestinal tract via activation of its 
receptors in nanomolar concentrations.  
Postprandially released secretin is transported to the pancreas and liver. Activation 
of secretin receptors leads to the elevation of cAMP or Ca2+ signalling pathways (Trimble t 
al., 1987). Stimulation of these pathways activates various ion transporters in the pancreatic 
and biliary duct epithelial cells, resulting in exocrine secretion of bicarbonate ions, water and 
other electrolytes to neutralise acidic gut contents so that an optimum pH is available for 
intestinal enzymes to act on food (Ishiguro et al., 2002).  
Secretin receptors are expressed in the cholangiocytes in the liver (Alpini et al., 
1994). Secretin, via cAMP and PKA pathway, increases bicarbonate rich bile secretion from 
the liver (Kanno et al., 2001). Secretin also acts on the proximal and distal epididymis to 
stimulate bicarbonate rich epididymal secretion in the rats (Chow et al., 2004).  
Secretin receptors are present on vagal afferent fibres (Wang et al., 1995). The 
physiological action of secretin is highly dependent o  the vagal afferent pathway. Thus, 
chemical ablation of vagal afferent fibres by perivagal application of capsaicin in rats 
resulted in a profound inhibition of the pancreatic secretion stimulated by a physiological, 
but not by a pharmacological, dose of secretin (Li et al., 1995).  
Physiological functions of secretin also include inhibition of gastric acid secretion, 
gastrin release and gastric emptying (Wormsley and Grossman, 1964; Vagne and Andre, 
1971; Straus et al., 1975) through a vagal-dependent pathway (Raybould and Holzer, 1993; 
Lu and Owyang, 1995; Li et al., 1998). Supraphysiologic blood levels of secretin (100-fold 
endogenous levels) affect pancreatic fluid release by a mechanism independent of the vagus 
(Lu and Owyang, 1995).  
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The half life of circulating secretin is 4.1min in humans (Kolts and McGuigan, 1977) 
and 1.5 - 3min in rats (de Smul et al., 1974; Lehnert et al., 1974; Tanaka and Katayama, 
1984). The release of secretin is controlled by a feedback mechanism mediated by pancreatic 
proteases (Green and Lyman, 1972). Secretin has been used for many years for evaluating 
the function of the exocrine pancreas (Dreiling andHollander, 1948). 
5.4.2. Secretin and its actions in the brain 
125I-[Tyr10]-Secretin was found to cross the blood–brain barrier and entered every 
brain region, with fastest uptake found in the hypothalamus and hippocampus (Banks et al., 
2002). Secretin crosses the vascular barrier by a nonsaturable process and the choroid plexus 
by a saturable process (Banks et al., 2002). Secretin promotes adenylate cyclase activity 
(Karelson et al., 1995), stimulates cAMP accumulation (Karelson et al., 1995) and 
modulates catecholamine metabolism (Fuxe et al., 1979; Ip and Zigmond, 2000) in the brain. 
It also increases TH activity in the hypothalamus (Babu and Vijayan, 1983), and increases 
glutamate and GABA levels in rat hippocampus (Yung et al., 2001; Kuntz et al., 2004). 
Central (i.c.v) administration of secretin stimulates pancreatic exocrine secretion in rats 
(Conter et al., 1996). Indeed, it is more potent in stimulating pancreatic secretion when given 
into the brain than when given intravenously (Conter e  al., 1996). 
Secretin (O'Donohue t al., 1981; Yung et al., 2001), secretin mRNA (Itoh et al., 
1991; Ohta et al., 1992; Yung et al., 2001), secretin receptor (Fremeau et al., 1983; Nozaki 
et al., 2002) and receptor mRNA (Yung et al., 2001) have been detected in the brain. 
However, Kopin et al failed to detect secretin mRNA in the central nervous system (CNS) 
(Kopin et al., 1990). Secretin is also found in the brainstem (Koves et al., 2002), and 
secretinergic neurones are found in the mPVN and SON (Welch et al., 2004). However, 
Koves et al and Ng et al failed to find secretin in the hypothalamus (Koves et al., 2002; Ng 
et al., 2002). Recent studies have indicated that secretin indeed may function as a 
neuropeptide. For example, secretin specifically stimulated adenylate cyclase in 
hypothalamus and hippocampus (Karelson et al., 1995). Hence, secretin seems to act as a 
peripheral hormone and central neuropeptide with boperipheral and central effects. 
Systemic (40µg/kg; i.v) administration of secretin induces Fos in the central nucleus 
of the amygdala (CeA), area postrema (AP), bed nucleus of the stria terminalis (BNST), 
SON, dorsal motor nucleus of the vagus (DMNV) and medial region of the NTS (Goulet t 
al., 2003). Systemic treatment with secretin (40 and 100µg/kg; i.p) induced Fos strongly in 
the CeA, AP, locus coeruleus (LC), NTS, external later l subnucleus of the parabrachial 
nucleus (PBel) and weakly in the dorsal motor nucles of the vagus (DMNV), arcuate 
nucleus (ARC) and Barrington’s nucleus (Bar) (Yang et al., 2004b). Central administration 
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of secretin (10 and 30µg; i.c.v) induced Fos expression in the dorsal vagal complex, NTS, 
AP, LC, PVN, medial and central amygdala (Welch et al., 2003). Hence, secretin of central 
and/or peripheral origin may activate behavioural and visceral reflex regulatory circuits 
(Welch et al., 2003).  
5.4.3. Secretin actions in the SON 
Central administration of secretin (1µg/rat; i.c.v) increased Fos expression in SON 
oxytocin and vasopressin neurones (peak at 5min after injection; returned to basal 60min 
after injection) and also dose dependently (0.1 -10µg) increased peripheral oxytocin and 
vasopressin release (Takayanaki and Onaka, 2007). Secretin (2-50µM) bath application 
increased the release of oxytocin and vasopressin from hypothalamic explants (Takayanaki 
and Onaka, 2007). Chu et al suggested that endogenously released secretin from the 
hypothalamus could possibly act via an autocrine pathw y to modulate excitability of 
magnocellular neurones, playing a role in central stres  responses (Chu et al., 2006a). In the 
same way, secretin is thought to stimulate c-fos and vasopressin expression and somato-
dendritic release of vasopressin by magnocellular neu ones (Chu et al., 2006a, b). 
Systemically administered secretin might influence th activity of magnocellular 
neurones of the SON at least in four ways.  
1. By crossing the blood-brain barrier and directly binding with secretin receptors 
in the SON.  
2. By stimulating AP neurones directly via the deficient blood-brain barrier.  
3. By stimulating vagal afferents and thus indirectly activating the brainstem 
neurones (NTS) that project to the SON. 
4. By promoting HCO3
-
 release into the intestinal lumen from the exocrine 
pancreas that accompanies transepithelial movement of Na+ and K+ to maintain 
electrical neutrality. This draws water from plasma into the intestine passively 
resulting in plasma hyperosmolality, and stimulates vasopressin release 
(Kitagawa et al., 1990). Vasopressin in turn acts on ductal cells in the pancreas 
to reduce secretin-stimulated pancreatic secretion (Kitagawa et al., 1990; Ko et 
al., 1999). 
Central administration of secretin (0.1 - 10µg; i.c.v) induced Fos expression in SON 
oxytocin and vasopressin neurones (Takayanagi and Onaka, 2007). However, behavioural 
effects induced by secretin have been found even with as little as 0.001µg secretin given by 
i.c.v. injection in mice (Babarczy et al., 1995). With respect to peripheral administration, 
secretin-induced Fos expression has been studied in the rat hypothalamus after 40µg/kg 
(13µg/rat of 300g body weight) given intravenously (Goulet et al., 2003). This dose is 
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equivalent to 0.02µg secretin entering the brain, as 0.12% of intravenous secretin enters the 
brain (Banks et al., 2002). However, intravenous infusion of secretin at 0.1µg/kg h-1 is 
similar to the rate at which secretin is released after  lipid meal in the rat (Lu and Owyang, 
1995). Hence, a dose of 0.1µg/rat (i.v) was chosen to study the effect of secretin on SON 
neurones to resemble closely the physiological level and route to the brain. 
5.4.4. Importance of in vivo electrophysiology in studying actions of secretin 
CCK, a peptide similar to secretin, with a circulating half-life of approximately 2min 
(Thompson et al., 1975; Hoffmann et al., 1993) increases the firing rate of SON oxytocin 
neurones immediately after administration with the rate reaching a peak within 5min and 
returning to basal level by 15min (Leng et al., 1991). The half-life of endogenous circulating 
secretin is 4.1min (Kolts and McGuigan, 1977) and 1.5-3min in rats (de Smul et al., 1974; 
Lehnert et al., 1974; Tanaka and Katayama, 1984). However, Fos expression in the SON 
induced by secretin (40µg/kg; i.v) was similar at 60 and 120min and absent by 240min 
(Goulet et al., 2003). Hence, the duration of neuronal electrical excitation is not clear with 
Fos studies. Moreover, Fos studies indicate the activity of cells but do not indicate the 
intensity of activation of individual cells. The ‘real-time’ activity of single cells can be best 
studied using electrophysiology. Fos studies show that the number of cells expressing Fos 
after secretin treatment is dose dependent (Yang et al., 2004b). However, the intensity of 
activation of individual cells in response to different doses can be studied only through 
electrophysiology. Hence in vivo electrophysiological experiments were planned to study the 
duration and degree of any activation of SON oxytocin and vasopressin neurones upon 
systemic administration of secretin.  
5.4.5. Mode of action of secretin on SON neurones 
Systemically administered (i.p) secretin signals to the brain by interacting with 
secretin receptors on vagal afferents and on AP neuro s outside the blood-brain barrier 
(Yang et al., 2004b; Li et al., 2005). Secretin binds to the NTS and other regions in 
brainstem, thalamus, hypothalamus and cortex with specificity and high affinity (Nozaki et 
al., 2002). Secretin depolarizes NTS neurones i  vitro through activation of a nonselective 
cationic conductance (Yang et al., 2004a). Double immunostaining with Fos and TH in NTS 
neurones showed that a substantial population of TH positive neurones were Fos positive 
after secretin given by i.p. injection at 40µg/kg (Yang et al., 2004b). NTS neurones relay 
signals received from the vagal afferents to higher brain structures via ascending adrenergic 
or noradrenergic pathways (Cunningham et al., 1990). Secretin-induced increases in Fos 
positive cells in the NTS were abolished by subdiaphr gmatic vagotomy (Yang et al., 
2004b); Fos positive cells were not only abolished in the NTS but also in pontine and limbic 
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nuclei (DMNV, LC, Bar, PBel and CeA) which suggested that the NTS conveys vagal 
afferent inputs to other nuclei through direct or indirect neural pathways (Yang et al., 
2004b). The SON receives excitatory noradrenergic inputs from the NTS (Alonso and 
Assenmacher, 1984). To investigate the involvement of adrenergic pathways in secretin-
induced effects in SON neurones, α-1 adrenergic receptors were blocked using benoxathian 
hydrochloride (a competitive α-1 adrenergic antagonist) and the effect on secretin-induced 
responses in SON neurones were studied during the blockade. 
5.4.6. Secretin-induced somato-dendritic oxytocin release from the SON 
There have been few studies on actions of secretin on feeding behaviour, and these 
have not shown anorectic or satiety effects in rats. Administration of 0.1 -100 clinical 
units/kg i.p. secretin had no effect on sham feeding in rats (Lorenz et al., 1979), and 
10nmol/kg i.p. secretin also had no effect on feeding in rats (Garlicki et al., 1990). However, 
in sheep, i.v. infusion of  secretin (8 clinical units/kg per hour) reduced food intake by 38% 
and 0.5 units/kg per hour reduced intake by 12% (Grovum, 1981).   
As oxytocin has central anorectic effects in rats (Olson et al., 1991a), it becomes of 
interest to test whether secretin increases central release of oxytocin. It has been proposed 
that oxytocin released from magnocellular neurone dendrites might act centrally to reduce 
appetite (Sabatier et al., 2007). Direct application of secretin (2-50µM) in vitro induces 
dendritic oxytocin release from the isolated SON (Takayanagi and Onaka, 2007). Here it was 
hypothesized that systemic secretin does not induce central oxytocin release from 
magnocellular dendrites because of lack of evidence for anorectic effects of secretin.  
5.4.7. Role of secretin in osmoregulation 
 Secretin like immunoreactivity has been found abundantly in the posterior pituitary 
(Charlton et al., 1982). The expression of secretin and its receptor is significantly increased 
during dehydration (Chu et al., 2009). Chronic hyperosmolality as a result of water 
deprivation and 0.9% saline drinking also elevates pla ma secretin level (Chu et al., 2009).  
Recently, secretin mediated osmoregulation has shown t  be one of the vasopressin 
independent mechanism regulating water balance (Cheng et al., 2009). Secretin receptors are 
found in the kidney (Ohta et al., 1992). In anaesthtized hydrated rats, secretin exhibits anti-
diuretic action (Charlton et al., 1986). Secretin receptor null mice (SCTR-/-), which does not 
have any alteration in the transcription levels of vasopressin mRNA, develops polydipsia and 
polyuria (Chu et al., 2007). The presence of aquaporin typte-2 (AQP2) water channels in the 
apical membrane of the collecting tubules is essential for water reabsorption and urine 
concentration (Deen et al., 1994). Secretin induces th  translocation of these channels to the 
apical membrane during water deprivation (Chu et al., 2009).  
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5.4.8. Secretin vs CCK: Similarities and differences  
 CCK and secretin are synergistic in their functions (Lee, 1979; Buchan et al., 1993; 
Li, 2007). Pancreatic exocrine secretion after a meal is mainly stimulated by synergistic 
interaction between secretin and CCK (You et al., 1983; Chey et al., 1984). A high dose 
(100U/kg) of secretin was found to be synergistic with CCK for satiety (Lorenz et al., 1979). 
However, Fos patterns in the brain induced by equimolar doses of CCK (15µg/kg; i.v) and 
secretin (40µg/kg; i.v) were different: Fos expression was more pronounced in the CeA and 
the AP after secretin than after CCK treatment (Goulet et al., 2003). In contrast to secretin, 
CCK treatment led to a pronounced increase in Fos expression in the NTS, DMVN and PVN 
(Goulet et al., 2003). The electrical response of SON vasopressin neurones to central CCK is 
excitatory and to intravenous CCK is either inhibitory or there is no effect (Renaud et al., 
1987). As central administration of secretin induces Fos in SON vasopressin neurones and 
increases peripheral release of vasopressin (Takayanagi and Onaka, 2007) and bath 
application of secretin induces vasopressin release in hypothalamic explants (Chu et al., 
2006a), we aimed to see whether, like CCK, the periph al administration of secretin inhibits 
or does not affect the activity of SON vasopressin neurones. 
5.5. Methods 
5.5.1. Experiment 1: Effect of systemic administration of secretin on the electrical 
activity of SON oxytocin and vasopressin neurones in urethane-anaesthetised 
fasted/unfasted virgin rats in vivo. 
Urethane-anaesthetized fasted/unfasted rats were fitted with an i.v. cannula on the 
day of the experiment. The SON and neural stalk were xposed via the ventral 
transpharyngeal surgery. After a minimum of 10min period of recording the basal activity, 
the effect of i.v. administration of 0.01µg, 0.1µg or 1µg secretin in 100µl normal saline on 
the electrical activity of SON oxytocin neurones was recorded. In the rats fasted for 18h, the 
response to 0.1µg secretin of SON oxytocin neurones was recorded. The response of phasic 
and non-phasic vasopressin neurones to 0.1µg secretin was also recorded in unfasted and 
fasted virgin rats.  
Groups: 
1. Unfasted rats 
a. Oxytocin neurones:  
i. 0.01µg secretin: n =  4 
ii. 0.1µg secretin: n =  26 
iii.  1µg secretin: n =  3 
b. Vasopressin neurones: 
 94 
i. 0.1µg secretin: Phasic: n = 11 
ii. 0.1µg secretin: Non-phasic: n = 21 
2. Fasted rats 
a. Oxytocin neurones: 0.1µg secretin: n = 3 
b. Vasopressin neurones: 0.1µg secretin: n = 5  
i. Phasic firing neurones: n = 3 
ii. Non-phasic firing neurones: n = 2 
5.5.2. Experiment 2: Effect of systemic secretin administration on plasma oxytocin 
release in urethane-anaesthetised rats. 
Urethane-anaesthetized virgin rats (n=6) were fitted with an i.v. cannula. After a 
minimum of 2h, a basal blood sample was taken. Subsequent sampling was done as per the 
following schedule. 
Blood Sampling Schedule: 
1. Sample 1 – Basal (2h after i.v. cannulation) 
2. Sample 2 – 5min after vehicle (100µl saline i.v) 
3. Sample 3 - 5min after secretin (0.1µg in 100µl saline; .v) 
4. Sample 4 – 10min after 0.1µg secretin  
5. Sample 5 - 25 min after s0.1µg ecretin  
6. Sample 6 - 5min after secretin (1µg in 100µl saline; i.v) 
7. Sample 7 - 10min after 1µg secretin  
5.5.3. Experiment 3. Effect of systemic administration of secretin on somato-dendritic 
oxytocin release from the SON in vivo in urethane-anaesthetized female rats.  
The SON was exposed through the ventral transpharyngeal surgical procedure (see 
Section 2.3.1). The loop of a microdialysis probe was positioned on the ventral surface of the 
SON (see Section 2.4). The SON was dialysed with aCSF at a flow rate of 3µl/min using an 
infusion pump. Collection of basal microdialysate samples were begun an hour after initial 
dialysis. Secretin (1µg/rat) was administered i.v. and samples were collected on ice once 
every 30min for 2.5h. Subsequently, hypertonic aCSF (1M NaCl) followed by isotonic aCSF 
was microdialysed as a positive control for central oxytocin release, as an increase in SON 
oxytocin release is expected following hypertonic aCSF microdialysis and a rebound 
increase is expected following subsequent isotonic aCSF (Ludwig et al., 1994; Ludwig and 
Leng, 2006). The samples (90µl/tube) were stored at -20C until sent to Prof. Rainer 
Landgraf’s Laboratory (Max Planck Institute of Psychiatry, Germany) for oxytocin RIA. 
Data from those rats that showed a positive response to hypertonic aCSF followed by 
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isotonic aCSF microdialyses were statistically analysed to seek evidence of secretin-induced 
central oxytocin release from the SON. 
5.5.4. Experiment 4: Effect of i.c.v. infusion of benoxathian on secretin-induced 
excitatory electrical activity of SON oxytocin and vasopressin neurones in vivo. 
The surgical procedure was carried out as per the procedure in i.v. and i.c.v. 
cannulated urethane-anaesthetized virgin rats. After an initial basal recording of firing rate of 
SON oxytocin (n=6) and vasopressin (n=3) neurones for a minimum period of 10min, 0.1µg 
secretin in 100µl normal saline was administered i.v. The same dose was repeated in some 
neurones to compare the responses so as to rule out receptor desensitization. Benoxathian 
was infused i.c.v. at a dose rate of 8µg/µl min-1. Another secretin injection was repeated 
during the infusion. The firing rate was recorded throughout the experiment. 
5.5.5. Experiment 5: Effect of benoxathian microdialysis onto the SON on secretin-
induced excitatory electrical activity of SON oxytocin neurones in vivo. 
The surgical procedure was carried out as per the procedure in i.v. cannulated 
urethane anaesthetized virgin rats. After an initial b sal recording of firing rate of SON 
oxytocin neurones (n=3) for a minimum period of 10min, 0.1µg secretin in 100µl normal 
saline was administered i.v. When the effect of secretin subsided, microdialysis of 
benoxathian (2mM) was begun at a flow rate of 3µl/min. Another secretin injection was 
repeated during the microdialysis. The firing rate was recorded throughout the experiment. 
5.6. Results  
5.6.1. Effect of systemic administration of secretin on SON oxytocin neurones in 
unfasted virgin rats 
Secretin (0.1µg/rat) was given intravenously after recording the basal firing-rate for 
a minimum period of 10min. Secretin excited all theSON oxytocin neurones tested (n=26; 
Fig. 5.1 and 5.2). The basal firing rate and the percentage increase in firing rate are 
negatively correlated (Fig. 5.2a). The number of spikes occurring within 0-0.5s after a spike 
is significantly increased after secretin administration which was reflected on the interspike 
interval histogram (Fig. 5.3). There was a significant positive shift in the hazard function 
(Fig. 5.4). The ratio of peak early (<0.07s) to mean late hazard (0.2-0.3s) 10min before (0.9 
± 0.05) and after secretin (0.9 ± 0.06) did not differ rom each other (Fig. 5.5). 
5.6.2. Effect of systemic administration of secretin on SON vasopressin neurones in 
unfasted virgin rats 
 The effect of systemic secretin administration (0.1µg/rat; i.v) was studied in 21 non-
phasic and 11 phasic firing SON vasopressin neurones.  
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5.6.2.1. Non-phasic vasopressin neurones  
Fourteen out of 21 non-phasic vasopressin neurones were excited (Fig. 5.6 and 5.7) 
while 6 out of 21 were inhibited (Fig. 5.8 and 5.9) and 1 out of 21 did not respond. There 
was no difference in basal firing rate among these neurones (P=0.3; t-test). On average, the 
basal firing rate of 6.3 ± 0.6 spikes/s was increased by 0.9 ± 0.2 spikes/s 4 min after secretin 
(n=21). However, the excitatory response observed 0-10min after secretin administration 
was not significantly higher compared to the basal period (Fig. 5.10). 
5.6.2.2. Phasic vasopressin neurones 
The response to systemic administration of secretin (0.1µg/rat; i.v) was tested in 
eleven phasically firing SON vasopressin neurones (Fig. 5.11). The average activity quotient 
increased and the mean interburst interval decreased 0-5min after secretin Fig. 5.12 and 
5.13). The mean frequency within bursts remained uncha ged (Fig. 5.14). Hence, systemic 
administration of secretin excited the phasic firing SON vasopressin neurones. This 
excitation did not reflect on the interspike interval histograms (Fig. 5.15a and b). There was 
no change in the shape of the hazard plot after secretin (Fig. 5.16). 
5.6.3. Effect of systemic administration of secretin on SON oxytocin neurones: Dose-
related responses 
 After recording basal firing rate for 10min, secretin was administered intravenously 
at three different dose rates: 0.01µg (n=4), 0.1µg (n=26) and 1µg (n=3) in 100µl normal 
saline; all doses were total per rat. Secretin-induce  excitatory responses in SON oxytocin 
neurones (e.g. Fig. 5.17, 5.18 and 5.19) were dose ep ndent. The responses observed 0-
10min after secretin between the three different groups were significantly different from 
each other (Fig. 5.20). 
5.6.4. Plasma oxytocin release upon systemic administration of secretin in unfasted 
anaesthetized rats 
 Systemic secretin dose-dependently elevated the plasma oxytocin concentration in 
unfasted rats (Fig. 5.21). Secretin (0.1 and 1µg per rat) significantly elevated the oxytocin 
level compared to the basal and vehicle-induced change in the level. The increase in the 
oxytocin concentration following 1µg secretin was significantly higher than 0.1µg secretin. 
5.6.5. Effect of systemic administration of secretin on somato-dendritic release of 
oxytocin from the SON in vivo in urethane-anaesthetized unfasted female rats 
 Four out of six rats that showed a positive respone to hypertonic and subsequent 
aCSF microdialysis were statistically analysed to seek evidence of secretin-induced central 
oxytocin release from the SON (Fig. 5.22a). These rats also showed an evident excitatory 
response to systemic administration of secretin (1µg/rat) (Fig. 5.22b). The response was seen 
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only more than 1h after administration of secretin. O  average, the excitatory response after 
secretin showed a trend to significance (Fig. 5.22c). Compared to peripheral oxytocin release 
following secretin, release at the SON is much delayed (Fig. 5.22d). 
5.6.6. Effect of secretin administration on electrical activity of SON neurones in fasted 
virgin rats compared to unfasted virgin rats 
5.6.6.1. SON oxytocin neurones 
 The average body weight, mean basal firing rate and secretin-induced change in the 
firing rate of SON oxytocin neurones in fasted virgin rats were not different from unfasted 
virgin rats (body weight: P=0.4, t-test; basal firing rate: P=0.8, t-test; secretin-induced 
change in the firing rate: P=0.9, t-test; Fig. 5.23)   
5.6.6.2. SON vasopressin neurones 
The average body weight of fasted and unfasted rats did not differ from each other 
(P=0.6; t-test). The response to systemic administrat on of secretin (0.1µg; i.v) was observed 
in 2 non-phasic and 3 phasic firing SON vasopressin neurones in fasted rats. One of the non-
phasic vasopressin neurone was inhibited by secretin wh le the other did not respond (data 
not shown). In contrast, all the three phasic firing vasopressin neurones tested were excited 
by secretin; however, the excitation was not signifcant. There was no difference in basal and 
secretin-induced activity of phasic firing SON vasopressin neurones between fasted and 
unfasted rats (Fig. 5.24, 5.25 and 5.26). 
5.6.7. Effect of i.c.v. benoxathian infusion and microdialysis of benoxathian onto the 
SON on secretin-induced excitation of SON oxytocin and vasopressin neurones 
As the experiments with benoxathian microdialysis and i.c.v. infusion required 
successive treatments with same dose of secretin, in an nitial experiment, the same dose of 
secretin was injected repeatedly and the responses were compared to examine the possibility 
of receptor desensitization.  The responses to repeat d injections of secretin were not 
different in both oxytocin (Fig. 5.27, 5.28 and 5.28a) and vasopressin neurones (Fig. 5.29 
and 5.29a) tested. 
5.6.8. Effect of i.c.v. infusion of benoxathian on secretin-induced excitation of SON 
oxytocin neurones 
Six SON oxytocin neurones were tested for the involvement of NA pathway in 
secretin-induced excitation. The basal firing rate nd percentage increase in the firing rate 
following secretin were negatively correlated (P=0.004; Pearson’s correlation coefficient = -
9.5). During benoxathian i.c.v. infusion (8µg/µl min-1), the average basal firing rate of 5.8 ± 
1.16 spikes/s was decreased by 29 – 100 % (28.83%, 38.67%, 58.49%, 79.26%, 100%, and 
100%) in those 6 neurones studied. As per the negativ  correlation, lesser the basal firing 
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rate, greater should be the increase in firing ratefollowing secretin. However, the secretin-
induced excitatory response was also suppressed in all the 6 neurones by i.c.v. benoxathian 
infusion which reduced or abolished the basal firing rate (e.g. Fig. 5.30). The excitatory 
response 0-5min after secretin, before benoxathian i.c.v. infusion, was significantly greater 
than that during benoxathian (Fig. 5.31). 
5.6.9. Effect of benoxathian i.c.v. infusion on secretin-induced excitation of phasic firing 
SON vasopressin neurones 
Benoxathian i.c.v. infusion totally blocked the basal activity of 3 out of 4 phasic 
vasopressin neurones in 20min since it was begun (e.g. Fig. 5.32). The firing rate of one of 
the four neurones increased uncharacteristically following the infusion and hence it was 
excluded from the analysis. Benoxathian also blocked th  excitatory response to secretin in 
all the three neurones tested (Fig. 5.33). After stopping the infusion, the cells started to 
resume their basal activity and upon secretin injection, elicited mild excitatory response. 
5.6.10. Effect of benoxathian (2mM) microdialysis onto the SON on secretin-induced 
excitation of SON oxytocin neurones 
The average basal firing rate before benoxathian microd alysis was 3.1 ± 0.5 spikes/s 
and it was reduced by 54.22%, 76.06% and 86.71% in the three neurones during benoxathian 
microdialysis. Benoxathian microdialysis also suppressed the secretin-induced excitatory 
response in all the three cells (Fig. 5.34). 
5.7. Discussion 
5.7.1. Responses of SON neurones to systemic secretin: Duration of action 
 Secretin clearly and consistently excited SON oxytcin neurones, and the activity 
returned to basal by 20min with doses up to 1µg i.v. The peak electrical activity observed 
2min after intravenous secretin injection in this study correlates with the maximum blood 
concentration 2min post-dosing observed by Goulet et al (2003). The half-life of circulating 
endogenous secretin is only 1.5 - 3min in rats (de Smul et al., 1974; Lehnert et al., 1974; 
Tanaka and Katayama, 1984). Bath application of secretin to brain preparations in vitro 
resulted in increase in firing frequency of action potentials in whole cell current clamp 
recording of NTS that lasted for only 7-12min (Yang et al., 2004a). However, secretin 
(40µg/kg; i.v) induced Fos expression in the SON was similar at 60 and 120min and absent 
by 240min (Goulet et al., 2003). The expression of Fos for up to 120min after intravenous 
secretin could be due to the higher dose used, or more likely to the secretin-induced Fos 
expression in SON neurones lasting longer than the electrical activity.  
The ratios of peak early to mean late hazard before and after secretin did not differ 
from each other suggesting that there is no change in the shape of the hazard after secretin 
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(Brown et al., 2008). A positive shift in the hazard function without a change in the shape of 
the hazard plot suggests that the increase in the probability of a spike firing might result from 
increased synaptic drive and/or a sustained depolarization upon which continued/increased 
synaptic drive is superimposed (Brown et al., 2008).  
5.7.2. Responses of SON neurones to physiologically similar dose  
 Secretin elicited robust excitatory responses in SON oxytocin and vasopressin 
neurones in pioneer studies in which higher doses were used (5, 10 µg i.v; data not shown). 
The dose was reduced gradually until it was found that doses less than 0.01µg were not 
effective. Secretin at a dose of 0.01µg i.v. was not always effective, while 0.1µg i.v. 
produced consistent excitation in SON oxytocin neurones. Thus a dose of 0.1µg i.v. secretin 
was used in further experiments. The dose chosen was ne rly physiological as i.v. secretin at 
0.1µg/kg h-1 is physiologically similar to the rate of  postprandial release (Lu and Owyang, 
1995).  
Only 0.12% of intravenous secretin enters brain (Banks et al., 2002), hence only 
0.12ng of secretin out of the 0.1µg i.v. dose used in our study is expected to enter brain. This 
is the lowest systemic dose of secretin to be report d to have central effects. Behavioural 
effects were found even with as little as 0.001µg given by the i.c.v. route in mice (Babarczy 
et al., 1995). Other studies have examined the secretin dose response relationship for 
induction of Fos expression in the CeA with doses starting from 0.4µg/kg i.v., but failed to 
find a significant increase in Fos at this dose, while Fos expression was significantly greater 
when the dose was increased 10-fold (Goulet et al., 2003). 
5.7.3. Dose-dependent responses of SON oxytocin neurones 
 Secretin dose-dependently excited the firing rate of SON oxytocin neurones. The 
excitation gradually subsided and returned to basal by 20min with all of the doses used. 
Systemic secretin dose-dependently increased the number of Fos expressing cells in the CeA 
(Goulet et al., 2003 and Yang et al., 2004b), suggesting that more cells are recruited to be 
activated as the dose increases. The results from the present study show that even the 
intensity of activation of single neurones is dose- d pendent.  
5.7.4. Secretin-induced increase in plasma oxytocin release 
 An increase in the electrical activity of SON oxytocin neurones represents increase 
in the peripheral release of oxytocin. This is furthe  confirmed by the study on plasma 
oxytocin release following secretin administration. Systemic secretin dose-dependently 
increased the plasma oxytocin level in unfasted anaesthetized rats. Previously, Takayanagi 
and Onaka also reported dose-dependent increase in th plasma oxytocin release following 
central administration of secretin (0.1-10 µg; i.c.v) (Takayanagi and Onaka, 2007).  
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5.7.5. Systemic secretin-induced somato-dendritic oxytocin release from the SON 
Secretin, given i.v, has been shown to reduce food intake in sheep (Grovum, 1981) 
but not in rats, when given i.p (Lorenz et al., 1979; Garlicki et al., 1990). From this 
perspective, it is interesting that systemic administration of secretin (1µg/rat) tended to 
increase release of oxytocin, an anorectic peptide, from the ventral surface of the SON. This 
finding indicates that further studies on the effect of intravenous secretin on food intake in 
rats are required.  
Secretin (1µg/rat, i.v.) excited SON oxytocin neurones immediately after its 
administration and the response subsided within 30min. Similarly, secretin elevated plasma 
oxytocin concentration immediately after its administration. However, any SON release of 
oxytocin following secretin seems to be delayed for more than an hour. This pattern is 
similar to the peripheral and central oxytocin releas  profile observed after systemic osmotic 
stimulation (Ludwig et al., 1994).  
The electrical activity is coupled with peripheral oxytocin release but is not always 
coupled with central somato-dendritic release from magnocellular neurones, which may be 
regulated independently (Ludwig et al., 1994; Ludwig and Leng, 2006). The increase in the 
intracellular Ca2+ level following action potential results in the activity-dependent exocytosis 
of small synaptic vesicles (SSV) at the axon terminals (Leng et al., 1999). This release is 
immediate as the SSV are aligned at the terminals re dy to be released. On the contrary, the 
exocytosis of oxytocin-containing large dense core vesicles (LDCV) at the dendrites requires 
the mobilization of the vesicles from the reserve pool to the releasable pool, which is a slow 
process. However, if the intracellular Ca2+ concentration is increased by stimulating Ca2+ 
release from the endoplasmic reticulum, the LDCV in the reserve pool are mobilised to the 
releasable pool and these are docked at the membrane re dy to be released upon subsequent 
electrical activity (Ludwig and Leng, 2006). This mechanism called ‘priming’ is also 
regulated by centrally released oxytocin which thus a to-regulates its own release (Ludwig 
and Pittman, 2003). The immediate activity-dependent peripheral oxytocin release and the 
subsequent dendritic oxytocin release at a later stage, following secretin administration, 
might be physiologically relevant: peripheral releas  might regulate the sodium balance on a 
moment-to-moment basis as the animal starts feeding; lack of central oxytocin release might 
promote feeding initially while the subsequent release after a period of time might gradually 
mediate satiety so that feeding stops. 
Oxytocin release from the isolated SON after direct application of secretin in vitro 
(Takayanagi and Onaka, 2007) suggests direct action of secretin on secretin receptors on 
oxytocin neurones (Chu et al., 2006a). The delayed SON oxytocin release following 
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systemic secretin administration observed in this preliminary study possibly indicates an 
indirect effect via inputs to the SON, for example via vagal afferents and a brainstem 
pathway, by analogy with CCK (Onaka et al., 1995a) or possibly via arcuate nucleus POMC 
neurones, as α-MSH stimulates somato-dendritic oxytocin release from the SON (Sabatier et 
al., 2003a). 
5.7.6. Secretin-induced responses in SON vasopressin neurones 
 Secretin is functionally related to CCK (Chey and Chang, 2001).  Systemic 
administration of CCK does not increase the electrical activity or peripheral release of 
vasopressin neurones (Verbalis et al., 1986a; Verbalis et al., 1986b; Renaud et al., 1987). 
However, direct local application of CCK evokes vasopressin release from perfused 
hypothalamic-neurohypophysial explants (Jarvis et al., 1995). Central administration of 
secretin resulted in Fos expression in SON vasopressin neurones and increased peripheral 
release of vasopressin (Takayanagi and Onaka, 2007). Bath application of secretin onto 
hypothalamic explants induced vasopressin release (Takayanagi and Onaka, 2007). 
However, the response of SON vasopressin neurones t sys emic administration of secretin 
was not previously known. The experiments here were aimed to see whether secretin-
induced responses in SON vasopressin neurones are similar to those induced by CCK when 
administered intravenously, i.e. either inhibitory or without any effect on the firing rate in 
contrast to excitatory effect seen during central administration. Interestingly, systemic 
secretin either excited or inhibited non-phasic vasopressin neurones, with excitatory effect 
being predominant, and excited all of the phasic vasopressin neurones. Physiologically, the 
passive movement of water from plasma into the intestinal lumen following secretin-induced 
exocrine pancreatic secretion of HCO3- results in plasma hyperosmolality and stimulates 
vasopressin release (Kitagawa et al., 1990; Ko et al., 1999). However, it is surprising that 
secretin action on vasopressin neurones is immediate suggesting that in addition to plasma 
hyperosmolality, other direct/indirect means of secretin-induced activation is possible for 
SON vasopressin neurones. 
5.7.7. Basal activity of SON oxytocin neurones in the fasted animals 
In the unfed state, the activation of SON oxytocin neurones might be suppressed to 
avoid natriuresis and diuresis. This is supported by the observation that Fos expression has 
been found in the SON of fed but not unfed sheep (Chaillou et al., 2000) and Fos expression 
in the SON in unfed rats was less than that in fed rats while feeding significantly increased 
Fos in SON in schedule-fed rats (Johnstone et al., 2006). Hence, the basal activity of SON 
neurones was expected to be less in fasted rats. However, the basal activity of SON neurones 
was not different between fasted and unfasted rats in this study. This might be due to the less 
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number of observations made in the fasted group. On the other hand, food deprivation might 
act as a stress stimulus increasing the basal activity of oxytocin neurones to release the stress 
hormone, oxytocin. Moreover, secretin levels are increased in fasted state in humans and 
dogs (Mason et al., 1979; Manabe et al., 1987) which, if it is the same case in rats, might 
overcome reduction, if any, of the basal activity of SON neurones. In addition, it might also 
be due to the anaesthetic used in the study. Urethan , the anaesthetic that preserves 
physiological function in the oxytocin neurones, like the milk-ejection reflex, which is 
impaired by most anaesthetics, is the anaesthetic of choice for studying this system (Leng 
and Dyball, 1991). However, urethane activates the neurones via its mild hyperosmotic 
effect as the SON neurones are physiologically osmosensitive (Mason, 1980). Hence, the 
anaesthetic effects might block the difference, if any, between the basal activity of SON 
neurones in unfasted and fasted rats. 
5.7.8. Secretin-induced activity of SON neurones in fasted animals 
 Secretin-induced activity of SON neurones is also not different between fasted and 
unfasted rats. This is in contrast to the lack of Fos expression seen in SON in fasted rats upon 
systemic administration of secretin (Goulet et al., 2003). Secretin (40µg/kg; i.v) increased 
the number of Fos positive neurones in the SON in unfasted rats but there was no Fos 
expression in 18-20h fasted rats (Goulet et al., 2003). This discrepancy in the secretin-
induced activation of SON neurones in conscious and anaesthetized rats might be the effect 
of anaesthetic (Sabatier t al., 2003a). The mild hyperosmotic effect of urethane activ ting 
the physiologically osmosensitive SON neurones might nullify the difference, if any, in the 
basal and secretin-induced activity of SON neurones i  unfasted and fasted rats. However, it 
is possible that secretin excites oxytocin neurones with fasting having no influence at all.  
5.7.9. Secretin-induced desensitization of secretin receptors 
 Desensitization of receptors to ligand stimulation is a phenomenon to protect cells 
from overstimulation which may result in cell damage (Siu et al., 2006). The desensitization 
of secretin receptors remains controversial (Siu et al., 2006). Chinese Hamster ovarian cells 
transfected with human secretin receptor were exposed to secretin and the extracellular 
acidification rate, an indicator of metabolic stimulation, was measured as a response to 
secretin (Ng et al., 1999). When the cells were continuously exposed to secretin, the 
response (i.e. acidification) increased rapidly at first and then attained a plateau that 
suggested occurrence of desensitization limiting the maximal response (Ng et al., 1999). 
However, when the cells were exposed to secretin repeat dly, the peak responses of the cells 
did not change significantly between exposures suggesting that the secretin receptor did not 
exhibit desensitization (Ng et al., 1999). In the present study, excitatory responses to 
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repeated injections of secretin were tested in SON oxytocin and vasopressin neurones to rule 
out the possibility of receptor desensitization so that the same dose of secretin could be given 
repeatedly in further experiments. Repeated injections of secretin produced almost identical 
excitatory responses in both oxytocin and vasopressin neurones, hence receptor 
desensitization did not occur with the pattern of secretin exposure in the current experimental 
model, and this enabled us to conduct further experiments involving repeated injections of 
secretin. 
5.7.10. Pathways involved in the systemic secretin-i duced activation of SON neurones 
 The activation of SON neurones following systemic secretin administration could 
occur in two ways (Fig. 5.35):  
1. Directly  by the binding of secretin to secretin receptors on the SON neurones (Chu et al., 
2006a) bypassing blood-brain barrier (Banks et al., 2002).  
2. Indirectly by the activation of vagal afferents and subsequently brainstem nuclei.  
 Secretin activates vagal afferents (Li et al., 2005) and depolarizes neurones in the 
NTS (Yang et al., 2004b). Subdiaphragmatic vagotomy abolishes Fos expression induced by 
systemic secretin in the NTS but it was maintained i  the AP (Yang et al., 2004b) suggesting 
that secretin may act directly on the AP neurones and indirectly, via vagal afferents, on the 
NTS neurones. Excitatory noradrenergic neurones of NTS (A2 group) project to the SON 
(Alonso and Assenmacher, 1984). The AP also has efferent projections to the SON via the 
A1 cell group (van der Kooy and Koda, 1983; Shapiro and Miselis, 1985; Johnson and 
Gross, 1993) and lateral parabrachial nucleus (Fulwiler and Saper, 1984; Shapiro and 
Miselis, 1985). The AP and NTS maintain reciprocal onnections (Shapiro and Miselis, 
1985; Ferguson, 1991; Hay and Bishop, 1991a, b), hence afferent input to the AP may be 
relayed first o the NTS and then conveyed to the SON or vice versa (Carlson et al., 1998).  
 Systemic administration of CCK activates gastric vagal afferents and hence activates 
oxytocin neurones probably via the NTS (Verbalis et al., 1986a; Renaud et al., 1987; Onaka 
et al., 1995a). To test whether secretin induced excitation of SON oxytocin neurones also 
involves a noradrenergic pathway, we studied the effect of secretin during benoxathian (α-1 
adrenergic antagonist) i.c.v. infusion and during microdialysis onto the SON.  
 Intracerebroventricular benoxathian infusion has been shown to successfully block 
the excitatory response of SON oxytocin neurones to CCK with an infusion rate of 
5.3µg/min (Brown et al., 1998). A benoxathian infusion rate of 4µg/min was found to be 
ineffective in reducing the basal firing-rate of SON neurones in this study (Fig. 5.30). Hence, 
benoxathian was infused i.c.v. at a rate of 8µg/min. Benoxathian significantly reduced the 
basal firing rate and secretin-induced excitation of SON oxytocin neurones. Hence 
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adrenergic pathways are involved in the excitation of SON oxytocin neurones induced by 
systemic secretin. This is in accordance with the positive shift in the hazard without change 
in the shape of the hazard plot of SON oxytocin neurones after secretin administration 
affirming that secretin merely increases the excitatory inputs without altering the intrinsic 
properties of the membrane.  
 Intracerebroventricular administration of benoxathian totally inhibited the basal 
firing and completely abolished the secretin-induced xcitatory response in phasic 
vasopressin neurones. Hence it appears that noradrenalin  facilitates the basal firing as well 
as secretin-induced excitation through α-1 adrenergic receptors in the phasic vasopressin 
neurones. 
 Though the results of this i.c.v. infusion study suggest the possibility of involvement 
of noradrenergic pathways in the secretin induced excitation of SON oxytocin neurones, it 
does not specify the role of excitatory noradrenergic projections from A2 group of NTS. 
Hence, benoxathian was microdialysed on the surface of the SON so as to block the local 
noradrenergic inputs which is predominantly from the NTS.  
Microdialysis application of benoxathian to the SON also reduced the basal firing 
rate of the SON oxytocin neurones tested by 72.3 ± 11.7%. Previously, oxytocin neurone 
firing rate has been to be reduced by 53% after benoxathian microdialysis (Brown et al., 
1998). Hence, α1 adrenoceptors, and NA, at least in part, facilitate onic excitation of SON 
oxytocin neurones. Technically, the reduction in the basal firing rate confirmed that 
benoxathian diffuses out of the microdialysis probe on to SON neurones, presumably 
blocking tonic activation via α1 adrenoceptors, and validating the whole experimental 
preparation suitable to carry out further experiments testing the effect of secretin during 
benoxathian microdialysis. Benoxathian microdialysis suppressed the secretin-induced 
excitatory response in all three SON oxytocin neurones tested suggesting that secretin-
induced excitation of SON oxytocin neurones is via α1 adrenoceptors, mediated presumably 
by NA inputs from the NTS. 
5.7.11. Secretin-induced oxytocin release: physiological implications 
5.7.11.1. Feedback and feed-forward effects?  
The results from this study suggest that some of the effects of secretin might, at least 
in part, be mediated through the activation of SON neurones and thus the release of oxytocin 
and possibly vasopressin. Secretinergic cells are found in the mPVN and SON (Welch et al., 
2004). SON neurones activated by secretin might even represent secretinergic neurones 
activated to modulate the somato-dendritic release of oxytocin, vasopressin or even secretin.  
Interestingly, oxytocin receptors are expressed in the intestine (Welch et al., 2009). Hence, 
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secretin-induced release of peripheral oxytocin might feed-forward to modulate the secretion 
of secretin from the duodenal S-cells.   
5.7.11.2. Gastroprotection? 
 Secretin and oxytocin have many regulatory roles in common (Fig. 5.36). 
Physiologically, intra-duodenal acidification is the only well established stimulus for secretin 
release (Oektedalen et al., 1982). In addition, stress-related gastrin and gastric acid secretion 
also act as an acute stimulus for the release of secretin (Li et al., 1998). Secretin is a gastro-
protective hormone (Bayliss and Starling, 1902). It prevents stress-induced gastric bleeding 
in the gastric mucosa in the rat (Murakami et al., 1985). Impaired secretin release and 
reduced duodenal S-cells have been documented in peptic ulcer patients (Love, 2008a, b). 
Similarly, oxytocin showed significant antisecretory and antiulcer activity in rats (Asad et 
al., 2001). It is possible that gastro-protective properties of secretin are complemented by 
secretin-induced oxytocin secretion. 
5.7.11.3. Gastric motility? 
Secretin receptors are localized on the longitudinal and circular muscle layers of the 
rat forestomach (Steiner et al., 1993). The inhibitory effect of secretin on gastric emptying 
might be produced through direct action of secretin on secretin receptors (Zhou and Wang, 
1990; Steiner et al., 1993). However, administration of secretin delays gastric emptying and 
inhibits gastric motility via a vagal afferent pathway originating from the gastroduodenal 
mucosa (Raybould and Holzer, 1993; Lu and Owyang, 1995). This pathway might culminate 
in the activation of oxytocin neurones and the release of oxytocin. Oxytocin inhibits gastric 
emptying and gastrointestinal transit in rats via a mechanism involving CCK stimulation and 
CCK1 receptor activation (Wu et al., 2002; Wu et al., 2003; Ohlsson et al., 2006; Wu et al., 
2008). Oxytocin excited almost all of the gastric-related NTS neurones (McCann and 
Rogers, 1990). Hence, a synergistic action is possible for secretin and oxytocin to govern 
gastric motility. 
5.7.11.4. Postprandial exocrine pancreatic secretion? 
 Postprandial release of oxytocin stimulates the rel ase of atrial natriuretic peptide 
(ANP) (Haanwinckel et al., 1995). ANP release also increases basal and hormone (CCK and 
secretin) evoked exocrine pancreatic secretion in a dose dependent manner (Sabbatini et al., 
2003).  Hence it is possible that postprandial secretin induces release of oxytocin which in 
turn triggers ANP release to augment exocrine pancreatic secretion. In addition, oxytocin 
receptors are found in a rat pancreatic cell line (Jeng et al., 1996). Oxytocin increases the 
release of insulin and glucagon from the endocrine pancreas (Bjorkstrand et al., 1996), both 
of which increase the secretion from the exocrine pancreas (Ferrer et al., 2000). Hence 
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secretin-induced oxytocin release might also augment exocrine pancreatic secretion through 
insulin and glucagon. 
5.7.11.5. Postprandial natriuresis? 
Postprandially released oxytocin promotes natriuress and diuresis (Haanwinckel t 
al., 1995). A secretin-oxytocin-ANP (or secretin-ANP) pathway might, if such a pathway 
exists, also govern post-prandial natriuresis. As ANP and oxytocin are colocalized in some 
hypothalamic magnocellular neurones (Jirikowski et al., 1986), secretin-induced excitation 
of oxytocin neurones might release ANP, in addition t  the release of oxytocin. The 
oxytocin-mediated natriuretic mechanisms are essential during the post-prandial period to 
regulate sodium balance. 
5.7.11.6. Antidiuresis? 
 Recently, secretion has shown to be involved in osmoregulation. Dehydration 
increases the expression of secretin and its receptor in hypothalamic neurones (Chu et al., 
2009) and water deprivation and saline drinking elevat  plasma secretin level (Chu et al., 
2009). Secretin receptors are found in the kidney (Ohta et al., 1992) and in anaesthetized 
hydrated rats, secretin exhibits anti-diuretic action (Charlton et al., 1986). Secretin receptor 
null mice (SCTR-/-), which does not have any alteration in the transcription levels of 
vasopressin mRNA, develops polydipsia and polyuria (Chu et al., 2007). Hence, secretin 
mediated osmoregulation is likely to be one of the vasopressin independent mechanism 
regulating water balance (Cheng et al., 2009).  
 Depending on the hydration status of the animal, oxytocin could be either diuretic or 
anti-diuretic. In Brattleboro rats, which congenitally lack vasopressin, the symptoms of 
diabetes mellitus were reversed by oxytocin infusion (Lyness et al., 1985). This anti-diuretic 
effect of oxytocin is mediated by V2 receptors in the kidney (Li et al., 2008). Hence, anti-
diuretic effects of secretin and oxytocin might complement each other, especially during 
periods of reduced water intake (e.g. fasting), during ingestion of dry feed or during 
excessive salt intake.  
5.7.11.7. Energy homeostasis during starvation? 
 Secretin level in plasma dramatically increases from day 1 to 3 of fasting in humans 
and dogs (Mason et al., 1979; Manabe et al., 1987). This increment is several times higher 
than that observed after intraduodenal acid load and can be suppressed by i.v. glucose or 
refeeding (Thuesen et al., 1987). In vitro experiments have shown that secretin stimulates 
lipolysis (Lazarus et al., 1968; Rudman and Del Rio, 1969; Rodbell et al., 1970), 
glycogenolysis (Matsumura et al., 1977) and gluconeogenesis (Matsumura et al., 1977). 
Similarly, oxytocin levels are significantly increased after short term food deprivation, and 
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insulin-induced hypoglycaemia elevates plasma oxytocin levels in female and male rats 
(Bjorkstrand et al., 1992). In hepatocytes from starved rats, oxytocin stimulates 
gluconeogenesis from lactate by 25-50% (Hems et al., 1978; Whitton et al., 1978). Hence, 
during periods of hypoglycaemia, secretin could also ct through oxytocin to elevate glucose 
levels. Interestingly, however, secretin did not stimulate Fos expression in the SON in fasted 
rats (Goulet et al., 2003).  
5.7.11.8. Secretin-induced central oxytocin release and regulation of appetite? 
 The evidence for the involvement of secretin in appetite regulation, such as food 
intake and satiety, is lacking in the literature. This study showed that secretin induces 
somato-dendritic oxytocin release from the SON. Central oxytocin is anorectic (Olson et al., 
1991a) but it is not known whether secretin induces ntral oxytocin release during the 
postprandial period to mediate satiety. Systemic administration of secretin (0.1-100 clinical 
units/kg; i.p) failed to elicit satiety in the sham feeding rat (Lorenz et al., 1979) and 
10nmol/kg i.p. secretin also had no effect on feeding in rats (Garlicki et al., 1990), unlike 
CCK which is a satiety peptide (Antin et al., 1975).  
5.7.11.9. Secretin-induced central oxytocin release and regulation of social behaviour? 
 Cyclosporine, an immunosuppressive drug, disrupts social behaviour by reducing the 
release of serotonin and dopamine in the prefrontal cortex (Sato et al., 2007). Centrally 
administered secretin (1µg/rat; i.c.v) partially restored abnormal social interaction after 
cyclosporine in rats (Takayanagi and Onaka, 2007). There is evidence that secretin is 
effective in some people with autistic spectrum disorders (Horvath et al., 1998; Lamson and 
Plaza, 2001; Alamy et al., 2004). There are some liited or mixed results available in the 
literature as well (Chez et al., 2000; Coniglio et al., 2001; Kern et al., 2002; Pallanti et al., 
2005; Ratliff-Schaub et al., 2005). Controversially, in several other studies, secretin 
produced no effect or brought about deterioration of behaviour and communication 
capabilities in autistic patients (Sandler et al., 1999; Dunn-Geier et al., 2000; Corbett et al., 
2001; Lightdale et al., 2001; Owley et al., 2001; Roberts et al., 2001; Robinson, 2001; Carey 
et al., 2002; Molloy et al., 2002; Sponheim et al., 2002; Unis et al., 2002; Levy et al., 2003).  
 Two single nucleotide polymorphisms in oxytocin receptors have been associated 
with autism in the Chinese Han population (Wu et al., 2005). Post mortem analyses of a 
developmental hyperserotonemia (DHS) model of autism in rats revealed that there is a loss 
of oxytocin neurones in the PVN (McNamara et al., 2008). Repetitive behaviour in autistic 
spectrum disorders was partially ameliorated by synthetic oxytocin infusion (Hollander et 
al., 2003). Both secretin and oxytocin have been implicated in the treatment of autistic 
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spectrum disorders (Welch and Ruggiero, 2005; Welch t al., 2005). This reinforces the idea 
that the effects of secretin might be mediated, at least in part, through oxytocin. 
5.7.12. Secretin-induced vasopressin release: physiological implications  
Plasma hyperosmolality following secretin release, which occurs due to the passive 
movement of water from the plasma into the intestin following bicarbonate secretion, 
stimulates vasopressin release (Kitagawa et al., 1990; Konturek et al., 2003a, b) which in 
turn acts on ductal cells in the pancreas to reduce se retin-stimulated pancreatic secretion 
(Kitagawa et al., 1990; Ko et al., 1999). In addition to this slow effect, secretin treatment 
results in rapid release of vasopressin into the plasma (Takayanagi and Onaka, 2007; Chu et 
al., 2009). Vasopressin is antidiuretic (Abboud et al., 1990). In addition to being one of the 
vasopressin-independent mechanisms by itself (Cheng et al., 2009), secretin is likely to 
regulate water balance via vasopressin. 
5.8. Conclusion 
 Systemic administration of secretin elicited a dose-dependent excitatory firing rate 
response in SON oxytocin neurones and a dose-dependnt increase in plasma oxytocin 
release. Systemic secretin seems to increase somato-dendritic release of oxytocin from the 
SON. The electrophysiological response of vasopressin neurones to systemic secretin was 
predominantly excitatory. Noradrenergic pathways, possibly involving the NA-ergic 
projections from the brainstem neurones to the SON, mediate the secretin-induced excitatory 
effects via α-1 adrenoceptors in SON oxytocin and vasopressin neuro s. Fasting did not 
alter the response of SON neurones to secretin. The influ nce of the gut peptide secretin on 
the electrical activity of SON neurones suggests that t e SON is important in the regulation 
of brain-gut axis. Secretin and oxytocin have several physiological functions in common or 
linked, hence it is possible that the central and peripheral physiological effects of secretin are 




6.1. Introduction  
Cholecystokinin (CCK) is synthesized in the I-cells of the intestinal mucosa (Polak 
et al., 1975) and is secreted when food enters the small intestine from the stomach. It 
stimulates enzyme secretion from the exocrine pancreas to digest fat, protein and 
carbohydrates.  Peripheral CCK also mediates satiety (Liddle, 1997).  
Systemic administration of CCK increases the electrical activity of SON oxytocin 
neurones in urethane-anaesthetized rats and increases the peripheral release of oxytocin in 
conscious and anaesthetized rats (Renaud et al., 1987; Hamamura et al., 1991). Although 
HPA axis and oxytocin responses to various stimuli are attenuated in late pregnancy (Russell 
et al., 2008), the CCK-induced excitatory response of SON oxytocin neurones in late 
pregnant rats is not different from virgin rats, exc pt importantly, that the response is 
enhanced by naloxone only in late pregnant rats (Douglas et al., 1995). As fasting is a 
stressor and oxytocin is a stress hormone in the rat (Lang et al., 1983), increased basal and 
CCK-induced activity of oxytocin neurones is expected upon fasting. In addition, as leptin 
antagonises HPA responses to many stressors, includi g insulin-induced hypoglycaemia and 
fasting (Gaillard et al., 2000; Giovambattista et al., 2000), oxytocin neuronal responses to 
CCK can be expected to be augmented in fasted animals because fasting reduces endogenous 
levels of leptin (Ladyman and Grattan, 2004). On the other hand, homeostatic mechanisms 
might suppress CCK-induced excitation of oxytocin neurones to conserve the sodium level 
during fasting when the salt intake is less. Hence, it will be interesting to study the excitatory 
responses of SON oxytocin neurones following CCK administration in fasted virgin and 
pregnant rats and to compare these with the responses i  unfasted rats. 
 Synergy between leptin and CCK has been observed in food intake and body weight 
regulation (Barrachina et al., 1997; Matson et al., 1997; Matson and Ritter, 1999; Matson et 
al., 2002). It is not known whether systemic leptin potentiates CCK-induced oxytocin 
neuronal excitation. The models of fasting and pregnancy, in which the endogenous leptin 
levels are decreased and increased, respectively, also provide a means to study this 
interaction between leptin and CCK.  
As CCK is synergistic with secretin (You et al., 1983; Chey et al., 1984) and closely 
interacts with leptin (Barrachina et al., 1997) and all these peptides are released during the 
postprandial period (Schafmayer et al., 1978; Saladin et al., 1995), it was considered of 
interest to compare the responses of SON oxytocin and v sopressin neurones to CCK with 
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the responses induced by secretin and leptin to analyse the effectiveness of the peptides and 
to understand their influence on postprandial oxytocin/vasopressin secretion. 
6.2. Hypotheses 
1. CCK-induced excitation of SON oxytocin neurones are alt red during fasting in 
virgin and pregnant rats. 
2. Systemic leptin potentiates the CCK-induced excitatory responses of SON 
oxytocin neurones. 
6.2.1. Objectives 
1. To study the electrophysiological responses of SON oxytocin neurones in vivo 
after systemic administration of CCK in fasted urethane-anaesthetized virgin and 
pregnant rats and to compare with unfasted virgin and pregnant rats. 
2. To study whether systemic administration of leptin otentiates the CCK-induced 
excitatory electrophysiological responses of SON oxyt cin neurones in unfasted 
virgin rats. 
3. To compare the electrophysiological responses of SON oxytocin and 
vasopressin neurones in unfasted/fasted virgin rats to systemic administration of 




Cholecystokinin (CCK) was discovered in 1928 by Ivyand Oldberg during studies 
on hormonal mechanisms involving gallbladder contraction in dogs (Ivy and Oldberg, 1928). 
As similar intestinal extracts also stimulated pancreatic enzyme secretion, the name 
‘pancreozymin’ was proposed (Harper and Raper, 1943). Purification and amino acid 
sequencing of the active substance showed that CCK and pancreozymin are the same and 
hence it goes now by the name cholecystokinin (Mutt and Jorpes, 1968). 
The endocrine I-cells of the intestinal mucosal epithel um, that produce CCK, are 
concentrated in the duodenum and proximal jejunum (Polak et al., 1975). The release of 
CCK is stimulated by ingestion of food, with fats and protein the most potent secretagogues, 
and carbohydrates the least potent (Liddle, 1997). CCK secretion is initiated when the food 
enters the small intestine from the stomach and continues until protein, fat and their 
metabolites have passed the upper small intestine (Liddle, 1997). Apart from stimulating 
exocrine pancreatic enzyme secretion and gall bladder contraction, CCK also stimulates 
intestinal peristalsis and inhibits gastric emptying (Liddle, 1997).  
6.3.2. Molecular forms of CCK 
CCK is a heterogeneous hormone and is present in different molecular forms in 
mammals: CCK-83, CCK-58, CCK-39, CCK-33, CCK-22, and CCK-8 (Wang and Cui, 
2007). The post-translational modification of the CCK gene product, preprocholecystokinin, 
results in CCK composed of varying numbers of amino acids. Originally, CCK was purified 
as a 33-amino acid peptide from the porcine intestin  (Mutt and Jorpes, 1968). Since the 
discovery of CCK, multiple molecular forms have been identified in the intestine, brain, and 
the circulation of several species. The CCK octapeptid  (CCK-8), consisting of the carboxy-
terminal 8 amino acids of CCK, is the most potent biologically active small peptide form of 
CCK (Nakajima, 1973), and is also the dominant form in the rat brain (Lamers et al., 1980). 
However, CCK-58 seems to be the only major circulating form of CCK in the rat and other 
smaller forms arise due to degradation of CCK-58 during sample processing (Reeve et al., 
2003). 
The CCK in plasma contains a mixture of CCK molecules such as CCK-58, CCK-33, 
CCK-22, and CCK-8 (Beinfeld, 2003; Rehfeld, 2004). Different studies have reported 
different concentrations of plasma CCK before and after feeding in the rat [1.9 ± 0.3 vs. 13.4 
± 3.8 pM (Douglas et al., 1990), 2.5 vs.9.7 ± 1.6 pM (Douglas et al., 1988), 0.5 ± 0.2 vs. 7.9 
± 1.9 pM (Liddle et al., 1986), 0.85 ± 0.1 vs. 8.2 ± 1.1 pM (Linden et al., 1989a), 2.5 ± 0.3 
vs. 8.9 ± 0.6 pM (Sharara et al., 1993)]. Overall, befor  feeding, plasma CCK concentration 
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was found to be in the range of 0.5 ± 0.2 to 2.5 ± 0.3 pM and after fe ding, it increased to 4.4 
± 0.8 to 13.4 ± 3.8 pM (Wang and Cui, 2007). 
6.3.3. CCK in the CNS 
CCK is also synthesized, stored and released in the CNS (Crawley, 1985). It is one 
of the most abundant peptides in the cerebral cortex, striatum and hippocampus (Beinfeld, 
2001) and is present in moderate quantities in hypothalamic nuclei (Beinfeld et al., 1981b). 
The posterior pituitary receives CCK-containing fibres from the hypothalamic magnocellular 
nuclei (Beinfeld et al., 1981a). CCK co-exists with dopamine in some of the mesencephalic 
neurones and with oxytocin in some of the hypothalamic neurones (Vanderhaeghen et al., 
1981). CCK modulates dopaminergic neurotransmission and has been implicated in 
dopaminergic regulation (Crawley, 1991). The blood-brain barrier completely blocks 
passage of CCK from the gut to the brain, although the movement of CCK from the CSF to 
the blood is controversial (Crawley, 1985; Zhu et al., 1986). 
6.3.4. CCK receptors 
CCK acts via its G-protein coupled receptors (GPCRs). Two CCK receptor subtypes 
have been identified - CCKA (CCK1) and CCKB (CCK2) receptors (R) - on the basis of 
differences in the affinity for the structurally and functionally related family of peptides, 
differences in the affinity for ligands with sulphation at the tyrosyl residues, differences in 
the responses to specific antagonists and differencs in the tissue distribution (Miyasaka and 
Funakoshi, 2003). The CCKAR binds sulphated CCK with higher affinity than gastrin, 
whereas the CCKBR binds sulphated and non-sulphated CCK and gastrin with almost the 
same affinity (Jensen et al., 1989). The CCKAR is predominantly found in the GI system and 
a few areas in the CNS whereas CCKBR is predominantly found in the CNS and some areas 
in the GI system (Wank, 1995). 
6.3.5. Role of vagal afferents in CCK-mediated effects 
CCK-induced exocrine pancreatic secretion occurs via two mechanisms:  
1. Activation of CCKAR on the exocrine pancreas (Zhou et al., 1995).  
2. Neural mediation involving activation of CCKAR on vagal afferents. 
CCK receptors are expressed in vagal afferents fromgut (Li et al., 1997; Patterson et 
al., 2002). Bilateral vagotomy, pretreatment with atropine or hexamethonium or perivagal 
treatment with capsaicin completely abolished exocrine pancreatic secretion in response to 
low doses of CCK, suggesting that CCK at physiological levels stimulates pancreatic enzyme 
secretion via a capsaicin-sensitive afferent vagal p thway originating from the 
gastroduodenal mucosa (Li and Owyang, 1993; Schwartz et al., 1993). CCK-induced 
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stimulation of vagal afferents opposes the inhibitory effects of ghrelin on exocrine pancreatic 
secretion which is also mediated via the vagal pathw y (Kapica et al., 2006). 
6.3.6. CCK and satiety 
Afferent axons of the vagus also mediate the satiety effects of peripheral CCK 
(Smith et al., 1985; Walls et al., 1995) via the low-affinity CCKAR in the vagus (Li et al., 
1997). Systemic administration of CCK results in Fos expression in the NTS (Rinaman et al., 
1995), primarily in regions where vagal afferent fibres terminate (Fraser and Davison, 1992). 
CCK acts directly on the AP neurones because of the deficient blood-brain barrier (Fraser 
and Davison, 1992). 70% of the CCK-activated neurones i  the NTS project to the PVN 
neurones (Rinaman et al., 1995) which probably are oxytocinergic (Blevins et al., 2003). 
However, the downstream pathways involving CCK-induced satiety are not very clear 
because, in addition to the activation of the NTS and AP, peripheral CCK administration 
results in Fos expression in many areas in the brain such as the LC, subcoeruleus nucleus 
(SC), dorsal vagal complex, external subdivision of the lateral parabrachial nuclei (PBel), 
BNST, CeA, DMH, PVN and SON (Fraser and Davison, 1992; Li and Rowland, 1995; 
Monnikes et al., 1997; Eckel et al., 2002; Kobelt et al., 2006). CCK-induced c-fos mRNA 
has also been observed in the brainstem (NTS and AP), amygdala (CeA) and hypothalamus 
(PVN and SON) (Hamamura et al., 1991; Day et al., 1994). However, the VMH and ARC 
did not show any Fos expression following peripheral administration of CCK (Kobelt et al., 
2006). The induction of Fos in the brain and brainstem involves activation of CCKAR 
(Monnikes et al., 1997) and capsaicin sensitive vagal afferents (Monnikes et al., 1997; 
Sayegh and Ritter, 2000). Destruction of NA neurones i  the NTS attenuates CCK-induced 
satiety (Rinaman, 2003). Recently, bilateral ablation of the SON has been found to abolish 
CCK-induced satiety (Takashi Higuchi, personal communication). 
Centrally released CCK might also contribute to satiety because CCK is released 
from hypothalamic neurones during feeding in primates and rats (Schick et al., 1987; De 
Fanti et al., 1998). Moreover, centrally administered CCK results in satiety (Shiraishi, 1990).  
6.3.7. Pathways involved in CCK-induced SON neuronal responses 
Systemic administration of CCK increases the electrical activity of SON oxytocin 
neurones in urethane-anaesthetized rats and increases the peripheral release of oxytocin in 
conscious and anaesthetized rats (Renaud et al., 1987; Hamamura et al., 1991). CCK-induced 
c-fos mRNA expression in the SON and peripheral release of oxytocin in conscious rats is 
abolished by gastric vagotomy (Verbalis et al., 1986a).  
Although the SON neurones possess CCK receptors (Day et l., 1989), peripheral 
CCK does not cross the blood-brain barrier (Crawley, 1985; Zhu et al., 1986). Hence, 
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peripheral CCK activates the NTS through the activation of vagal afferents via the CCKAR, 
(Glatzle et al., 2001), subsequently resulting in the activation of SON neurones (Onaka et al., 
1995a). However, AP neurones are directly activated by CCK (Fraser and Davison, 1992). 
The A2 cell group within the NTS and the Al cell group within the VLM are the sources of 
direct NA projections to the SON and the PVN (Sawchenko and Swanson, 1982). The axon 
terminals of the NA neurones in the A2 cell group make synaptic contact with the SON 
neuronal cell bodies (Alonso and Assenmacher, 1984). Peripheral CCK injections are 
followed by a marked increase in the NA release within he dorsal oxytocin-rich regions of 
the SON as measured by microdialysis (Kendrick et al., 1991; Tobin et al., 2009). In 
addition, destruction of NA fibres in the vicinity of the SON significantly decreased the 
CCK-induced Fos expression in the SON (Onaka et al., 1995a). The NA terminals mediating 
CCK-induced excitation of SON oxytocin neurones are sensitive to opioids because direct 
morphine administration into the SON blocks the NA release in the SON and systemic 
morphine administration blocks CCK-induced Fos exprssion in the SON and oxytocin 
release (Onaka et al., 1995b). 
Although a projection from the A2 cell group of the NTS to the oxytocin and 
vasopressin neurones of the SON has been established, this projection does not contribute 
directly to the control of SON vasopressin neuronal activity (Day, 1989). Rather, NTS 
stimulation excites SON vasopressin neurones due to activation of a relay projection through 
the A1 cell group of the caudal VLM (Day, 1989; Day nd Sibbald, 1989). This pathway is 
thought to be involved in the stimulation of vasopressin secretion by haemorrhage and its 
inhibition by baroreceptor activation (Day, 1989). Systemic CCK administration does not 
increase Fos expression in the NA neurones in the A1 region of the brainstem that project to 
the SON (Onaka et al., 1995a), inhibits NA release into the vasopressin-rich region of the 
SON (Tobin et al., 2009) and does not increase either vasopressin release or vasopressin 
neuronal activity (Verbalis et al., 1986a; Renaud et al., 1987).  
However, direct application of CCK is excitatory to b th oxytocin and vasopressin 
neurones of the SON (Brown et al., 2000a). In vitro application of CCK depolarizes SON 
neurones (Jarvis et al., 1992) and increases the release of oxytocin and vasopressin from 
isolated neurohypophysial nerve terminals and from hypothalamo-neurohypophysial 
explants (Bondy et al., 1989; Jarvis et al., 1995). 
6.3.8. CCK and leptin interaction 
Peripheral administration of CCK reduces meal size in several species (Woods et al., 
1981). Interestingly, recent studies on meal patterns after leptin administration show that 
leptin-induced reduction in food intake is targeted specifically on reducing the amount rather 
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than changing the frequency of meal (Eckel et al., 1998; Flynn et al., 1998; Kahler et al., 
1998). Hence, through within-meal satiety peptides like CCK, long-term satiety signals like 
leptin regulate food intake (Emond et al., 1999; Wang et al., 2000).  
Synergy between leptin and CCK has been observed both in short term responses 
such as food intake and long term responses such as body weight regulation (Barrachina et 
al., 1997; Matson et al., 1997; Matson and Ritter, 1999; Matson et al., 2002). Leptin limits 
food intake on a meal-to-meal basis by regulating NTS and AP responses to CCK (Morton et 
al., 2005). Peripheral injections of a combination of CCK and leptin, at doses inefficient 
when given singly, suppressed food intake by 80% in fasted lean mice (Barrachina et al., 
1997). Leptin injected with CCK increased Fos expression in the PVN by 71% in 24h fasted 
lean mice (Wang et al., 1998). The mechanism by which CCK reduces body weight is 
partially dependent on central leptin pathways (Merino et al., 2008). In turn, CCK promotes 
leptin transport across the blood-brain barrier (Cano et al., 2008) and reduced CCK signaling 
influences the action of leptin (Barrachina et al., 1997).  
In summary, administration of leptin augments respon es to CCK (Barrachina et al., 
1997; Wang et al., 1998; Emond et al., 1999) while genetic or fasting-induced reduction in 
leptin signaling diminishes CCK-induced responses (McLaughlin and Baile, 1980; Niederau 
et al., 1997; McMinn et al., 2000). However, it is not known whether CCK-induced 
excitatory responses of SON oxytocin neurones are potentiated by systemic leptin 
administration.  During pregnancy, the circulating level of leptin is increased (Kawai et al., 
1997) and during fasting, it is decreased (Ladyman and Grattan, 2004). Hence, pregnancy 
and fasting are excellent models to study the interac ion of CCK and leptin on oxytocin 
neurones. 
6.3.9. CCK-induced SON oxytocin neuronal responses during pregnancy 
During pregnancy, alterations in the CCK-induced excitatory responses of SON 
oxytocin neurones are expected for at least four reasons: 
1. The plasma volume is elevated during pregnancy (Brown and Pike, 1960; Rosso and 
Streeter, 1979). Oxytocin release and hence natriuresis are expected to be attenuated 
during pregnancy to maintain the elevated plasma volume. Hence, basal and CCK-
induced oxytocin neuronal activity is expected to be attenuated. 
2. Peripheral and central oxytocin release might be associated with, or be independent 
of each other (Wotjak et al., 1998; Sabatier et al., 2003a). However, systemic CCK 
administration results in peripheral as well as central release of oxytocin (Verbalis et 
al., 1986a; Renaud et al., 1987; Neumann et al., 1994). During pregnancy, to 
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maintain hyperphagia, CCK-induced central excitatory responses may be attenuated, 
which might be reflected in the peripheral response. 
3. CCK activates the HPA axis (Kamilaris et al., 1992). But HPA axis responses to 
various stimuli are attenuated during pregnancy (Russell et al., 2008). CCK 
stimulates the SON oxytocin neurones by evoking NA release onto them (Onaka et 
al., 1995a). This NA release is sensitive to endogen us opioid peptides as they act 
presynaptically near or within the SON to block CCK-evoked NA release and thus 
oxytocin neuronal activation (Onaka et al., 1995a). A tonic endogenous µ-opioid 
inhibition of oxytocin neuronal activity emerges centrally towards the end of 
pregnancy and is exerted at the presynaptic opioid receptors on the NA-ergic nerve 
terminals in the SON (Douglas et al., 1995; Brown et al., 2000a). This opioid tone 
attenuates the IL-1β-induced oxytocin neuronal (secretory and electrophysiological) 
responses during pregnancy, and naloxone reverses this (Brunton et al., 2006). 
Hence, it is expected that CCK-induced excitatory electrophysiological responses of 
SON oxytocin neurones are also attenuated during pre nancy.  
4. During pregnancy, the circulating level of leptin is elevated (Herrera et al., 2000). 
Although some hypothalamic regions become resistant o he actions of leptin 
(Ladyman and Grattan, 2004), present studies (Chapter IV - Leptin) show that SON 
oxytocin neurones are responsive to leptin during pregnancy. Hence, because of the 
elevated level of leptin, potentiation by leptin of CCK-induced responses might be 
expected during pregnancy in SON oxytocin neurones. However, it also appears that 
the CCK-NTS-SON pathway is not influenced by leptin in the normal non-pregnant 
state and hence there may not be any influence of pregnancy-induced elevation of 
leptin levels on the CCK-induced excitatory responses of SON oxytocin neurones.  
Despite the above first three consensus, the CCK-induced oxytocin neuronal 
excitatory response in late pregnant rats was not different from the virgin rats (Douglas et al., 
1995). However, the opioid antagonist, naloxone, potentiated the CCK-induced oxytocin 
response in late pregnant rats suggesting that oxytocin neurone responses to CCK are 
attenuated by endogenous opioid peptides during prenancy (Douglas et al., 1994; Douglas 
et al., 1995). For comparison with fasted pregnant r ts, CCK-induced responses of SON 
oxytocin neurones were also studied in unfasted pregnant rats in this study. 
6.3.10. Comparison of CCK responses with responses to secretin and leptin 
Secretin, the brain-gut peptide, and leptin, the anorexigenic peptide from adipose 
tissue, are also released postprandially (Schafmayer et al., 1978; Saladin et al., 1995). 
Secretin and CCK are physiologically similar peptides and both are synergistic in some of 
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the physiological functions (You et al., 1983; Chey t al., 1984). Leptin potentiates the 
peripheral and central actions of CCK (Barrachina et l., 1997; Wang et al., 1998; Emond et 
al., 1999; Matson and Ritter, 1999). Hence, CCK closely interacts with secretin and leptin. 
The present electrophysiological study shows that tese peptides alter the electrical activity 
of SON neurones upon systemic administration. Hence, the electrophysiological responses of 
SON oxytocin and vasopressin neurones to systemic administration of secretin and leptin 
were compared to the responses to CCK in an attempt to understand the overall response of 
SON neurones during the postprandial period. 
6.4. Methods 
6.4.1. Experiment 1: Effect of systemic administration of CCK on electrical activity of 
SON oxytocin and vasopressin neurones in urethane-an esthetized unfasted/fasted 
virgin/pregnant rats in vivo. 
Urethane-anaesthetized unfasted virgin rats were fitted with an i.v. cannula on the 
day of the experiment. The SON and neural stalk were xposed via the ventral 
transpharyngeal surgery. The effects of CCK (25µg/kg; i.v) on oxytocin and vasopressin 
neurones were compiled from previous experiments on other peptides where CCK was used 
to differentiate these neurones.  
Groups: 
1. Oxytocin neurones 
a. Unfasted virgin: n = 45 
b. Unfasted pregnant: n = 14 
c. Fasted virgin: n = 6 
d. Fasted pregnant: n = 4 
2. Vasopressin neurones: Unfasted virgin:  
i. Non-phasic: n = 30 
ii. Phasic: n = 7 
6.4.2. Experiment 2: Effect of systemic administration of leptin on the CCK-induced 
excitatory responses of SON oxytocin neurones in unfasted virgin rats  
Urethane-anaesthetized unfasted virgin rats were fitted with an i.v. cannula on the 
day of the experiment. The SON and neural stalk were xposed via the ventral 
transpharyngeal surgery and the SON neurones were id ntif ed and recorded. Once an 
oxytocin neurone was identified with an excitatory response to CCK (25µg/kg; i.v) leptin 
(100µg/rat; i.v) was injected; 20min after leptin, CCK was injected again to compare the 
excitatory responses to CCK of SON oxytocin neurones before and after leptin. 
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6.5. Results 
6.5.1. Body weight 
 Fasting did not alter the body weight significantly in virgin or pregnant rats, while 
pregnancy contributed to significant increase in body weight whether they are fasted or 
unfasted (Fig. 6.1).  There was no interaction betwe n feeding and reproductive status with 
respect to body weight (F1, 64=0.95, P=0.3, two-way ANOVA).  
6.5.2. Basal firing rate 
 The basal firing rate of oxytocin neurones in unfasted pregnant rats was significantly 
higher than all the other groups (Fig. 6.2). There was a significant interaction between 
feeding and reproductive status with respect to the basal firing rate (F1, 71=7.5, P=0.008, two-
way ANOVA). 
6.5.3. Effect of systemic administration of CCK on the firing rate of SON oxytocin 
neurones in unfasted virgin rats 
 Systemic administration of CCK increased the electrical activity of SON oxytocin 
neurones (e.g. Fig. 6.3). The mean change in firing rate 0-10min after CCK was significantly 
higher than the basal rate across 10min (n=45; Fig. 6.4)  The incidence of spikes occurring 
between 0-0.5s was significantly increased 0-10min after CCK compared to the basal 10min 
period as it is seen in the interspike interval histogram (Fig. 6.5a, b). There was a positive 
shift in the hazard plot after CCK (Fig. 6.6) without a significant increase in the ratio of peak 
early (<0.07s) to mean late (0.2-0.3s) hazard after CCK (Fig. 6.7) suggesting that there is no 
change in the shape of the hazard after CCK administration. 
6.5.4. Effect of systemic administration of CCK on the firing rate of SON oxytocin 
neurones: Influence of fasting and pregnancy 
 The influence of fasting and pregnancy on the CCK-induced excitation of SON 
oxytocin neurones was studied in fasted virgin rats(n=6) and unfasted (n=14) and fasted 
(n=10) pregnant rats. 
• Fasted virgin: Pre vs. 0-10min post-CCK: P=0.06, paired t-test.  
• Fasted virgin vs. unfasted virgin: P=0.4, t-test (Fig. 6.8). 
• Unfasted pregnant: Pre vs. 0-10min post-CCK: P=0.005, paired t-test. 
• Unfasted pregnant vs. unfasted virgin: P=0.012, t-test (0-2min after CCK); 
P=0.2, t-test (0-10min after CCK) (Fig. 6.9). 
• Fasted pregnant: Pre vs. 0-10min post-CCK: P=0.002, paired t-test 
• Fasted pregnant vs. fasted virgin: P=0.99, t-test (Fig. 6.10) 
• Fasted pregnant vs. unfasted pregnant: P=0.9, t-test (Fig. 6.11). 
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Overall, there was no interaction between feeding ad reproductive status (F1, 65 
=0.01, P=0.9, two-way ANOVA; Fig. 6.12).  
6.5.5. Effect of systemic leptin administration on CCK-induced excitatory response of 
SON oxytocin neurones in virgin female rats 
CCK (25µg/kg; i.v) was administered before and after leptin (100µg/rat; i.v) and the 
responses were compared (e.g. Fig. 6.13). The basal firing-rate of 2.9 ± 0.32 spikes/s was 
increased significantly 1.5min after CCK injection in SON oxytocin neurones (n=21). After 
leptin, a repeat injection of CCK significantly increased the firing rate of 3.03 ± 0.36 spikes/s 
to a similar extent. The rates returned to basal by 15min after CCK. There was no significant 
difference between these two basal rates.  The average firing rate 0-10min after CCK was 
significantly higher than the respective basal rates both before and after leptin treatment.  
The CCK-induced excitatory responses before and after leptin were not different from each 
other (Fig. 6.14). 
6.5.6. Comparison of CCK-induced response of SON oxytocin neurones to the 
responses induced by systemic administration of secr tin and leptin: Unfasted virgin 
female rats 
The electrophysiological responses of SON oxytocin neurones to secretin (0.1µg/rat; 
i.v; n=26) and leptin (100µg/rat; i.v; n=23) were studied and compared to the response after 
CCK (25µg/kg; i.v; n=45). The firing rate 0-10min after the administration of these peptides 
were significantly higher than during the respective basal period. The excitatory response 0-
10min after the administration of each of the peptides differed significantly (Fig. 6.15).  
Secretin was far more potent than CCK: the lesser number of moles of secretin 
injected (0.1µg or 0.33pmoles in 100µl saline or 33nM solution; MW: 3027.4) brought about 
more excitation than the 199-fold greater number of m les of CCK (7.5µg or 6.6nmoles of 
CCK in 150µl saline for a 300g rat or 43.77µM soluti n; MW: 1142.2) and 187-fold greater 
number of moles of leptin (100µg or 6.17nmoles in 100µl saline or 61.7µM solution; MW: 
16.2kD).  Hence, in comparison with CCK, leptin was the least effective while secretin was 
the most effective peptide in terms of excitation of SON oxytocin neurones upon systemic 
administration.  
The change in firing rate for the peptides from the peak of excitation fitted well with 
exponential curves (Fig. 6.16). For an exponential decay process, the equation is: 
R(t) = R0 e
-λt 
where R(t) is the rate at time t after the peak and R0 is the rate at the peak of excitation. λ 
(lambda) is called the decay constant.  
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The equation obtained for secretin, CCK and leptin are: R(t) = 2.3 e
-0.1t, R(t) = 1.6 e
-0.2t 
and R(t) = 0.5 e
-0.2t, respectively. The half-life (t1/2) was calculated from the formula 
t1/2 = τ x logn2 
where τ (tau) is 1/ λ. 
The estimated half lives of the peptides from the literature are: secretin: 1.5-3min (de 
Smul et al., 1974; Lehnert et al., 1974; Tanaka andKatayama, 1984), CCK: 1–2 min 
(Hameed et al., 2009) and leptin: 9.4 ± 3.0 min (Zeng t al., 1997). The half lives calculated 
from the change in firing rate in this study are: scretin: 5.1min, CCK: 3.8min, and leptin: 
3.3min.  
The decay of the number of moles of the peptides (Fig. 6.17a, b, c and d) in the 
circulation was calculated from the formula  
N(t) = N0 2
-t/t1/2 
where N(t) is the number of moles at time t, N0 is the initial number of moles in the 
circulation and t1/2 is the half-life of the peptide.  
6.5.7. Comparison of CCK-induced excitatory responses of SON oxytocin neurones to 
the responses induced by systemic administration of secretin and leptin: Fasted virgin 
female rats 
The electrophysiological response of SON oxytocin neurones to secretin (0.1µg/rat; 
i.v; n=3) and leptin (100µg/rat; i.v; n=8) were studied in fasted rats and compared to the 
response after CCK (25µg/kg; i.v; n=6). The increase in firing rate 0-10min after the 
administration of secretin was significantly higher than during the basal period while the 
responses observed 0-10min after leptin and CCK administration were not significantly 
different from the respective basal firing rate. The excitatory response 0-10min after the 
administration of secretin differed significantly from the responses 0-10min after leptin and 
CCK (Fig. 6.18).  
The secretin-, CCK- and leptin-induced responses in fasted rats did not differ from 
unfasted rats. 
 There was no interaction observed between feeding status and peptide administration 
(F2, 105=0.7, P=0.5, two-way ANOVA). Fasting did not influence the response (F1, 105=0.001, 
P=0.97, two-way ANOVA) while the responses were signif cantly different for the peptides 
(F2, 105=11.6, P<0.001, two-way ANOVA).  
6.5.8. Effect of CCK on non-phasic SON vasopressin neurones in unfasted virgin female 
rats 
 The effect of CCK (25µg/kg; i.v) was studied in non-phasic (n=30) and phasic (n=7) 
vasopressin neurones.  Twenty three of 30 non-phasic v sopressin neurones were inhibited 
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(Fig. 6.19 and 6.20) while seven did not respond to CCK (Fig. 6.21). On average, the 
response observed 0-5min after CCK was significantly lower than the change in firing rate 
during the basal period (Fig. 6.22). 
6.5.9. Effect of CCK on phasic SON vasopressin neurones in unfasted virgin female rats 
 All the phasic vasopressin neurones tested were inhibited by CCK (e.g. Fig. 6.23). 
The activity quotient was reduced significantly 5min after CCK (Fig. 6.24). In 4 of 6 
neurones, there was a rebound excitation 5-10min after CCK following CCK-induced 
inhibition which resulted in a higher activity quotient than the basal. However, there were no 
significant changes in the mean interburst interval (Fig. 6.25) or frequency within bursts 
(Fig. 6.26) after CCK administration. 
 The interspike interval histogram before and after CCK administration was plotted 
from non-phasic and phasic vasopressin neurones (n=37; 30 non-phasic and 7 phasic 
vasopressin neurones; Fig. 6.27a). There was a decrease in the number of spikes occurring 
with the interspike interval of less than 0.3s following CCK. The single negative exponential 
curves fitting well with the distal tails of the histograms but leaving the intervals of less than 
0.2s unfit characterise vasopressin neurones (Fig. 6.27b). There was no change in the shape 
of the hazard plot following CCK (Fig. 6.28). 
6.5.10. Comparison of secretin-, CCK- and leptin-induced electrophysiological 
responses of non-phasic SON vasopressin neurones in unfasted virgin rats  
  Systemic administration of secretin, CCK or leptin resulted in mixed responses from 
the non-phasically firing SON vasopressin neurones. S cretin (0.1µg/rat; i.v; n=21) excited 
14 neurones (66.7%), inhibited 6 neurones (28.6%) and did not affect the activity of 1 
neurone (4.8%) of 21 neurones tested. CCK (25µg/kg; i.v; n=30) inhibited 23 (76.7%) and 
did not affect 7 of 30 neurones. Leptin (100µg/rat; i.v; n=11) excited 3 neurones, inhibited 4 
and did not affect the activity of 4 of 11 neurones tested.  
 Overall, there were no significant changes in the firing rate 0-10min after 
administration of secretin and leptin compared to the rate during the respective basal periods. 
However, CCK significantly decreased the electrical activity 0-5min after its administration. 
The change in firing rate 0-5min after CCK was signif cantly different from that after 
secretin and leptin (Fig. 6.29). 
6.5.11. Comparison of secretin-, CCK- and leptin-induced responses of phasic SON 
vasopressin neurones in unfasted virgin rats  
 The effects of secretin (0.1µg/rat; i.v) and leptin (100µg/rat; i.v) on the responses of 
phasic SON vasopressin neurones were compared to the inhibitory response to CCK 
(25µg/kg; i.v). All phasic vasopressin neurones were excited after secretin (n=11), while in 
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the leptin group, 6 of 8 neurones were inhibited while 2 of 8 were excited. Systemic CCK 
inhibited all 7 phasic vasopressin neurones tested. 
 The activity quotient was significantly increased by secretin and decreased by CCK 
while leptin did not have any effect (Fig. 6.30).  
The mean interburst interval was significantly decreased by secretin and unaffected 
by CCK and leptin. The mean interburst interval during the basal period and 0-5min after 
administration of peptides did not differ between the groups (Fig. 6.31). 
The frequency within bursts during the basal period and during 0-5min after 
administration of peptides was not different from each other within or between the groups 
(Fig. 6.32). 
To summarise:  
1. As shown in earlier studies (Hamamura et al., 1991; Douglas et al., 1995), the 
electrical activity of SON oxytocin neurones was significantly increased by systemic 
administration of CCK in unfasted virgin and pregnant rats, and the response in 
unfasted pregnant rats was not different from the virgin rats. 
2. Fasting did not attenuate CCK-induced responses of SON oxytocin neurones in 
virgin and pregnant rats. 
3. Exogenous administration of leptin did not potentiate CCK-induced excitation of 
SON oxytocin neurones in unfasted virgin rats. 
4. Systemic administration of CCK either inhibited (77%) or did not affect (23%) the 
firing rate of SON vasopressin neurones, as shown previously (Renaud et al., 1987). 
5. Secretin was more effective peptide than CCK or leptin in terms of excitation of 
SON oxytocin neurones in unfasted and fasted virgin rats. CCK significantly 
inhibited phasic and non-phasic vasopressin neurones but secretin significantly 
excited phasic vasopressin neurones in unfasted virgin rats. 
6.6. Discussion 
6.6.1. CCK-induced excitation of SON oxytocin neurones in unfasted virgin rats 
Food intake is accompanied by fluid intake (i.e. prandial drinking) resulting in 
volume expansion (Franci et al., 1989) and oxytocin mediates ANP release and thus 
natriuresis after volume expansion (Verbalis et al., 1991; Haanwinckel et al., 1995). Hence, 
postprandial CCK-induced excitation of SON oxytocin neurones and the consequent 
peripheral release of oxytocin are important for the regulation of postprandial natriuresis.  
From the electrophysiological recordings in this study, there was no change in the 
shape of the hazard plot and in the ratio of peak early to mean late hazard before and after 
CCK. These findings indicate that CCK-induced activation of oxytocin neurones involves 
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increased activity in the excitatory inputs to the SON rather than changes in the intrinsic 
properties of the neurones. This is in accordance with the findings that CCK-induced 
excitation of oxytocin neuronal activity and peripheral oxytocin secretion are due to the 
increased NA excitatory inputs from the NTS (Onaka et l., 1995a).  
6.6.2. CCK-induced excitation of SON oxytocin neurones in pregnant rats 
Unlike the earlier reports (Douglas et al., 1995; Brunton et al., 2006), the basal rate 
of oxytocin neurones was higher in unfasted pregnant rats in this study. The reason for this 
discrepancy is not known. Compared to virgin rats, the oxytocin neurones recorded from the 
late-pregnant rats displayed a delay in the increase in firing rate following CCK: the increase 
in firing rate 0-2min after CCK was significantly different between these groups. This could 
be due to the increase in the plasma volume during pre nancy essentially diluting the 
concentration of CCK and thus delaying the peak respon e or due to changes in the 
expression of CCK receptors in the vagal afferents, if any. The attenuation of CCK-induced 
oxytocin neuronal excitation by endogenous opioid peptides that emerges towards the end of 
pregnancy (Douglas et al., 1995) might also be respon ible for this delayed response. 
However, in accordance with earlier reports (Douglas et al., 1995), the overall excitation (0-
10min after CCK) in late pregnant rats was not different from virgin rats. The plasma 
oxytocin concentration during late pregnancy following systemic injection of CCK was also 
similar to that of virgin rats in other studies (Koehler et al., 1994; Douglas et al., 1995). As 
oxytocin mediates its natriuretic effects mainly via ANP (Haanwinckel et al., 1995) and 
ANP-induced natriuretic responses are attenuated in late pregnant rats (Masilamani et al., 
1994), if CCK-induced oxytocin release regulates natriuresis, it is possible that the 
natriuretic responses to CCK through ANP are attenuated, even without alteration in CCK-
induced oxytocin release. 
6.6.3. CCK-induced excitation of SON oxytocin neurones in fasted rats 
CCK is a short term satiety signal (Peikin, 1989) and CCK administration results in 
central (anorectic) and peripheral (natriuretic) oxyt cin release (Neumann et al., 1994). 
Hence, homeostatic mechanisms during fasting might be expected to strive to restrain CCK-
induced anorectic and natriuretic effects of oxytocin resulting in the attenuation of basal 
activity and CCK-induced SON oxytocin neurone responses in fasted virgin and pregnant 
rats. On the other hand, fasting, as a stressor, might also be expected to increase the basal 
and CCK-induced activity. However, fasting for 18h did not alter CCK-induced responses in 
virgin and pregnant rats.  
 124 
6.6.4. Leptin and CCK interaction in the excitation of SON oxytocin neurones 
Leptin has been shown to synergistically interact with CCK or potentiate the effects 
of CCK in suppressing food intake, reducing body weight and inducing Fos expression in the 
hypothalamus (Barrachina et al., 1997; Wang et al., 1998; Emond et al., 1999; Matson and 
Ritter, 1999; Matson et al., 2000; Wang et al., 2000; Matson et al., 2002). However, 
subthreshold doses of either CCK or leptin or both were used in these studies and thus it is 
not clear whether leptin influences CCK-mediated effects. In another study, when effective 
doses were used, leptin reduced the level of Fos expression induced by CCK in the SON and 
PVN (Caquineau and Leng, 2009). In the present study, the doses of leptin and CCK 
administered were effective in inducing a significant response in oxytocin neurones when 
given alone. However, there was no interaction observed in the excitation of SON oxytocin 
neurones between leptin and CCK. This is in accordance with the lack of change in CCK-
induced oxytocin neuronal response following reduction in the endogenous level of leptin in 
fasted rats or increase in the level of leptin in pregnant rats. As systemic CCK acts via a 
vagus-NTS-SON pathway, lack of potentiation of CCK-induced excitation by leptin 
observed in this study suggests that leptin does not influence this pathway.  
The other possibilities for the lack of interaction observed in the study are: 
Insufficient dose of exogenous leptin to potentiate th  response and inadequate interval 
between leptin administration and observation of the CCK response. 
 The dose of leptin (100µg/rat; i.v) seemed sufficient because doses less than or 
similar to this dose have been effective for other leptin mediated effects (Matson et al., 1997; 
Merino et al., 2008). Although some leptin mediated effects can be rapid (Spanswick et al., 
1997; Powis et al., 1998; Honda et al., 2002), the pot ntiation by leptin of the pathway under 
consideration might be a slow process requiring administration of leptin well before the 
measurement of the CCK response.   
6.6.5. Comparison of secretin-, leptin- and CCK-induced responses 
The excitatory effects on SON oxytocin neurones of ecretin (0.1µg/rat; i.v) and of 
leptin (100µg/rat; i.v) were compared to that of CCK (25µg/kg; i.v). The secretin-induced 
response was significantly greater, and the leptin-induced excitatory response was 
significantly lesser than the CCK-induced response; th  responses induced by all the 
peptides gradually subsided and the basal firing rate was reached by 15 min. The 
homogeneous excitatory responses of SON oxytocin neuro s to secretin, CCK and leptin 
suggest that these peptides contribute to fluid homeostasis through postprandial oxytocin 
release. 
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A solution of 0.1µg/100µl (33pmoles/100µl or 33nM solution; MW 3027.4) secretin 
contains 133 times fewer molecules than 5µg/100µl (4.4nmoles/100µl or 44µM solution; 
MW 1142.2) solution of CCK and 187 times fewer molecul s than 100µg/100µl (6.2 
nmoles/100µl or 61.7µM; MW 16.2 kD) solution of leptin used in the study.  Hence, the 
excitation induced by i.v. secretin is robust considering the dose used in the study.  
The estimated circulating half-lives of the peptides in rats are: CCK: 1–2 min 
(Hameed et al., 2009), secretin: 1.5-3min (de Smul et al., 1974; Lehnert et al., 1974; Tanaka 
and Katayama, 1984) and leptin: 9.4 ± 3.0 min (Zeng t al., 1997) i.e. the half-life of CCK ≤ 
secretin < leptin. The basal plasma level of secretin is 5.5-6 pg/ml (1.8 pM) (Kawamura et 
al., 1991; Li et al., 1995), of leptin is ca. 2ng/ml (12.3mM) (Kawai et al., 1997) and of CCK-
8 is 7.7pg/ml (6.7 pM) (Linden et al., 1989a; Linden et al., 1989b) i.e. the plasma level of 
secretin < CCK < leptin. Hence, it appears that secretin, though at a lower circulating 
concentration, is more potent in its effects on oxyt cin neurones than CCK and leptin. The 
affinity of the receptors to their respective ligands and the effectiveness of the activation of 
vagal afferents in response to the receptor signalling might be different for these peptides 
resulting in differences in the dose-response charateristics. These differences might be 
important in the differential regulation of their shared physiological functions such as 
activation of the SON neurones. 
6.6.6. CCK-induced inhibition of vasopressin neurones 
The pathway leading to inhibition of SON vasopressin neurones by CCK is not 
clear. However, the CCK-induced inhibition of vasopressin neurones might be the result of 
regulation by central oxytocin and vasopressin release within the SON following systemic 
CCK. Central vasopressin auto-inhibits vasopressin neuronal activity via V1a receptors 
(Ludwig and Leng, 2006); but it is not known whether systemic CCK results in central 
vasopressin release. On the contrary, systemic CCK results in central release of oxytocin 
(Neumann et al., 1994) but it is not clear whether c ntral oxytocin suppresses vasopressin 
neuronal activity. However, retrodialysis of an oxytocin receptor antagonist onto the SON 
elevated plasma vasopressin secretion under basal conditions (Neumann et al., 2006) 
suggesting a role for central oxytocin in the regulation of vasopressin neuronal activity.  
In another study (see Chapter V - Secretin), benoxathian, an α1-adrenoceptor 
antagonist, blocked the basal activity of SON vasopressin neurones. Hence, it appears that 
the basal activity of the SON vasopressin neurones depends on the excitatory NA inputs via 
α1-adrenoreceptors. SON vasopressin neurones receive excitatory NA projections from the 
A1 cell group of the VLM (Day, 1989; Day and Sibbald, 1989) that are not activated by 
CCK but by baroreceptor activation following reduction in blood pressure (Day, 1989). 
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However, SON application of NA, although it excited vasopressin neurones, also depressed 
their response to activation of the A1 input (Khann et al., 1993). The latter effect was 
mimicked by the α2-adrenoceptor agonist clonidine (Khanna et al., 1993). Hence, CCK-
induced inhibition of vasopressin neurones might be the result of action of CCK-induced NA 
release in the vicinity of SON vasopressin neurones on the α2-adrenoceptors on the 
presynaptic terminals of the axons from A1 cell groups, thus abolishing the tonic NA release 
and the basal activity.  
Parvocellular vasopressinergic neurones in the PVN are activated during fever and 
central administration of vasopressin is antipyretic acting via V1 receptors (Cooper et al., 
1987; Naylor et al., 1987; Naylor et al., 1988; Wilkinson and Kasting, 1989; Landgraf et al., 
1990; Wilkinson and Kasting, 1993). Peripheral vasopressin results in hypothermia i.e. 
decreases normal body temperature by suppressing thermogenesis (Shido et al., 1984). As 
systemic administration of CCK also lowers body temp rature (Kapas et al., 1988; Kapas et 
al., 1989; Rezayat et al., 1999; Szelenyi, 2001; Szelenyi et al., 2004), the CCK-induced 
inhibition of vasopressin neurones might be a thermoregulatory mechanism by abolishing the 
antipyretic actions of central vasopressin (if CCK administration inhibits central vasopressin 
release) and hypothermic actions of peripheral vasopressin.  
Leptin did not induce significant responses in SON vasopressin neurones. The 
responses to secretin were variable: either excitatory or inhibitory. However, the inhibitory 
or lack of responses to CCK of vasopressin neurones were consistent. Hence, it appears that 
SON vasopressin neurones are predominantly in an inhibited state under the influence of 
CCK during the postprandial period. Physiologically, depending upon the water intake 
during feeding and fluid balance during the postprandi l period, vasopressin neuronal 
activity might be modulated by the peptides released postprandially: activated by secretin or 
inhibited/ unaffected by CCK.  
6.7. Conclusion 
Systemic CCK excited SON oxytocin neurones and either inhibited or did not affect 
vasopressin neurones. CCK-induced excitation of SON oxytocin neurones was not different 
in unfasted/fasted virgin/pregnant rats. Leptin did not influence the CCK-induced excitation 
of oxytocin neurones. Secretin-induced excitation was greater than the CCK-induced 
response while the leptin-induced response was the least. In conclusion, appetite regulating 
peptides that are released postprandially, such as secretin, leptin and CCK, target SON 
neurones. Overall, these peptides excite oxytocin neurones and inhibit vasopressin neurones 
which may regulate postprandial natriuresis and thus ensuring fluid homeostasis, the 
alteration of which is inevitable during food intake. 
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CHAPTER VII 
DISCUSSION AND CONCLUSION 
7.1. Neuropeptide Y 
 The NPY chapter (Chapter III) showed that the NPY-induced oxytocin release is 
centrally mediated. Brunton et al. have shown that central NPY induces Fos expression in 
the SON and increases peripheral oxytocin release (Brunton et al., 2006a). This study clearly 
showed that NPY increases the electrical activity of oxytocin neurones. 
 The physiological implications behind this oxytocin secretion by the 
neurohypophysis induced by central NPY are hypothetical as the regulation of SON oxytocin 
neurones by NPY neurones in the brainstem and ARC lacks evidence:  
Firstly, though there is enough evidence that NPY is co-localized with NA neurones 
in the VLM (i.e. in the A1 cell group that sends projections to SON vasopressin neurones) 
(Sawchenko et al., 1985; Harfstrand et al., 1987), the evidence for NPY co-localization with 
NA in the NTS in particular (i.e. in the A2 cell group that sends projections to the SON 
oxytocin neurones) is not clear. There is evidence that NPY is present in the A2 cell group 
(Harfstrand et al., 1987; Simonian and Herbison, 1997), and that it is absent (Sawchenko et 
al., 1985). It is also not known whether the NA neurones that project to the SON in particular 
co-express NPY (Fig. 7.1). NPY negatively and positively modulates NA-induced excitation 
of SON vasopressin neurones via pre- and post-synaptic receptors, respectively (Khanna et 
al., 1993). It is not known whether there is a similar mechanism operating in the NPY-
induced excitation of SON oxytocin neurones.  
Secondly, though it is known that NTS-NA neurones are ctivated by food intake, 
gastric distension, stimulation of vagal afferents, gut peptides and stress (Monnikes et al., 
1997; Willing and Berthoud, 1997; Rinaman et al., 1998; Conde et al., 1999; Krukoff et al., 
1999; Ohiwa et al., 2006; Appleyard et al., 2007), it is not known whether these neurones are 
NPY neurones and whether these neurones project to the SON oxytocin neurones.  
Thirdly, though there is an evidence for ARC projection to the SON (Leng et al., 
1988), it is not known whether ARC-NPY neurones in particular project to SON oxytocin 
neurones (Fig. 7.1). In addition, it is not known whether NPY-induced effects on oxytocin 
neurones are direct or involve interneurones. Whether NPY modulates central release of 
oxytocin is also not known. Hence, to understand the p ysiological implications behind NPY 
induced oxytocin secretion, these gaps in the literature need to be filled. 
 The NPY chapter also produced a controversy: central NPY excited SON oxytocin 
neurones in the late pregnant anaesthetized rats (Fig. 3.12) in contrast to the suppressed 
oxytocin secretion and Fos activation observed in late pregnant conscious rats (Brunton et 
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al., 2006a). In vivo electrophysiology is an excellent tool to study the effects of 
drugs/peptides on the nervous system with all the synaptic inputs intact; however, 
anaesthesia is the limitation which cuts off sensory inputs that might modify the effect of the 
peptide under study. With urethane in particular, the disadvantage is that it alters body fluid 
homeostasis, preservation of which is likely to be crucial, especially in pregnant animals. To 
resolve the controversial issues that arose between conscious and pregnant animals, the 
complex procedure of electrophysiological studies in conscious animals (to preserve sensory 
inputs and other physiological functions such as food and water intake) may be attempted as 
changing the anaesthetic to one that does not interfere with physiological functions seems 
not possible. 
 Another interesting finding was the excitation of SON oxytocin neurones by 
systemic NPY (Fig. 3.15). NPY is released from NA nerve terminals upon sympathetic 
stimulation (Lundberg et al., 1987; Morris et al., 1987; Pernow, 1988). Recently it has been 
shown that peripheral NPY modulates adiposity and me iates stress-induced obesity (Kuo et 
al., 2007). The pathway and the importance of oxytocin neurones in NPY-mediated 
sympathetic effects and adiposity are yet to be explored. 
7.2. Leptin 
 This chapter (Chapter IV) answered the question whether systemic leptin exerts any 
effect on SON oxytocin neurones. Interestingly, theanswer was ‘yes’. However, in turn, 
several questions arose out of this chapter: Will a physiological level of leptin have any 
effect on SON oxytocin neurones [100µg/kg/day subcutaneous infusion of leptin in starved 
rats results in physiological leptin level measured in control rats (Watanobe et al., 1999); 
hence though the dose of leptin (100µg/rat; i.v) used in the study is nearly physiological, the 
bolus intravenous injection may not resemble the slow physiological release of leptin from 
the adipose tissue]? What is the non-genomic mechanism behind the immediate effect of 
leptin on electrical activity? Why was the response ot potentiated in fasted animals [fasting-
induced low endogenous level of leptin was expected to augment the response to exogenous 
leptin because fasting decreases insulin level in the circulation (Szepesi et al., 1971) and 
reduction in the insulin level increases hypothalamic sensitivity to leptin (Rosenbaum et al., 
2002; Lustig et al., 2004)]? Hypothalamic leptin resistance seems region-specific (Ladyman 
and Grattan, 2004). Is the finding that SON oxytocin neurones in late-pregnant rats respond 
to leptin suggest that SON is not resistant to leptin during late pregnancy or is it another 
controversy arising through use of anaesthetized rats? What is the physiological implication 
behind leptin-induced oxytocin release? If it is postprandial natriuresis, is leptin 
indispensable in postprandial oxytocin release? Does leptin induce central oxytocin release 
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from the dendrites of magnocellular oxytocin neurones [because leptin-induced reduction in 
food intake seems to be partly mediated via central oxytocin (Blevins et al., 2004)]? 
Obviously, more studies are required to answer these questions.  
7.3. Secretin 
 This chapter (Chapter V) answered several interesting questions that have never 
been asked since the discovery of the hormone more than a hundred years ago (Bayliss and 
Starling, 1902). Secretin was found to be a powerful peripheral stimulus for oxytocin 
neuronal activity and peripheral oxytocin release at a dose that is almost physiological (Fig. 
5.20 and 5.21). NA pathways were found to be involved in secretin-induced activation of 
SON oxytocin and vasopressin neurones (Fig. 5.31, 5. 3 and 5.34). Secretin seems to induce 
dendritic oxytocin release from the SON but this warrants more observations. However, the 
physiological implications behind secretin-induced peripheral and central oxytocin release 
need to be explored further. It is not known whether secretin is more important than CCK in 
regulating postprandial oxytocin release or it is ju t another example for redundancy in a 
physiological system.  
CCK-induced satiety may partly be mediated via central oxytocin release (Neumann 
et al., 1994). Though secretin seems to induce central oxytocin release and secretin is 
released postprandially, it has never been shown to act as a satiety peptide. The two studies 
that observed food intake following intraperitoneal secretin in rats report that secretin does 
not reduce food intake (Lorenz et al., 1979; Garlicki et al., 1990); however, intravenous 
secretin decreased food intake in sheep (Grovum, 1981). Hence, more studies are needed to 
explore the involvement of secretin in postprandial satiety and food intake. In addition, as 
secretin receptor or oxytocin knockout results in impaired social behaviour (Winslow and 
Insel, 2002; Nishijima et al., 2006), a secretin-oxyt cin link in behavioural regulation needs 
to be investigated.  
Another interesting study would be to explore the pathway involved in the secretin-
induced excitation of vasopressin neurones: the direct projections from the NTS to the SON 
vasopressin neurones are relatively few and do not influence vasopressin neuronal activity 
(Day and Sibbald, 1989; Shioda et al., 1990); instead, NTS stimulation activates vasopressin 
neurones through an indirect relay projection via the A1 cell group (Day and Sibbald, 1989). 
This study (Fig. 5.33) showed that secretin-induced excitation of vasopressin neurones is 
mediated via a NA pathway – it is not known whether it is one of the A1 or A2 pathways or 
other indirect pathways. The projections from the A1 cell group to the SON vasopressin 
neurones are involved in blood pressure regulation – they are activated in response to low 
blood pressure, hypovolaemia or haemorrhage and are inhibited during baroreceptor 
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activation and hence either increasing and decreasing vasopressin neuronal activity and 
peripheral vasopressin release, respectively, to regulate effective circulating blood volume 
and blood pressure (Day and Sibbald, 1990; Day et al., 1992; Smith et al., 1995). However, 
secretin administration, even at high doses (0.75-3 µmol/kg; i.v), results in only a slight 
increase in blood pressure (Sitniewska and Wisniewska, 1999) and thus secretin-induced 
excitation of vasopressin neurones remains unexplained in terms of mechanism and 
physiological role. 
7.4. Cholecystokinin 
 This chapter (Chapter VI) addressed whether there are any differences in the 
response of SON oxytocin neurones to systemic CCK in unfasted/fasted virgin/pregnant rats: 
no differences were observed between these groups.; Douglas et al., have also reported that 
the response to CCK of SON oxytocin neurones during late pregnancy was similar to the 
virgin rats with augmentation by naloxone administration (Douglas et al 1995).  
The interesting observation was that the basal activity in fasted virgin rats did not 
differ from unfasted virgin rats, in contrast to the expectation that fasting might either reduce 
or increase the basal activity of oxytocin neurones as a consequence of hydration status or 
stress response, respectively. It is not known whether fasting-induced alterations in fluid 
homeostasis (that might strive to restrict natriuresis and thus reduce oxytocin release) and 
fasting-induced stress response (which increases the release of oxytocin – a stress hormone) 
compensate each other and thus nullify changes in the basal activity of SON oxytocin 
neurones. 
 A controversy that was pointed out in this and other chapters that studied pregnant 
rats was that the basal firing-rate of SON oxytocin neurones was higher in unfasted pregnant 
rats (Fig. 6.2). This is in contrast to the expectation that oxytocin neuronal activity is 
suppressed during late pregnancy and also contrasted wi h the observation of reduced basal 
activity of oxytocin neurones in late pregnant in urethane-anaesthetized rats by Douglas et 
al. and Brunton et al. (Douglas et al., 1995; Brunton et al., 2006b). The reason for this 
discrepancy is not known. 
 The study on the influence of leptin on CCK-induced SON oxytocin neuronal 
excitatory responses showed that leptin did not potentiate the CCK response (Fig. 6.14). 
Though the literature reports potentiating, synergistic or subadditive12 effects of leptin on 
                                                
12 Additive effect: An effect in which two substances u ed in combination produce a total effect the 
same as the sum of the individual effects (The American Heritage® Medical Dictionary, 2004 by 
Houghton Mifflin Company). Subadditive effect: the function for the sum of two elements always 
returns something less than or equal to the sum of the function's values at each element 
(www.wikipedia.org/wiki/Subadditivity) 
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CCK-mediated food intake, daily calorie intake, body weight regulation and Fos expression 
in the hypothalamus, except for Yuan et al (Yuan et al., 2000) who have used effective doses 
of CCK and leptin and reported subadditive effects, o hers have used subthreshold doses of 
either CCK or leptin or both (Barrachina et al., 1997; Wang et al., 1998; Emond et al., 1999; 
Matson and Ritter, 1999; Matson et al., 2000; Wang et al., 2000; Matson et al., 2002) and 
thus it is not clear whether leptin indeed exerts any effect on CCK-mediated effects. 
However, the lack of potentiation observed here in th s study on the influence of leptin on 
CCK-induced excitation of oxytocin neurones was notc nclusive: as it was said above, 
though the doses of CCK and leptin employed here are the effective doses in inducing an 
excitatory response in oxytocin neurones, they are supraphysiological [<0.12µg/kg/h and 
100µg/kg/day are the physiological rates of release for CCK and leptin, respectively 
(Moriyoshi et al., 1991; Watanobe et al., 1999)], and hence may not be applicable for the 
physiological systems. As CCK is a within-meal satiety signal and exerts its effect 
immediately and leptin is a long-term satiety signal and requires longer time to exert its 
actions, leptin was given 20min before CCK in expectation of potentiating effects of leptin. 
However, the 20min duration between leptin and CCK injections might have not been 
sufficient for leptin to exert its effects in case low genomic mechanisms are involved, or 
leptin and CCK should have been injected at the same ti e point as a means of showing 
synergistic effect of leptin in case rapid non-genomic mechanisms are involved; hence, the 
mechanism of leptin action in this particular pathway needs to be more fully understood to 
study CCK-leptin interaction in the excitation of SON oxytocin neurones. 
7.5. Conclusion 
 It is tempting to hypothesize that NPY, leptin and secretin that are released during 
the postprandial period excite SON oxytocin neurones, similarly to CCK, resulting in 
peripheral oxytocin release so as to regulate postprandial natriuresis (Fig. 7.2). Central 
release induced by these peptides might contribute to negative regulation of feeding related 
behaviour.  
As CCK, secretin and leptin are involved in regulating exocrine pancreatic secretion, 
it is possible that oxytocin release is an additional mechanism through which all these 
peptides regulate exocrine pancreatic secretion as oxytocin itself modulates exocrine 
pancreatic secretion via insulin and glucagons (Bjorkstrand et al., 1996; Ferrer et al., 2000). 
It is also possible that peripheral oxytocin is involved in the feedback regulation of leptin, 
secretin and CCK via oxytocin receptors in the adipose tissue, the gut and the enteric 
nervous system (Bonne and Cohen, 1975; Egan et al., 1990; Welch et al., 2009) (Fig. 7.3).  
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Regulation of natriuresis and exocrine pancreatic secretion are important 
requirements during the postprandial period. Natriuresis is essential for fluid homeostasis 
while exocrine pancreatic secretion and central oxytocin-induced anorexia/satiety are 
essential for energy homeostasis. Hence, it appears th t these peptides target SON oxytocin 
neurones ensuring water and energy homeostasis (Fig. 7.4). This redundancy in the 
regulation of SON oxytocin neurones by appetite peptid s signifies the importance of 
oxytocin in appetite regulation. 
In conclusion (Fig. 7.5), this study has shown that
1. NPY, leptin, secretin and CCK excite SON oxytocin neurones (Fig. 3.6, 4.5, 5.2 and 
6.4). 
2. Secretin-induced excitatory responses were greater, even at lower molar doses, than 
responses to other peptides tested (CCK, leptin, NPY) (Fig. 6.15). 
3. Secretin dose-dependently increased SON oxytocin neuro  electrical activity and 
peripheral oxytocin release (Fig. 5.20 and 5.21) (and possibly SON somato-dendritic 
oxytocin release; Fig. 5.22b) in anaesthetized rats.  
4. Intracerebroventricular infusion and microdialysis studies with benoxathian (α1 
adrenergic antagonist) revealed that secretin-induce  excitation of SON oxytocin and 
vasopressin neurones involves central excitatory noadrenergic pathways (Fig. 5.31, 5.33 
and 5.34).  
5. Fasting for 18h did not alter the excitation of SON oxytocin neurones induced by 
secretin, CCK or leptin (Fig. 6.18).  
6. The pathway leading to excitation of oxytocin neurones by CCK was not influenced by 
prior leptin administration (Fig. 6.14).  
7. SON oxytocin neurones were responsive to leptin during late pregnancy; i.e. leptin 
resistance was not seen in late pregnancy (Fig. 4.10).  
8. NPY-induced excitation of oxytocin neurones was intact in anaesthetised late pregnant 
rats, contrasting with attenuated oxytocin secretory responses observed previously in 
conscious late pregnant rats (Fig. 3.13).  
9. Systemic NPY excited SON oxytocin neurones (fig. 3.15).  
10. Systemic CCK administration inhibited or did not affect SON vasopressin neurones, as 
shown by others (Leng et al., 1991) (Fig. 6.22 and 6.24), while leptin had no significant 
effect (Fig. 4.18 and 4.20), and responses to secretin w re predominantly excitatory (Fig. 
5.10 and 5.12). Systemic NPY resulted in a non-significant inhibition of vasopressin 




1. Artificial cerebrospinal fluid (aCSF) 
Solution A 
8.1g/L Sodium chloride (138mM) 
0.25g/L Potassium chloride (3.36mM) 
0.8g/L Sodium bicarbonate (9.52mM) 
0.07g/L Disodium hydrogen phosphate dihydrate (0.49mM) 
0.13g/L Urea (2.16mM) 
Solution B 
0.14g/L Calcium chloride (1.26mM) 
0.24g/L Magnesium chloride hexahydrate (1.18mM)  
Solutions were made up with sterile double distilled water and stored at 4oC until use. For use, 
solutions A and B were mixed at 9:1 ratio. 
Final pH: 7.2 
Osmolality: 295-300 mOsm  
2. Reagents for plasma oxytocin radioimmunoassay 
(1) Assay buffer 
0.25g/L Sodium dihydrogen orthophosphate monohydrate  
1.19g/L Disodium hydrogen orthophosphate anhydrous  
1g/L Sodium azide (mM) 
2.5g/L Bovine serum albumin 
(2) Oxytocin standards 
Standard oxytocin was obtained from the National Institute for Biological Standards and 
Controls (Hertfordshire, UK) as a freeze-dried aliquot containing 21µg of oxytocin. This was 
resuspended in assay buffer to give a 50ng/ml solution and stored in 1ml aliquots at -20oC. This 
standard oxytocin aliquot was serially diluted to generate the following standards with a range of 
concentrations from 2.4 to 2500pg/ml. 
A = 2500pg/ml 100µl of 50ng/ml stock + 1900µl assay buffer 
B = 1250pg/ml 500µl A + 500µl assay buffer 
C = 625pg/ml  500µl B + 500µl assay buffer 
D = 312pg/ml  500µl C + 500µl assay buffer 
E = 156pg/ml  500µl D + 500µl assay buffer 
F = 78pg/ml  500µl E + 500µl assay buffer 
G = 39pg/ml  500µl F + 500µl assay buffer 
H = 19.5pg/ml  500µl G + 500µl assay buffer 
I = 9.7pg/ml  500µl H + 500µl assay buffer 
J = 4.8pg/ml  500µl I + 500µl assay buffer 
K = 2.4pg/ml  500µl J + 500µl assay buffer 
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(3) Assay control standards 
The following oxytocin standards of 10, 50, 100, 250 and 500pg/ml were prepared in assay 
buffer, duplicate aliquots of which were incorporated at the beginning and end of the assay in order to 
assess the intra- and inter-assay variations. The remaining standards were stored at -20oC for use in 
the subsequent assays.  
IAS 0 = 1000pg/ml  400µl A + 600µl assay buffer 
IAS 1 = 500pg/ml  500µl IAS 0 + 500µl assay buffer 
IAS 2 = 250pg/ml  500µl IAS 1 + 500µl assay buffer 
IAS 3 = 100pg/ml  500µl IAS 2 + 500µl assay buffer 
IAS 4 = 50pg/ml  500µl IAS 3 + 500µl assay buffer 
IAS 5 = 10pg/ml  500µl IAS 4 + 500µl assay buffer 
(4) First antibody buffer 
Normal rabbit serum obtained from Sigma (stored at -20oC) was diluted 1:400 in assay buffer 
on the day of assay. 
(5) First antioxytocin antibody 
Rabbit antioxytocin antibody THF-3, donated by Takashi Higuchi (University of Fukui, 
Japan) was diluted 1:200 in assay buffer and stored at -20oC. It was further diluted 1:1000 in first 
antibody buffer on the day of assay to give a final dilution of 1:200,000. 
(6) Secondary antibody 
Donkey anti-rabbit gammaglobulin (A-PPT1) was obtained from IDS Ltd (Boldon, UK) and 
stored at 4oC. On the day of assay, it was diluted 1:25 in assay buffer. 
(7) Tracer: 125I-oxytocin 
370KBq of radioiodinated oxytocin (125I-oxytocin) was obtained from Perkin Elmer Life and 
Analytical Sciences (Buckinghamshire, UK). It was diluted in 1ml of assay buffer and stored at -20oC 
in 200µl aliquots. It is used at a concentration to give between 6000 and 8000cpm/50µl.  
To calculate the volume of tracer required: 
Total volume of tracer required = (Tube number of assay tubes X 0.05) + 2 = A ml 
Activity required = 3.7KBq x A ml = B Kbq 
If total volume of tracer available is C and current activity is D after decay, then the volume 
needed was: B/D x C. This was added to the required volume of buffer (A ml). 
(8) Standardized Pansorbin cells  
Pansorbin cells were obtained from Calbiochem Ltd (Nottingham, UK) as a 10% w/v 
solution containing 0.1% w/v sodium azide and stored at 4oC. This was diluted 1:25 in assay buffer 
on the day of use. 
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Fig. 1.1a. A coronal section of hypothalamus showing oxytocin system in the rat brain - 
Major sources of oxytocin: PVN and SON. Oxytocin neurones are stained with fluorescent 
red and vasopressin neurones with fluorescent green. Abbreviations: PVN, paraventricular 
nucleus; SON, supraoptic nucleus; 3V, third ventricle [From: Dr. Vicky Tobin, with 
permission].  
    
 
Fig. 1.1b. A coronal section showing supraoptic nucle s (SON) in the rat. Oxytocin neurones 
are stained with fluorescent red and vasopressin neuro s with fluorescent green. The ventral 
























Fig. 1.2. An illustration of a magnocellular oxytocin neurone depicting regulation of 
various physiological processes by central and periph al oxytocin. The role of 
peripheral oxytocin regulation of reproduction, fluid homeostasis, gastrointestinal 
system, cardiovascular system and stress has long been well established (Murphy, 1952; 
Chan and Sawyer, 1962; Nakano and Fisher, 1963; Fendler et al., 1964; Kaneto and 
Kosaka, 1970; Wakerley et al., 1973). The importance of central oxytocin in the control 
of reproductive and social behaviours, learning, memory and anxiety and stress was 
realised more recently (Engelmann et al., 2000; Heinrichs and Domes, 2008; Leng et al., 

































       
 
Fig. 1.3. Anatomical location of the SON in rat hypothalamus in relevance to the location of 
other appetite regulating centres: a 3D view from dorsal and caudal of major hypothalamic 
nuclei in the right hemisphere of rat hypothalamus. Abbreviations: AHA, anterior 
hypothalamic area; ARC, arcuate nucleus; AV3V, anterov ntral area of third ventricle; CI, 
capsula interna; DP, dorsal parvocellular subnucleus of paraventricular nucleus (PVN); 
DMN, dorsomedial nucleus; F, fornix; LHA, lateral hypothalamic area; LM, lateral 
magnocellular subnucleus of paraventricular nucleus; LPOA, lateral preoptic area; ME, 
median eminence; MP, medial parvocellular PVN; MPO, medial preoptic area; OT, optic 
tract; SCh, suprachiasmatic nucleus; SON, supraoptic nucleus; SI, substantia inomminata; 
ST, subthalamic nucleus; VMN, ventromedial nucleus; VP, ventral parvocellular subnucleus 
of paraventricular nucleus. [Adapted from: Berthoud, 2002].  
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Fig. 1.4. Illustration showing the circuitry connecting abdominal vagal afferents, brainstem 
and hypothalamus. Connections in red show an autonom us reflex arc that forms a direct 
regulator of digestion. Connections in blue shows pathways required to integrate the reflex 
arc and the indirect regulators of feeding. Sensory afferents and motor efferents of the vagus 
serve as the connection between the gut and the dorsal vagal complex involves. 
Abbreviations: AP, area postrema; CC, central canal; DMX, dorsal motor nucleus of the 
tenth cranial nerve; NTS, nucleus of the tractus solitarius. [Adapted from: Luckman and 




Fig. 1.5. Objectives of this thesis: To explore theresponses of SON oxytocin neurones to 
four different appetite peptides of central and peripheral origin involved in stimulating or 
inhibiting appetite or in the signalling between the brain and the gut:  neuropeptide Y (NPY, 
a central orexigenic peptide), leptin (a peripheral anorexigenic peptide from the adipose 
tissue), secretin (a brain-gut peptide from the gut) and cholecystokinin (CCK; a peripheral 
anorexigenic peptide from the gut). The influence of fasting and pregnancy on the effects on 
SON oxytocin neurones induced by the appetite peptid s was also studied. The interaction 
between the long term anorectic peptide leptin and the short term anorectic peptide CCK was 
explored. The involvement of noradrenergic (NA) inputs on secretin-induced effects on SON 
oxytocin neurones was investigated. 
NPY 
Fat Gut 






 Fasting (Leptin, CCK, secretin) 
 Pregnancy (NPY, leptin, CCK) 
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Fig. 2.1. In vivo electrophysiological experimental set-up: This illustration shows a urethane-
anaesthetized rat positioned in a stereotaxic frame with the SON and neural stalk exposed 
through the ventral transpharyngeal surgical approach (Leng and Dyball, 1991). The 
stimulating and recording electrodes were held in place using stereotaxic holders. 










Fig. 2.2. Illustration showing the positioning of stimulating and recording electrodes in a rat 
model in which the SON and neural stalk were exposed through the ventral transpharyngeal 
approach. The stimulating electrode is positioned at the neural stalk to antidromically 
stimulate SON neurones with 1mA rectangular pulses for a duration of 1ms every 3s. This 
antidromic stimulation evokes an action potential at the cell body which is picked up by the 
recording electrode as a spike occurring at a constant latency following the stimulation 
artefact. [Illustration modified from: Ludwig and Leng, 1997]. 
  






















Fig. 2.3. Continuous firing pattern of a SON neurone (Cell No. 167-1). Mean +/- s.e.m. 
firing rate: 1.7 ± 0.05 spikes/s. This neurone is further classified as an oxytocin or 
vasopressin neurone depending upon the shape of the interspike interval histogram and 






















Fig. 2.4. Phasic firing pattern of a SON vasopressin neurone (Cell No. 119-1). Activity 


























Fig. 2.5a. Interspike interval distribution of a single SON neurone (Cell No. 55-4). As the 
descending slope of the histogram fits perfectly with the single negative exponential curve 
(see below), this neurone was classified as a putative oxytocin neurone. 
 
















Fig. 2.5b. Interspike intervals of a single SON neurone (Cell No. 55-4) fitted to an 
exponential curve. The single negative exponential fi s well with all data points (R2 value of 
0.98 indicates good fit), which is a characteristic of interspike interval histogram for SON 



























Fig. 2.6a. Interspike interval histogram constructed from 67 SON neurones identified as 
oxytocin neurones. Values are mean ± s.e.m; not normalised. 
















Fig. 2.6b. Interspike interval histogram constructed from 67 identified SON oxytocin 
neurones fitted to an exponential curve. Values are mean ± s.e.m. The single negative 
exponential fits well with all intervals which characterises SON oxytocin neurones. R2 value 



















Fig. 2.7a. Interspike interval histogram of a single SON neurone (Cell No. 54-3). When fitted 
to a single negative exponential curve, the intervals less than 0.2s do not fit while the distal 
tail of the histogram fits well with the curve (see b low).  This is a characteristic of 
vasopressin neurones and hence, this neurone was clas ified as a putative vasopressin 
neurone. 
 














Fig. 2.7b. Interspike interval histogram of a single putative SON vasopressin neurone (Cell 
No. 54-3) fitted to a single negative exponential curve. The curve fits well with the distal tail 
of the histogram leaving behind the intervals less than 0.2s unfitted, which characterises this 





















Fig. 2.8a. Interspike interval histogram constructed from 69 non-phasic SON neurones 
identified as vasopressin neurones. Values are mean ± s.e.m; not normalised. 
 














Fig. 2.8b. Interspike interval histogram constructed from 69 identified non-phasic SON 
vasopressin neurones fitted to a single negative exponential curve. Values are mean ± s.e.m. 
The curve fits well with the distal tail of the histogram leaving the intervals below 0.2s 




























Fig. 2.9a. Interspike interval histogram constructed from 31 identified phasic SON 
vasopressin neurones. Values are mean ± s.e.m; not normalised. 
 

















Fig. 2.9b. Interspike interval histogram constructed from 31 identified phasic SON 
vasopressin neurones fitted to a single negative exponential curve. Values are mean ± s.e.m. 
The curve fits well with the distal tail of the histogram leaving the intervals below 0.2s 

























Fig. 2.10a. Interspike interval histogram constructed from 100 SON vasopressin neurones 
(69 non-phasic and 31 phasic cells combined). Values ar  mean ± s.e.m; not normalised. 
 















Fig. 2.10b. Interspike interval histogram constructed from 100 SON vasopressin neurones 
(69 non-phasic and 31 phasic cells combined) fitted o a single negative exponential curve. 
Values are mean ± s.e.m. The curve fits well with the distal tail of the histogram leaving the 
intervals below 0.2s unfitted. This is a characteris ic of histograms constructed from the 
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Fig. 2.11a. Hazard analysis of a single SON oxytocin neurone (Cell No. 55-4) classified as 
an oxytocin neurone based on the shape of the hazard plot. Hazard functions for oxytocin 
neurones show an initial refractory period, then a steady increase in hazard to a plateau after 
a post-spike interval of about 50ms, implying that after about 50ms, there are no detectable 
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Fig. 2.11b. Hazard plot constructed from 67 SON neurones identified as oxytocin neurones. 
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Fig. 2.12a. Hazard analysis of a single SON neurone (Cell No. 54-3) classified as a putative 
vasopressin neurone based on the shape of the hazard plot. Hazard analysis of vasopressin 
neurones show a low probability of discharge immediately after a spike, indicating a 
refractory period, followed  by a peak of increased probability after each spike (from about 
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Fig. 2.12b. Hazard plot constructed from 69 non-phasic SON neurones identified as 
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Fig. 2.12c. Hazard plot constructed from 31 phasic SON vasopressin neurones. Values are 
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Fig. 2.12d. Hazard plot constructed from 100 SON vasopressin neurones (69 non-phasic and 
































Fig. 2.13. Differentiation of oxytocin and vasopressin neurones by systemic CCK 
administration: The basal firing rate of 1.9spikes/s was increased by 2.6spikes/s (140% 
increase) 1.5min after administration of CCK (25µg/kg; i.v), which is a characteristic of 






















Fig. 2.14. Differentiation of oxytocin and vasopressin neurones by systemic CCK 
administration: The basal firing rate of 15spikes/s was decreased by 14.9spikes/s (99% 
decrease) 1min after administration of CCK (25µg/kg; i.v) which is a characteristic of 
vasopressin neurones. Hence, this neurone was classified as a SON vasopressin neurone 













Fig. 2.15. This illustration shows the placement of a microdialysis probe in an in vivo 
electrophysiological set-up that allows simultaneous recording of firing rate of a SON 
neurone while a drug is microdialysed to study the local effect of the drug. This set-up was 
also used to collect the microdialysate to evaluate dendritic release of oxytocin in response to 
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Fig. 2.16. Standard curve obtained for the measurement of plasma oxytocin concentration by 




























Fig. 3.1. Average body weights of virgin and pregnant rats used in the NPY study. Values 




































Fig. 3.2. The average basal firing rate of SON oxytcin neurones in the NPY study. Values 

































Fig. 3.3. Effect of central administration of NPY (5µg/2µl aCSF; i.c.v) on the firing rate of a 
SON oxytocin neurone in a virgin rat (Cell No. 93-1). Basal firing rate of 5 ± 0.05 spikes/s 























Fig. 3.4. Effect of central administration of vehicle (2µl aCSF; i.c.v) on the firing rate of a 







































Fig. 3.5. Effect of central administration of NPY (5µg/2µl aCSF; i.c.v) on the firing rate of 
SON oxytocin neurones in virgin rats (n=5 cells; 4 rats). Values are mean ± s.e.m. Pre- vs. 0-
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Fig. 3.6. Effect of central administration of NPY (5µg/2µl aCSF; i.c.v; n=5 cells; 4 rats) or 
vehicle (2µl aCSF; i.c.v; n=4 rats) on the firing rate of SON oxytocin neurones in virgin rats. 
Values are mean ± s.e.m. Change in firing rate during 0-30min after respective injections 
between virgin aCSF and virgin NPY groups: P=0.02, t-test. Virgin NPY group: P=0.01, 
paired t-test, pre- vs. 0-30min post-NPY within group. Virgin aCSF group: P=0.7, paired t-
test, pre- vs. 0-10min after aCSF within group. Central administration of NPY significantly 

























10min before NPY 10min after NPY
 
Fig. 3.7a. Effect of central administration of NPY (5µg/2µl aCSF; i.c.v) on the interspike 
interval histogram of SON oxytocin neurones in virgin rats (n=5 cells; 4 rats). Values are 
mean ± s.e.m; not normalised. Pre- vs. 10min post-NPY: P=0.049, paired t-test.  
y = 163.97e -6.1261x
R2 = 0.9797
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Fig. 3.7b. Interspike interval histogram fitted to exponential curves. Values are mean ± 
s.e.m. The regression equations are: before NPY: y = 163.97e-6.1261x; after NPY: y = 223.96e-
6.8726x.  R2 values of 0.98 and 0.99 indicate that the exponential curves perfectly fit the data 
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Fig. 3.8. Effect of central administration of NPY (5µg/2µl aCSF; i.c.v) on the mean post-
spike probability of SON oxytocin neurones in virgin rats (n=5 cells; 4 rats): Hazard 



























Fig. 3.9. Effect of central administration of NPY (5µg/2µl aCSF; i.c.v) on the mean post-
spike probability of SON oxytocin neurones in virgin rats (n=5 cells; 4 rats): Ratio of peak 
early (<0.07s) to mean late (0.2 – 0.3s) hazard. Values are mean ± s.e.m. Before vs. after 






























Fig. 3.10. Effect of central administration of vehicle (2µl aCSF; i.c.v) on the firing rate of a 






















Fig. 3.11. Effect of central administration of NPY (5µg/2µl aCSF; i.c.v) on the firing rate of 
a SON oxytocin neurone in a pregnant rat (Cell No. 89P-3). Basal firing rate of 4 ± 0.08 





































Pregnant aCSF (n=4) Pregnant NPY (n=6)
 
Fig. 3.12. Effect of central administration of NPY (5µg/2µl aCSF; i.c.v; n=6 rats) or vehicle 
(2µl aCSF; i.c.v; n=4 rats) on electrical activity of SON oxytocin neurones in late pregnant 
rats. Values are mean ± s.e.m. Pre- vs. 0-30min post-NPY within pregnant NPY group 
P=0.03, paired t-test. Pre- vs. 0-30min post-aCSF within pregnant aCSF group: P=0.053, 
paired t-test. P=0.048, t-test, 0-30min after aCSF/NPY between pregnant aCSF and pregnant 
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Fig. 3.13. Effect of central administration of NPY (5µg/2µl aCSF) on electrical activity of 
SON oxytocin neurones in virgin (n=5 cells; 4 rats) and late pregnant (n=6 rats) rats. Values 
are mean ± s.e.m. Pre- vs. 0-30min after NPY within virgin NPY group: P=0.01, paired t-
test. Pre- vs. 0-30min after NPY within pregnant NPY group: P=0.03, paired t-test. 0-30min 

































Fig. 3.14. Effect of systemic administration of NPY (20µg; i.v) on the firing rate of a SON 
oxytocin neurone in a virgin rat (Cell No. 25-10). Basal firing rate of 1.3 spikes/s was 

























Fig. 3.15. Effect of systemic administration of NPY (20µg/rat; i.v) on the firing rate of SON 
oxytocin neurones in virgin rats (n=5 rats). Values are mean ± s.e.m. P=0.04, paired t-test, 









































Fig. 3.16. Effect of central administration of NPY (5µg/2µl; i.c.v) on firing rate of SON 
vasopressin neurones in virgin rats (n=4 rats). Values are mean ± s.e.m. Pre- vs 0-10min 
















Before NPY After NPY
 
Fig. 3.17a. Effect of central administration of NPY (5µg/2µl; i.c.v) on the interspike interval 
histogram of SON vasopressin neurones in virgin rats (n=5 rats). Values are mean ± s.e.m; 
















y = 212.21e -6.5223x
R2 = 0.9675
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Fig. 3.17b. Interspike interval histograms of vasopressin neurones before and after central 
NPY administration fitted to exponential curves. Values are mean ± s.e.m. The distal tail of 
the histograms fit well to exponential lines, indicated by the R2 values of 0.95 and 0.97, but 
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Fig. 3.18. Effect of central administration of NPY (5µg/2µl; i.c.v) on the mean post-spike 
probability of SON vasopressin neurones in virgin rats (n=5 rats): Hazard analysis. Values 





























Fig. 3.19. Effect of systemic administration of NPY (20µg/rat; i.v) on the firing rate of a 
non-phasic SON vasopressin neurone in a virgin rat (Cell No. 15-1). Basal firing rate was 8.4 

































Fig. 3.20. Effect of systemic administration of NPY (20µg/rat; i.v) on the firing rate of non-
phasic SON vasopressin neurones in virgin rats (n=6rats). Values are mean ± s.e.m. Pre- vs. 


































Fig. 3.21. Effect of systemic administration of NPY (20µg/rat; i.v) on the firing rate of a 
phasic SON vasopressin neurone in a virgin rat (Cell No. 9-5). Activity quotient and 
frequency within bursts decreased from 0.2 (basal) to 0.1 and 3.2 spikes/s (basal) to 2.9 
spikes/s, respectively, 0-5min after NPY, while them an interburst interval increased from 






















Fig. 3.22. Effect of systemic administration of NPY (20µg/rat; i.v) on the firing rate of 
phasic SON vasopressin neurones in virgin rats (n=3 rats): Activity quotient. Values are 







































Fig. 3.23. Effect of systemic administration of NPY (20µg/rat; i.v) on the firing rate of 
phasic SON vasopressin neurones in virgin rats (n=3rats): Frequency within bursts. Values 


























Fig. 3.24. Effect of systemic administration of NPY (20µg/rat; i.v) on the firing rate of 
phasic SON vasopressin neurones in virgin rats (n=3rats): Mean interburst interval. Values 




















Fig. 4.1. Hypothesis for response to leptin in pregnant rats. As oxytocin neurone responses to 
various stimuli are attenuated during pregnancy in rats, it was hypothesized that leptin-
induced effects on SON oxytocin neurones are also suppressed in pregnant rats. Hence, a 
reduction in the response to a particular dose of leptin or shift to right in the dose response 
































Fig. 4.2. The mean body weights of fasted/unfasted virgin and pregnant rats used in leptin 
study. Values are mean ± s.e.m. *P<0.001, F1, 62=124.9, two-way ANOVA, virgin vs. 
pregnant groups. Fasting for 18h did not alter the body weight significantly within virgin 
(fasted virgin vs. unfasted virgin: P=0.7, Mann-Whitney rank sum test) or pregnant (fasted 



































Fig. 4.3. Basal firing rates of SON oxytocin neurones in the four groups of rats used in leptin 
study. Values are mean ± s.e.m. *P<0.001, F1, 61=15.2, two-way ANOVA, virgin vs. pregnant 
groups. #P=0.035, Two-way ANOVA followed by all pair-wise multiple comparison 
procedure (Holm-Sidak method), unfasted pregnant vs. fasted pregnant groups. There is a 
significant interaction between feeding (unfasted/fasted) and reproductive (virgin/pregnant) 



































Fig. 4.4. Effect of systemic administration of leptin (100µg; i.v) on electrical activity of a 
SON oxytocin neurone in an unfasted virgin rat (Cell No. 188-3). The basal firing rate of 5.7 
























Fig. 4.5. Effect of systemic administration of leptin (100µg; i.v) on electrical activity of SON 
oxytocin neurones in unfasted virgin rats (n=23). Values are means ± s.e.m. of average 



























Before leptin (n=23) After leptin (n=23)
 
Fig. 4.6a. Effect of systemic administration of leptin (100µg; i.v) on mean interspike interval 
of SON oxytocin neurones 10min before and 10min after administration of leptin in unfasted 
virgin rats (n=23). Values are mean ± s.e.m; not normalised. Pre- vs. 0-10min post-leptin 
P=0.004, paired t-test.  
y = 100.44e -4.526x
R2 = 0.9949















Before leptin After leptin 
 
Fig. 4.6b. The interspike interval histograms befor and after leptin fitted to the exponential 























Before leptin (n=23) After leptin (n=23)
 
Fig. 4.7. Effect of systemic administration of leptin (100µg; i.v) on mean post-spike 
probability of SON oxytocin neurones 10min before and 10min after administration of leptin 
in unfasted virgin rats (n=23): Hazard analysis. Values are mean ± s.e.m; not normalised. 
There is no change in the shape of the hazard plot after administration of leptin. 






























Fig. 4.8. Effect of systemic administration of leptin (100µg; i.v) on mean post-spike 
probability of SON oxytocin neurones in unfasted virgin rats (n=23): Ratio of peak early 
(<0.07s) to mean late (0.2-0.3s) hazard 10min before and 10min after administration of 





























Fig. 4.9. Effect of systemic administration of leptin (100µg; i.v) on electrical activity of SON 
oxytocin neurones in an unfasted pregnant rat (No. 142P-2). The basal rate of 7.6 ± 0.06 
spikes/s was increased by 1.5 spikes/s 15.5min after leptin treatment. The rate returned to 
basal by 25min.  
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Unfasted virgin Unfasted pregnant 
 
Fig. 4.10. Effect of systemic administration of leptin (100µg; i.v) on electrical activity of 
SON oxytocin neurones in unfasted virgin (n=23) andpregnant (n=5) rats. Values are means 
± s.e.m. of average changes from across 10min of basal in 30s bins. The oxytocin neurones 
in the unfasted virgin groups were recorded only for 20min after leptin administration and 
hence the data appears truncated. Pre- vs 0-10min post-leptin within unfasted virgin group: 
P=0.01, paired t-test; pre- vs 0-20 or 0-30min post-lep in within unfasted pregnant group: 































Fasted Virgin Fasted Pregnant 
 
Fig. 4.11a. Effect of systemic administration of leptin (100µg; i.v) on electrical activity of 
SON oxytocin neurones in fasted virgin (n=8) and fasted pregnant (n=8) rats. Values are 
means ± s.e.m. of average changes from across 10 min of basal in 30 s bins. Some of the 
oxytocin neurones in the fasted pregnant rats were lost 30min after leptin and hence the data 
was truncated. Pre- vs. 0-10min post leptin within the fasted virgin group: P=0.051, paired t-
test; pre vs. 20-30min after leptin within the fasted virgin group: P=0.2, paired t-test; pre- vs. 
0-10min after leptin within the fasted pregnant group: P=0.8, paired t-test; fasted virgin vs.























Fasted Virgin Fasted Pregnant 
 
Fig. 4.11b. Effect of systemic administration of leptin (100µg; i.v) on electrical activity of 
SON oxytocin neurones in fasted virgin (n=8) and pregnant (n=8) rats during the first 0-
20min period after leptin injection. Values are means ± s.e.m. of average changes from 
across 10 min of basal in 30 s bins. Pre- vs. 0-10min post leptin within fasted virgin group: 
P=0.051, paired t-test; fasted pregnant: pre- vs. 0-10min after leptin within the group: P=0.8, 
































Unfasted Virgin Fasted Virgin 
 
Fig. 4.12a. Effect of systemic administration of leptin (100µg; i.v) on electrical activity of 
SON oxytocin neurones in unfasted (n=23) and fasted virgin (n=8) rats. Values are means ± 
s.e.m of average changes from across 10min of basal in 30s bins. The oxytocin neurones in 
the unfasted virgin group were recorded only until 20min after leptin and hence the data 
appears truncated. Pre- vs.0-10min post-leptin within unfasted virgin group: P=0.01, paired 
t-test. Pre- vs. 0-10min post-leptin in fasted virgin rats: P=0.051, paired t-test (pre- vs. 20-
30min post-leptin: P=0.2, paired t-test). The respon e after leptin did not differ significantly 























Unfasted Virgin Fasted Virgin 
 
Fig. 4.12b. Effect of systemic administration of leptin (100µg; i.v) on electrical activity of 
SON oxytocin neurones in unfasted (n=23) and fasted (n=8) virgin rats during the initial 0-
20min after leptin. Values are means ± s.e.m of average changes from across 10min of basal 
in 30s bins. Pre- vs. 0-10min post-leptin within unfasted virgin group: P=0.01, paired t-test. 
Pre- vs. 0-10min post-leptin in fasted virgin rats: P=0.051, paired t-test. The response after 
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Fig. 4.13. Effect of systemic administration of leptin (100µg; i.v) on electrical activity of 
SON oxytocin neurones in unfasted (n=5) and fasted (n=8) pregnant rats. Values are means ± 
s.e.m. of average changes from across 10min of basal in 30s bins. Pre- vs. 0-20min (and 0-
30min) post-leptin within unfasted pregnant group: P=0.006, paired t-test. Pre- vs. 0-10min 
post-leptin within fasted pregnant group: P=0.8, paired t-test. 0-10min and 0-20min after 






































Fasted Virgin 1µg Leptin (n=6)
Fasted Virgin 10µg Leptin (n=6)
Fasted Virgin 100µg Leptin (n=8)
 
Fig. 4.14. Effect of systemic administration of different doses of leptin on electrical activity 
of SON oxytocin neurones in fasted virgin rats. Values are means ± s.e.m. of average 
changes from across 10min of basal in 30s bins. The basal firing rates were 4.2 ± 0.8 
spikes/s, 4.55 ± 0.8 spikes/s and 4.45 ± 0.75 spike/s, respectively, in the 1, 10 and 100µg 
leptin groups and they did not differ (P=0.98, one-way ANOVA). Pre- vs. 0-10min post-
leptin within 100µg leptin group P=0.051, paired t-test. Pre- vs. 0-10min post-leptin: 1µg: 







































Fasted Pregnant 1µg Leptin (n=3)
Fasted Pregnant 10µg Leptin (n=6)
Fasted Pregnant 100µg Leptin (n=8)
Fasted Pregnant 1mg Leptin (n=6)
 
Fig. 4.15. Effect of systemic administration of different doses of leptin on electrical activity 
of SON oxytocin neurones in fasted pregnant rats. Values are means ± s.e.m. of average 
changes from across 10 min of basal in 30 s bins. Ba al firing rates: 4.3 ± 2.1 spikes/s (1µg), 
6 ± 1.1 spikes/s (10µg), 4.6 ± 0.7 spikes/s (100µg) and 5.9 ± 1 spikes/s (1mg); they did not 
differ (P=0.6, one-way ANOVA). Pre- vs. 0-10min post-leptin within groups: 1µg: P=0.3; 
10µg: P=0.7; 100µg: P=0.8; 1mg: P=0.1, paired t-test. 0-10min post-leptin between groups: 


























Fasted Virgin Fasted Pregnant 
 
Fig. 4.16a. Effect of systemic administration of leptin (1µg; i.v) on electrical activity of SON 
oxytocin neurones in fasted virgin (n=6) and fasted pregnant (n=3) rats. Values are means ± 
s.e.m. of average changes from across 10 min of basal in 30 s bins. Pre- vs. 0-10min post-
leptin within fasted virgin group: P=0.2, paired t-test. Pre- vs. 0-10min post-leptin within 
fasted pregnant group: P=0.3, paired t-test. 0-10min after leptin between fasted virgin and 

























Fasted Virgin Fasted Pregnant 
 
Fig. 4.16b. Effect of systemic administration of leptin (10µg; i.v) on electrical activity of 
SON oxytocin neurones in fasted virgin (n=6) and fasted pregnant (n=6) rats. Values are 
means ± s.e.m. of average changes from across 10 min of basal in 30 s bins. Pre- vs. 0-10min 
post-leptin within fasted virgin group: P=0.08, paired t-test. Pre- vs. 0-10min post-leptin 
within fasted pregnant group: P=0.7, paired t-test. 0-10min after leptin between fasted virgin 





























Fig. 4.17. Effect of systemic administration of leptin (100µg; i.v) on electrical activity of a 
non-phasic vasopressin neurone (Cell No. 214-1) in an unfasted virgin rat. The basal rate of 




























Fig. 4.18. Effect of systemic administration of leptin (100µg; i.v) on electrical activity of 
non-phasic vasopressin neurones in unfasted virgin rats (n=13). Values are means ± s.e.m. of 
average changes from across 10min of basal in 30s bins. Pre vs. 0-5min post-leptin: P=0.6, 






























Fig. 4.19. Effect of systemic administration of leptin (100µg; i.v) on electrical activity of a 
phasic SON vasopressin neurone (Cell No. 220-1) in an unfasted virgin rat. Leptin elicited 
an inhibitory effect in this particular neurone. Comparing basal firing and firing 5-10min 
after leptin, the activity quotient decreased from 0.15 to 0.08, mean frequency within bursts 


















Fig. 4.20. Effect of systemic administration of leptin (100µg; i.v) on the electrical activity of 
phasic vasopressin neurones in unfasted virgin rats (n=8): Activity quotient. Values are mean 








































Fig. 4.21. Effect of systemic administration of leptin (100µg; i.v) on the electrical activity of 
phasic vasopressin neurones in unfasted virgin rats (n=8): Frequency within bursts (spikes/s). 























Fig. 4.22. Effect of systemic administration of leptin (100µg; i.v) on the electrical activity of 
phasic vasopressin neurones in unfasted virgin rats (n=8): Mean interburst interval (s). 

























Before leptin After leptin
 
Fig. 4.23a. Effect of systemic administration of leptin (100µg; i.v) on the mean interspike 
interval of vasopressin neurones in unfasted virgin ats [n=19 (11 non-phasic and 8 phasic)]. 
Values are mean ± s.e.m; not normalised. There was no change in the histogram following 
leptin administration. 
y = 297.68e -8.4583x
R2 = 0.9502














Before leptin After leptin
 
Fig. 4.23b. Effect of systemic administration of leptin (100µg; i.v) on the mean interspike 
interval of vasopressin neurones in unfasted virgin ats [n=19 (11 non-phasic and 8 phasic)]. 
Values are mean ± s.e.m. The descending slope of the histograms were fitted with 
exponential curves which fit only the distal tail of the histogram leaving intervals less than 
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Before leptin After leptin
 
Fig. 4.24. Effect of systemic administration of leptin (100µg; i.v) on the mean post-spike 
probability of vasopressin neurones in unfasted virgin rats [n=19 (11 non-phasic and 8 
phasic)]. Values are mean ± s.e.m; not normalised. There was no change in the shape of the 

























Fig. 5.1. Effect of systemic administration of secretin (0.1µg) on electrical activity of a SON 
oxytocin neurone (Cell No. 183-1) in an unfasted virgin rat. The basal firing rate of 2.9 ± 
0.05 spikes/s was increased by ca. 3 spikes/s 5min after secretin. Firing rate gradually 

























Fig. 5.2. Effect of systemic administration of secretin (0.1µg; i.v) on the firing rate of SON 
oxytocin neurones in unfasted virgin rats (n=26). Values are mean +s.e.m. P<0.001, paired 
t-test, pre- vs. 0-10min post secretin. Change from mean basal, calculated over 10 min before 
i.v. secretin injection. Average basal firing rate: 4.1 ± 0.4 spikes/s. Systemic secretin, given 
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Fig. 5.2a. Correlation between the basal firing rate of SON oxytocin neurones and the 
percentage increase in firing rate after secretin (0.1µg/rat; i.v) administration in virgin rats. 
Basal firing rate and percentage increase in firing ate after secretin are negatively correlated 






















10min before secretin (n=26) 10min after secretin (n=26)
  
Fig. 5.3a. Effect of systemic administration of secretin (0.1µg; i.v) on the interspike interval 
histogram of SON oxytocin neurones in unfasted virgin ats. Values are mean ± s.e.m; not 
normalised. These interspike interval histograms 10min before and after the administration 
of secretin show that the number of spikes occurring within 0-0.5s after a spike is 
significantly increased after secretin. Pre- vs. post-secretin: P<0.001, paired t-test. 
y = 177.56e -6.2398x
R2 = 0.9957
















Fig. 5.3b. The interspike interval histograms fitted with exponential curves. Values are mean 
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10min before secretin (n=26) 10min after secretin (n=26)
 
Fig. 5.4. Effect of systemic administration of secretin (0.1µg; i.v) on hazard analysis of SON 
oxytocin neurones in unfasted virgin rats. Values are mean ± s.e.m; not normalised. Pre- vs. 
post-secretin: P<0.001, Wilcoxon signed rank test. Secretin administration resulted in a 
positive shift in the hazard without a change in the s ape of the hazard plot, suggesting that 
secretin-induced increase in the firing results from increase in the excitatory inputs not from 






























Fig. 5.5. Effect of systemic administration of secretin (0.1µg; i.v) on the ratio of peak early 
(<0.07s) to mean late (0.2-0.3s) hazard of SON oxytocin neurones in virgin rats (n=26). 
Values are mean ± s.e.m. Secretin administration did not alter the ratio of peak early to mean 
late hazard significantly (P=0.2, paired t-test) which confirms that there is no change in the 




























Fig. 5.6. Effect of systemic administration of secretin (0.1µg, i.v.) on the firing rate of a non-
phasic SON vasopressin neurone in an unfasted virgin rat (Cell No. 235-2). Basal firing rate 
of 4.3 ± 0.07 spikes/s was increased by 2.6 spikes/s 3min after secretin. The rate returned to 






























Fig. 5.7. Excitatory effects of systemic administration of secretin (0.1µg; i.v) on the 
electrical activity of non-phasic SON vasopressin neurones in unfasted virgin rats (n=14 out 
of 21). Values are mean ± s.e.m. Pre- vs 0-10min post-secretin: P=<0.001, paired t-test. 































Fig. 5.8. Effect of systemic administration of secretin (0.1µg, i.v.) on firing rate of a non-
phasic SON vasopressin neurone (245-1) in an unfasted virgin rat. CCK (25µg/kg; i.v) was 
given at 15 min. Basal rate before CCK was 9.9 ± 0.1 spikes/s and was decreased by 9.9 
spikes/s 1 min after CCK. The rate remained low for 3min after CCK. Secretin (0.1µg; i.v) 
was given at 43 min. Firing rate before secretin injection was 9.7 ± 0.2 spikes/s and the rate 





























Fig. 5.9. Inhibitory effect of systemic administration of secretin (0.1µg; i.v) on firing rate of 
non-phasic SON vasopressin neurones in unfasted virgin rats (n=6 out of 21). Values are 
mean ± s.e.m. Pre- vs. 0-10min post-secretin: P=0.02, paired t-test. Averag  basal firing rate 














































Fig. 5.10. Overall effect of systemic administration f secretin (0.1µg; i.v) on the firing rate 
of non-phasic SON vasopressin neurones in unfasted virgin rats (n=21). Values are mean ± 
s.e.m. Pre- vs. 0-10min post-secretin: P=0.2, paired t-test. Averag  basal firing rate: 6.3 ± 0.6 
spikes/s. The effect of secretin on non-phasic SON vasopressin neurones was predominantly 

























Fig. 5.11. Effect of systemic administration of secretin (0.1µg; i.v) on firing rate of a phasic 
SON vasopressin neurone in an unfasted virgin rat (Cell No. 246-3). Secretin (0.1µg; i.v) 
was given at 0min. Comparing the activity 5min befor  and 5min after secretin, the activity 
quotient increased from 0.2 to 0.5, frequency within bursts increased from 10.6 to 11.2 






















Fig. 5.12. Effect of systemic administration of secretin (0.1µg; i.v) on electrical activity of 
SON phasic vasopressin neurones in unfasted virgin rats (n=11): Activity Quotient. Values 
are mean ± s.e.m. *P=0.02, paired t-test, pre- vs. 0-5min post-secretin. Secretin 


































Fig. 5.13. Effect of systemic administration of secretin (0.1µg; i.v) on electrical activity of 
SON phasic vasopressin neurones in unfasted virgin rats (n=11): Mean interburst interval (s). 
Values are mean ± s.e.m. *P=0.014, Wilcoxon signed rank test, pre- vs. 0-5min post-secretin. 
Secretin administration significantly decreased the int rburst interval and hence activated the 






























Fig. 5.14. Effect of systemic administration of secretin (0.1µg; i.v) on electrical activity of 
SON phasic vasopressin neurones in virgin rats (n=11): Frequency within bursts (spikes/s). 
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Fig. 5.15a. Effect of systemic administration of secretin (0.1µg; i.v) on interspike interval of 
SON vasopressin neurones in virgin rats (n=34; 21 non-phasic and 13 phasic vasopressin 
neurones). Values are mean ± s.e.m; not normalised. There was no change in the shape of the 
interspike interval histogram following secretin (P=0.2, paired t-test). 
. 
y = 237.29e -7.2707x
R2 = 0.9644
















Fig. 5.15b. Interspike interval histograms of SON vasopressin neurones in virgin rats fitted 
with single negative exponential curves (n=34; 21 non-phasic and 13 phasic vasopressin 
neurones). Values are mean ± s.e.m. The negative expon ntial fits well with the distal tail of 
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Fig. 5.16. Effect of systemic administration of secretin (0.1µg; i.v) on mean post-spike 
probability of SON vasopressin neurones in virgin rats (n=34; 21 non-phasic and 13 phasic 
vasopressin neurones). Values are mean ± s.e.m; not normalised. There was a significant 
positive shift in the hazard plot (P=0.001, Wilcoxon signed rank test) without obvious 

































Fig. 5.17. Effects of systemic administration of increasing doses of secretin on a SON 
oxytocin neurone in a virgin rat (Cell No. 238-1). CCK (25µg/kg; i.v), secretin 0.1µg, 0.5µg 
and 1µg were given at 14, 38 80 and 117min, respectively. CCK briefly increased the firing 
rate. The firing rates before 0.1µg, 0.5µg and 1µg of secretin were 7 ± 0.09 spikes/s, 7.6 ± 
0.05 spikes/s and 7.3 ± 0.05 spikes/s, respectively, and were increased by 2.3 spikes/s by 
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Fig. 5.18. Effects of systemic administration of increasing doses of secretin on firing rate of 
a SON oxytocin neurone (Cell No. 183-1) in a virgin rat. The basal firing rates before 
0.01µg, 0.05 µg and 0.1 µg secretin were 2.5 ± 0.05 spikes/s, 2.5 ± 0.06 spikes/s and 2.9 ± 
0.05 spikes/s, respectively. 0.01µg of secretin did not affect the firing rate while the rate was 































Fig. 5.19. Effects of increasing doses of secretin on firing rate of a SON oxytocin neurone 
(No. 238-1) in a virgin rat. The firing rates before 0.1µg, 0.5 µg and 1 µg secretin were 7 ± 
0.09 spikes/s, 7.6 ± 0.05 spikes/s and 7.3 ± 0.05 spike /s, respectively. The rate was 
increased by 2.3 spikes/s by 2.5min, 3.4 spikes/s by 2min and 4.4 spikes/s by 1.5min 
















































Secretin 0.01µg (n=4) Secretin 0.1µg (n=26) Secretin 1µg (n=3)
 
Fig. 5.20. Effects of systemic administration of different doses of secretin on SON oxytocin 
neurones in virgin female rats. Values are means ± s.e.m. Group numbers are: 1µg: n=3; 
0.1µg: n=26; 0.01µg: n=4. P=0.04, paired t-test, pre- vs. 0-10min post-secretin within the 
1µg group; P<0.001, paired t-test, pre- vs. 0-10min post-secretin within the 0.1µg group. 0-
10min post-secretin between the groups: P<0.001, one-way ANOVA. Secretin-induced 






































Fig. 5.21. Effect of systemic administration of secretin (0.1 and 1µg/rat; i.v; n=6) on the 
plasma oxytocin secretion in urethane anaesthetized unfasted rats. Values are mean ± s.e.m. 
Basal sample (B) was collected 2h after the cannulation surgery; a sample (V) was taken 
5min after vehicle (100µl normal saline; i.v). Subsequently, samples were collected 5, 10 
and 25min after administration of 0.1µg secretin and 5 and 10min after 1µg secretin. * 
P<0.05 (0.1µg secretin) and P=0.001 (1µg secretin), one-way RM ANOVA, vs. basal and 
vehicle control. φ P<0.05, one-way RM ANOVA, vs. 5 min after 0.1µg secretin. # P=0.001, 
one-way RM ANOVA, vs. 5 and 10min after 0.1µg secretin, at respective time points. 
Systemic secretin dose-dependently increased plasma oxytocin release. 
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Fig. 5.22a. Effect of microdialysis of hypertonic aCSF on somato-dendritic oxytocin release 
from the SON in vivo in four urethane-anaesthetized female rats (No. 1-6). Hypertonic aCSF 
(1M NaCl) was microdialysed at the end of the experim nt followed by isotonic aCSF. Four 
out of six rats (No. 1-4) showed a positive response to hypertonic and subsequent aCSF 
microdialysis and were statistically analysed to seek vidence of secretin-induced central 
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Fig. 5.22b. Effect of systemic administration of secretin (1µg/rat, i.v.) on central oxytocin 
release in vivo in four urethane-anaesthetized female rats (No. 1-6). Secretin was 
administered immediately after collecting the basal sample. Four out of six rats showed a 
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Fig. 5.22c. Effect of systemic administration of secretin (1µg/rat) on somato-dendritic 
oxytocin release from the SON in vivo in urethane-anaesthetized female rats (n=4). Values 
are mean ± s.e.m. Secretin was administered immediately fter collecting the basal sample. 
Data are for the four out of six rats that showed excitatory response to hyperosmotic 
stimulation. The excitatory response after secretin approached significance (F=2.7, P=0.06, 
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Fig. 5.22d. Effect of systemic administration of secretin (1µg/rat) on peripheral (n=6; data 
from Fig. 5.21) and SON (n=4; data from Fig 5.22c) oxytocin release in vivo in urethane-
anaesthetized female rats. Values are mean ± s.e.m. Systemic secretin-induced peripheral 
oxytocin release was immediate while SON release was delayed. Increase in peripheral 
oxytocin release following secretin was significant (* vs. basal, F=39.8, P<0.001, one-way 
RM ANOVA followed by Bonferroni’s pairwise multiple comparison procedure) while SON 



















































Unfasted virgin (n=26) Fasted virgin (n=3)
 
Fig. 5.23. Comparison of the effects of systemic administration of secretin (0.1µg; i.v) on the 
electrical activity of SON oxytocin neurones in fasted with unfasted rats. Values are mean ± 
s.e.m. P=0.05, paired t-test, pre- vs. 0-10min post-secretin within fasted group. P<0.001, 
paired t-test, pre vs. 0-10min post-secretin within unfasted group. Fasted vs unfasted rats: 0-
10min after secretin: P=0.9, t-test. Secretin-induced change in the firing rate of SON 










































Fig. 5.24. Effect of systemic administration of secretin (0.1µg; i.v) on the electrical activity 
of phasic firing SON vasopressin neurones in fasted an  unfasted rats: Activity quotient. 
Values are mean ± s.e.m. *P=0.02, paired t-test, pre- vs. 0-5min post-secretin within unfasted 
rats. Pre- vs. post-secretin in fasted rats: P=0.1, paired t-test. Fasted vs. unfasted rats: basal: 
P=0.3, t-test; post-secretin: P=0.2, t-test. There was no difference between fasted and 
unfasted rats in basal and secretin-induced activity of phasic firing SON vasopressin 
neurones.  

































Fig. 5.25. Effect of systemic administration of secretin (0.1µg; i.v) on the electrical activity 
of phasic firing SON vasopressin neurones in fasted an  unfasted rats: Mean interburst 
interval (s). Values are mean ± s.e.m. *P= 0.014, Wilcoxon signed rank test, pre- vs.0-5min 
post-secretin within unfasted rats. Pre- vs. post-secretin in fasted rats: P= 0.4, paired t-test. 
Fasted vs. unfasted rats: basal: P=0.97, t-test; post-secretin: P=0.4, t-test. There was no 
difference between fasted and unfasted rats in basal and secretin-induced activity of phasic 




































Fig. 5.26. Effect of systemic administration of secretin (0.1µg; i.v) on the electrical activity 
of phasic firing SON vasopressin neurones in fasted (n=3) and unfasted (n=11) virgin rats: 
Frequency within bursts (spikes/s). Values are mean ± s.e.m. Pre- vs. post-secretin in 
unfasted rats: P=0.3, paired t-test. Pre- vs. post-secretin in fasted rats: P=0.3, paired t-test. 
Fasted vs. unfasted rats: basal: P=0.5, t-test; post-secretin: P=0.8, t-test. There was no 
difference between fasted and unfasted rats in basal and secretin-induced activity of phasic 
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Fig. 5.27. Excitatory responses to repeated injections of secretin (0.01µg; i.v) in a SON 
oxytocin neurone in an unfasted rat (Cell No. 202-3). The average basal firing rates before 
secretin treatments were 3.3 ± 0.04 spikes/s and 2.9 ± 0 04 spikes/s. These were increased by 
1.2 spikes/s 2min after the first secretin injection and by 1.3 spikes/s 4min after the second 
secretin injection. The responses gradually returned to basal rate by 15min after secretin. The 
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Fig. 5.28. Excitatory responses to repeated injections of secretin (0.1µg; i.v) in a SON 
oxytocin neurone in a virgin rat (Cell No. 266-2). The average basal firing rates before 
secretin treatment were 5.4 ± 0.09 spikes/s and 4.8 ± 0.06 spikes/s. These were increased by 
2.4 spikes/s 1.5min after the first secretin injection and by 3.0 spikes/s 6min after the second 
secretin injection. The responses gradually returned to basal rate by 10-15min after secretin. 









































Fig. 5.28a. Excitatory responses to repeated injectons of secretin (0.1µg; i.v) in a SON 
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Fig. 5.29. Excitatory responses to repeated injections of secretin (0.1µg; i.v) in a SON 
vasopressin neurone in a virgin rat (Cell No. 267-1). The average basal firing rates before 
secretin treatments were 4.7 ± 0.09 spikes/s and 4.3 ± 0 08 spikes/s. These were increased by 
2.05 spikes/s 3.5min after the first secretin injection and by 2.2 spikes/s 4.5min after the 
second secretin injection. The responses gradually returned to basal rate by 15min after 
























Fig. 5.29a. Excitatory responses to repeated injectons of secretin (0.1µg; i.v) in a SON 






























Fig. 5.30. Effect of i.c.v. benoxathian infusion on secretin-induced excitatory firing rate response of a SON oxytocin neurone in a virgin rat (Cell No. 
258-1). CCK (25µg/kg; i.v) was given at 23min (befor  benoxathian i.c.v. infusion) and 200min (73.5 min after starting higher dose of benoxathian). 
Secretin (0.1µg; i.v) was given 45.5min (before benoxathian i.c.v. infusion), 162min (35.5min after starting higher dose of benoxathian) 178.5th (52 
min after starting higher dose of benoxathian) and 243min. Benoxathian i.c.v. infusion (4µg/0.5µl min-1) was started at 66.5min. The dose rate was 
increased to 8µg/1µl min-1 from 126.5min as the lower dose did not reduce the basal rate. I.c.v. benoxathian infusion was stopped at 203.5min. Basal 
firing rate before starting the higher dose of benoxathian was 7.87±0.08 spikes/s and was decreased by 4.47 spikes/s 35min after starting 
benoxathian. I.c.v. Benoxathian infusion blocked the secretin-induced excitatory response in this neurone. The response returned after stopping the 
infusion. [Note: The basal rate of only two out of the six cells tested was suppressed by benoxathian]. 
 Benoxathian i.c.v. 4µg/µl min-1 
 
Benoxathian i.c.v. 8µg/µl min-1 




































Response to secretin before benoxathian i.c.v. infu sion (n=6)
Response to secretin during benoxathian i.c.v. infu sion (n=6)
 
Fig. 5.31. Effect of i.c.v. benoxathian infusion onsecretin (0.1µg; i.v)-induced excitatory 
firing rate response of SON oxytocin neurones in unfasted virgin rats. Values are mean + 
s.e.m. Pre- vs. 0-10min post-secretin before benoxathian: P<0.001, paired t-test. 0-5min post-
secretin before vs. during benoxathian: P=0.006, t-test. Pre- vs. 0-10min post-secretin during 
benoxathian: P=0.7, Wilcoxon signed rank test. Basal firing rates before secretin before and 
during benoxathian i.c.v. infusion were 5.65 ± 1.05 spikes/s and 2.2 ± 0.9 spikes/s, 
respectively. Secretin-induced excitation of SON oxyt cin neurones was significantly 
decreased by benoxathian i.c.v. infusion. 


































Fig. 5.32. Effect of benoxathian i.c.v. infusion onsecretin-induced excitatory response in a phasic firing SON vasopressin neurone (Cell No. 272-1). 
Benoxathian infusion (8µg/µl; min-1; i.c.v) was started at 100min and stopped at 171min. Secretin (0.1µg; i.v) was given at (1) 23min (befor  
benoxathian infusion), (2) 67min (before benoxathian infusion), (3) 123min (23min after starting benoxathian infusion), (4) 159min (58min after starting 
benoxathian infusion) and at (5) 291min (120min after stopping benoxathian infusion). Secretin given bfore benoxathian infusion at 23 and 67min 
increased the activity quotient [secretin (1): from 0.07 to 0.38; secretin (2): from 0.28 to 0.43]. Secretin (3) given 23min after starting benoxathian 
infusion elicited an excitatory response (activity quotient increased from 0 to 0.3) probably because it was given too early that benoxathian had not 
exerted its effect yet. Benoxathian infusion totally b ocked the basal activity and secretin (4) given 58min after starting benoxathian infusion did not 
induce any activity. The cell started to regain its ba al activity from 30min after stopping benoxathin infusion. Secretin (5) given 120min after stopping 
the infusion elicited a mild excitatory response (activity quotient increased from 0.03 to 0.18). 
Benoxathian i.c.v. infusion 








































Fig. 5.33. The effect of benoxathian i.c.v. infusion n the basal and secretin-induced activity of 
phasic firing SON vasopressin neurones in unfasted rats (n=3): Activity quotient. Values are 
mean ± s.e.m. * P=0.04, one-way ANOVA, basal activity before vs. during benoxathian infusion; 
# P=0.03, one-way ANOVA, secretin-induced activity before vs. during benoxathian infusion. 
Benoxathian i.c.v. infusion completely blocked the basal activity and secretin-induced increase 
in activity of SON vasopressin neurones. 
*  
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Response to secretin during vehicle microdialysis ( n=3)
Response to secretin during benoxathian microdialys is (n=3)
 
 
Fig. 5.34. Effect of benoxathian (2mM) microdialysis onto the SON on secretin-induced 
(0.1µg; i.v) excitatory response of SON oxytocin neurones in unfasted female rats. Values 
are mean ± s.e.m. Secretin-induced excitatory response during vehicle microdialysis vs. 
during benoxathian microdialysis: P=0.03; t-test. Pre- vs. post-secretin during vehicle 
microdialysis: P=0.03, paired t-test (basal rate: 2.5 ± 0.6 spikes/s). Pre- vs. post-secretin 
during benoxathian microdialysis: P=0.1, paired t-test (basal rate: 1.7 ± 0.5 spikes/s). 0-5min 
after secretin during vehicle vs. benoxathian microdialysis: P=0.03, t-test. Benoxathian 
microdialysis significantly attenuated the secretin induced excitatory response in SON 






















Fig. 5.35. Mode of action of systemic secretin on SON oxytocin neurones. Systemic secretin 
activates vagal afferents (Li et al., 2005) and, perhaps, subsequently the brainstem nuclei 
(Yang et al., 2004). SON receives noradrenergic inputs from the brainstem (Alonso and 
Assenmacher, 1984) that activates SON oxytocin neurones. The increase in electrical activity 
is accompanied by peripheral release of oxytocin into the circulation. Systemic secretin 
might also act directly on the secretin receptors on the SON neurones (Chu et al., 2006) 


























































Fig. 5.36. Possible synergistic actions of secretin and oxytocin in gastrointestinal functions 
and water and electrolyte homeostasis. Upon entry of acidic contents from the stomach to the 
intestines, secretin is released from the duodenal S-cells (Oektedalen et al., 1982). Secretin 
increases exocrine pancreatic secretion containing water and bicarbonate to neutralise the 
acidity (Chey et al., 1984). Oxytocin is also releas d postprandially in response to blood 
volume expansion accompanying prandial drinking (Haanwinckel et al., 1995). A cascade of 
activation of brainstem and hypothalamic neurones ends up with peripheral oxytocin 
secretion that regulates natriuresis directly or indirectly (Haanwinckel et al., 1995). The 
results from the present study show the possibility that, physiologically, secretin might be 
another stimulus like CCK, in activating oxytocin neurones for postprandial regulation of 
fluid balance. Secretin itself is natriuretic (Waldum et al., 1980b; Waldum et al., 1980a; 
Waldum et al., 1981; Londong et al., 1987). Oxytocin, in turn, like secretin, protects the 
gastric mucosa (Asad et al., 2001) and might act on its receptors in the enteric nervous 
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Fig. 6.1. Average body weight of the four groups of animals used in CCK study. Values are 
mean ± s.e.m. * P<0.001, F1, 64=58.7, two-way ANOVA, virgin vs. pregnant groups. 
































Fig. 6.2. Average basal firing rate of SON oxytocin neurones in the four groups of animals 
used in CCK study. Values are mean ± s.e.m. *P=0.001, F1, 71=11.3, two-way ANOVA, 






































Fig. 6.3. The effect of CCK (25µg/kg; i.v) on the firing rate of a SON oxytocin neurone in an 
unfasted virgin rat (Cell No. 63-1). Basal firing rate of 3.05 spikes/s was increased by 1.6 






























Fig. 6.4. The effect of systemic administration of CCK (25µg/kg; i.v) on the firing rate of 
SON oxytocin neurones in unfasted virgin rats (n=45). Values are mean ± s.e.m. Pre- vs. 0-
10min post-CCK: P<0.001, Wilcoxon signed rank test. Basal firing rate: 3.6 ± 0.3 spikes/s. 























Before CCK (n=45) After CCK (n=45)
 
Fig. 6.5a. The effect of systemic administration of CCK (25µg/kg; i.v) on the interspike 
interval of SON oxytocin neurones in unfasted virgin rats. Values are mean ± s.e.m; not 
normalised. Incidence of interspike intervals occurring between 0–0.5s after a spike 0-10min 
after CCK vs. 10min basal period: P<0.001, Wilcoxon signed rank test. CCK administration 
significantly increased incidence of interspike intervals occurring between 0–0.5s after a 
spike. 
y = 122.09e -5.1596x
R2 = 0.9978













Before CCK After CCK 
 
Fig. 6.5b. The interspike interval histograms befor and after CCK fitted with exponential 
curves. The regression equations are y = 122.09e-5.1596x and y = 156.91e-5.6322x. R2 value of 
0.99 indicates that the regression lines perfectly fit the data. 
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Fig. 6.6. The effect of CCK (25µg/kg; i.v) on the mean post-spike probability of SON 
oxytocin neurones in unfasted virgin rats (n=45): Hazard analysis. Values are mean ± s.e.m; 
not normalised. The comparison shows that the profile of activity-dependent changes in 
excitability is very similar before and after CCK, the main difference being a small change in 
the late hazard level. This suggests that the effects of CCK reflect an increase in synaptic 






























Fig. 6.7. The effect of CCK (25µg/kg; i.v) on the mean post-spike probability of SON 
oxytocin neurones in unfasted virgin rats (n=45): Ratio of peak early (<0.07s) to mean late 
(0.2-0.3s) hazard: Values are mean ± s.e.m. Pre- vs. 0-10min post-CCK: P=0.2, paired t-test. 
[n.s] 
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Fig. 6.8. The effect of CCK (25µg/kg; i.v) on the firing rate of SON oxytocin neurones in 
unfasted vs. fasted virgin rats. Values are mean ± s.e.m. Pre- vs. 0-10min post-CCK within 
the unfasted virgin group: P<0.001, Wilcoxon signed rank test. Pre- vs. 0-10min post-CCK 
within the fasted virgin group: P=0.06, paired t-test. 0-10min after CCK between the 
unfasted and fasted virgin groups: P=0.4; t-test. Basal firing rates (unfasted virgin: 3.6 ± 0.3 
spikes/s; fasted virgin: 3.5 ± 0.9 spikes/s) did not differ significantly (P=0.9, t-test) between 
the groups. 
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Fig. 6.9. The effect of CCK (25µg/kg; i.v) on the firing rate of SON oxytocin neurones in 
unfasted virgin vs. pregnant rats. Values are mean ± s.e.m. Pre- vs 0-10min post-CCK within 
the unfasted virgin group: P<0.001, Wilcoxon signed rank test. Pre- vs 0-10min post-CCK 
within the unfasted pregnant group: P=0.005, paired t-test. 0-2min after CCK between 
unfasted virgin and pregnant groups: P=0.012, t-test (0-10min after CCK: P=0.2, t-test). 
Basal firing rates (unfasted virgin: 3.6 ± 0.3 spikes/s; unfasted pregnant: 7.2 ± 0.6 spikes/s) 





























Fig. 6.9a. The effect of CCK (25µg/kg; i.v) on the firing rate of SON oxytocin neurones in 
unfasted pregnant rats: 15s bin. The response to CCK begins immediately after CCK; 
however, the time to reach the peak excitation is gradual and delayed, unlike in virgin rats in 
which the peak excitation was reached rapidly within 2min.  
CCK 
CCK 
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Fig. 6.10. The effect of CCK (25µg/kg; i.v) on the firing rate of SON oxytocin neurones in 
fasted virgin vs. pregnant rats. Values are mean ± s.e.m. Pre- vs. 0-10min post-CCK within 
the fasted pregnant group: P=0.002, paired t-test. Pre- vs. 0-10min post-CCK within the 
fasted virgin group: P=0.06, paired t-test. 0-10min after CCK between the fasted virgin and 
pregnant groups: P=0.99, t-test. Basal firing rates (fa ted virgin: 3.5 ± 0.9 spikes/s; fasted 
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Fig. 6.11. The effect of CCK (25µg/kg; i.v) on the firing rate of SON oxytocin neurones in 
unfasted and fasted pregnant rats. Values are mean ± s.e.m. Pre- vs. 0-10min post-CCK 
within the unfasted pregnant group: P=0.005, paired t-test. Pre- vs. 0-10min post-CCK 
within the fasted pregnant group: P=0.002, paired t-test. 0-10min after CCK between 
unfasted and fasted pregnant groups: P=0.9, t-test. Ba al firing rates (unfasted pregnant: 7.2 
± 0.6 spikes/s; fasted pregnant: 3.9 ± 0.8 spikes/s) differed significantly (p=0.002, t-test) 
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Fig. 6.12. The effect of CCK (25µg/kg; i.v) on the firing rate of SON oxytocin neurones in 
unfasted/fasted virgin/pregnant rats. Values are mean ± s.e.m. P=<0.001, Wilcoxon signed 
rank test, pre- vs. 0-10min post-CCK within the unfasted virgin group. P=0.005, paired t-test, 
pre- vs. 0-10min post-CCK within the unfasted pregnant group. P=0.002, paired t-test, pre- 
vs. 0-10min post-CCK within the fasted pregnant group. Pre- vs. 0-10min post-CCK within 
the fasted virgin group: P=0.06, paired t-test. Basal firing rate of unfasted pregnant group 
(7.2 ± 0.6 spikes/s) differed significantly from all other groups (unfasted virgin: 3.6 ± 0.3 
spikes/s; fasted virgin: 3.5 ± 0.9 spikes/s; fasted pregnant: 3.9 ± 0.8 spikes/s; P=0.001, F1, 
71=11.3, two-way ANOVA). The CCK-induced excitatory responses observed in 
unfasted/fasted virgin/pregnant rats during 0-10min after CCK injection were not different 
from each other Hence, there was no interaction between feeding and reproductive status in 
the CCK-induced responses (F1, 65=0.01, P=0.9, two-way ANOVA). 
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Fig. 6.13. Effect of leptin administration (100µg; i.v) on the CCK-induced (25µg/kg; i.v) 
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Fig. 6.14. Effect of leptin (100µg; i.v) on CCK-induced (25µg/kg; i.v) response of SON 
oxytocin neurones.  Values are mean ± s.e.m. P<0.001, paired t-test, 0-10min responses after 
CCK vs. respective basal. Basal rates (2.9 ± 0.3 spikes/s and 3 ± 0.4 spikes/s) did not differ 
from each other (P=0.9, paired t-test). The CCK-induced excitatory responses before and 








Leptin CCK CCK 
CCK 






























Secretin (n=26) CCK (n=45) Leptin (n=23)
 
Fig. 6.15. Effect of secretin (0.1µg/rat; i.v), leptin (100µg/rat; i.v) and CCK (25µg/kg; i.v) on 
the electrical activity of SON oxytocin neurones in u fasted virgin rats. Values are mean ± 
s.e.m. P<0.001, paired t-test, pre- vs. 0-10min post-secretin within the secretin group. 
P<0.001; Wilcoxon signed rank test, pre- vs. 0-10min post-CCK within the CCK group. 
P=0.01; paired t-test, pre- vs. 0-10min post-leptin within the leptin group. P<0.01, Kruskal-
Wallis one-way ANOVA on ranks, 0-10min after administration all peptides between the 
groups. Basal firing rates (secretin group: 4.1 ± 0.4 spikes/s; leptin group: 3.4 ± 0.4 spikes/s; 
CCK group: 3.6 ± 0.3 spikes/s) did not differ significantly (P=0.3, one-way ANOVA). In 
comparison with CCK, secretin was the most effectiv and leptin was the least effective 
peptide in terms of excitation of SON oxytocin neurones. 
Secretin/CCK/Leptin 






y = 2.2521e -0.1353x
R2 = 0.9502
y = 1.6231e -0.1829x
R2 = 0.8909
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Fig. 6.16. The change in firing rate after secretin/CCK/leptin administration fitted with 
exponential curves. The half-lives of the electrical activity calculated from this for these 
three peptides are: secretin: 5.1min, CCK: 3.8min, and leptin: 3.3min. 































Fig. 6.17a. The decay of secretin, CCK and leptin in the circulation. The number of moles of 
secretin, CCK and leptin administered initially are 0.033, 6.6 and 6.17 nmoles, respectively. 
The decay of these peptides in the circulation was calculated from the half-lives of the firing 
rate. The decay for each peptide is given in the following figures. 
 






























Fig. 6.17b. The decay of secretin in the circulation. The decay of circulating secretin was 
calculated from the decrease in firing rate after peak excitation. Firing rate reaches basal by 
































Fig. 6.17c. The decay of CCK in the circulation. The decay of circulating CCK was 
calculated from the decrease in firing rate after peak excitation. Firing rate reaches basal by 

































Fig. 6.17d. The decay of leptin in the circulation. The decay of circulating leptin was 
calculated from the decrease in firing rate after peak excitation. Firing rate reaches basal by 
10min while the leptin level in the circulation decayed to near 0 only by 18min. 





































Secretin (n=3) CCK (n=6) Leptin (n=8)
 
Fig. 6.18. Effects of secretin (0.1µg/rat; i.v), leptin (100µg/rat; i.v) and CCK (25µg/kg; i.v) 
on the electrical activity of SON oxytocin neurones in fasted virgin rats. Values are mean ± 
s.e.m. P=0.047; paired t-test, pre- vs. 0-10min post-secretin within the secretin group. Pre vs. 
0-10min post-leptin within the leptin group: P=0.05, paired t-test. Pre- vs. 0-10min post-
CCK within the CCK group: P=0.06, paired t-test. 0-10min after the administration of 
peptides between the groups: P=0.03, one-way ANOVA (Holm-Sidak multiple comparison 
test: secretin vs. CCK: P=0.01; secretin vs. leptin: P=0.02). Between fasted and unfasted 
groups: Secretin response: 0.9, t-test; CCK response:  P=0.4, Mann-Whitney rank sum test; 
leptin response:  P=0.2, t-test. Basal firing rates (secretin group:  3.8 ± 0.6 spikes/s; leptin 
group: 4.5 ± 0.8 spikes/s; CCK group: 3.5 ± 0.9 spikes/s) did not differ between fasted virgin 
groups (P=0.8, one-way ANOVA) and did not differ from the unfasted virgin groups (P=0.7, 
one-way ANOVA). The excitatory responses of SON oxyt cin neurones to secretin, leptin 
and CCK in fasted rats were not different from unfasted rats. 
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Fig. 6.19. The effect of CCK (25µg/kg; i.v) on the firing rate of a non-phasic SON 
vasopressin neurone in an unfasted virgin rat (Cell No. 15-4). The basal firing rate was 7.7 
spikes/s. After CCK administration, the cell remained inhibited for ca. 3min after which it 




























Fig. 6.20. The effect of CCK (25µg/kg; i.v) on the firing rate of non-phasic SON vasopressin 
neurones in unfasted virgin rats (n=23). Values are mean ± s.e.m. Pre- vs. 0-5min post-CCK: 
P<0.001, paired t-test. The basal firing rate of 6.1 ± 0.5 spikes/s was decreased by 3.6 ± 0.5 
spikes/s 1min after CCK. The rate gradually returned to basal rate by 15min. These twenty 
three of 30 non-phasic vasopressin neurones were inhibited by CCK while the seven other 
neurones did not respond to CCK. 
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Fig. 6.21. The effect of CCK (25µg/kg; i.v) on the unresponsive non-phasic SON 
vasopressin neurones in unfasted virgin rats (n=7). Values are mean ± s.e.m. In these 































Fig. 6.22. The effect of systemic administration of CCK (25µg/kg; i.v) on the firing rate of 
all recorded non-phasic SON vasopressin neurones in unfasted virgin rats (n=30): Values are 
mean ± s.e.m. Basal firing rate: 5.7 ± 0.5 spikes/s. Pre- vs. 0-5min post-CCK: P<0.001, 
Wilcoxon signed rank test. Twenty three of 30 non-phasic vasopressin neurones were 
inhibited by CCK while the seven other neurones did not respond to CCK. On average, CCK 




























Fig. 6.23. The effect of CCK (25µg/kg; i.v) on phasic SON vasopressin neurone in an 
unfasted virgin rat (Cell No. 9-5). The activity quotient, frequency within bursts and mean 
interburst interval during the basal period were 0.03, 4.3 spikes/s and 10.8s, respectively. 
























Fig. 6.24. The effect of CCK (25µg/kg; i.v) on phasic SON vasopressin neurones in unfasted 
virgin rats: Activity quotient. Values are mean ± s.e.m. * P=0.02, paired t-test, pre- vs. 0-
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Fig. 6.25. Effect of CCK (25µg/kg; i.v) on phasic SON vasopressin neurones in unfasted 
virgin rats: Mean interburst interval (s). Values are mean ± s.e.m. Pre- vs. 0-5min post-CCK: 


































Fig. 6.26. The effect of CCK (25µg/kg; i.v) on phasic SON vasopressin neurones in unfasted 
virgin rats: Frequency within bursts (spikes/s). Values are mean ± s.e.m. Pre- vs. 0-5min 
post-CCK: P=0.8, paired t-test. There was no change i  the frequency within bursts after 























Before CCK After CCK
 
Fig. 6.27a. Effect of systemic administration of CCK on the interspike interval of SON 
vasopressin neurones (n=37; 30 non-phasic and 7 phasic v sopressin neurones). Values are 
mean ± s.e.m; not normalised. The number of spikes occurring with the interspike interval of 
less than 0.3s is reduced following CCK administration. 
y = 215.39e -7.1058x
R2 = 0.9671
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Fig. 6.27b. The interspike interval histograms befor  and after CCK fitted with exponential 
curves. The distal tail of the histograms fitted well with exponential curves while the 
intervals of less than 0.2s were left unfit, which s a characteristic of vasopressin neurones 
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Fig. 6.28. Effect of systemic administration of CCK on the mean post-spike probability of 
SON vasopressin neurones (n=37; 30 non-phasic and 7 phasic vasopressin neurones). Values 
are mean ± s.e.m; not normalised. There was no change in the shape of the hazard plot 
following CCK. 
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Fig. 6.29. Effect of secretin (0.1µg/rat; i.v), leptin (100µg/rat; i.v) and CCK (25µg/kg; i.v; 
n=30) on the electrical activity of non-phasic SON vasopressin neurones in unfasted virgin 
rats. Values are mean ± s.e.m. P<0.001, Wilcoxon sig ed rank test, pre- vs. 0-5min post-
CCK within the CCK group. Pre- vs. 0-5min post-secretin within the secretin group: P=0.1, 
paired t-test. Pre- vs. 0-5min post-leptin within the leptin group: P=0.9, paired t-test. 0-5min 
after administration of peptides between the groups: P<0.001, Kruskal-Wallis one-way 
ANOVA on ranks (multiple comparison procedures by Dunn's Method: CCK vs. secretin 
and CCK vs. leptin: p<0.05). The basal firing rates (secretin group: 6.3 ± 0.6 spikes/s; CCK 
group: 5.7 ± 0.5 spikes/s and leptin group: 8.8 ± 1.4 spikes/s) did not differ between groups 
(P=0.1, Kruskal-Wallis one-way ANOVA on ranks). CCK significantly inhibited while 
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Fig. 6.30. Effects of secretin, leptin and CCK on phasic SON vasopressin neurones in 
unfasted virgin rats: Activity quotient. Values are m an ± s.e.m. * P=0.02, paired t-test, pre- 
vs. 0-5min post-secretin within the secretin group. # P=0.02, paired t-test, pre- vs. 0-5min 
post-CCK within the CCK group.  Pre- vs. 0-5min post-leptin: P=0.3, paired t-test. φ P=0.03, 
Kruskal-Wallis one-way ANOVA on ranks (multiple comparison procedures by Dunn's 
Method: CCK vs. secretin: P<0.05), activity quotient 0-5min after administration of peptides 
between the groups. Basal activity quotient did notdiffer between the groups: P=0.8, 
Kruskal-Wallis one-way ANOVA on ranks. Secretin significantly increased and CCK 
significantly decreased the activity quotient of phasic SON vasopressin neurones while leptin 
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Fig. 6.31. Effect of secretin, leptin and CCK on phasic SON vasopressin neurones in 
unfasted virgin rats: Mean interburst interval (s). Values are mean ± s.e.m. * P=0.01, 
Wilcoxon signed rank test, pre- vs. 0-5min post-secretin within the secretin group. Pre- vs. 0-
5min post-CCK within the CCK group: P=0.4, paired t-test.  Pre- vs. 0-5min post-leptin 
within the leptin group: P=0.7, Wilcoxon signed rank test. Mean interburst interval during 
the basal period and 0-5min after administration of peptides did not differ between the 
groups: P=0.25 and P=0.2, one-way ANOVA. Secretin sig ificantly decreased the mean 
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Fig. 6.32. Effect of secretin, leptin and CCK on phasic SON vasopressin neurones in 
unfasted virgin rats: Frequency within bursts (spikes/s). Values are mean ± s.e.m. Pre- vs. 0-
5min post-secretin within the secretin group:  P=0.3, paired t-test. Pre- vs. 0-5min post-CCK: 
P=0.4, paired t-test.  Pre- vs. 0-5min post-leptin: P=0.9, paired t-test. The mean frequency 
within bursts during basal (p=0.06, Kruskal-Wallis one-way ANOVA on ranks) and 0-5min 
after administration of peptides (p=0.1, one-way ANOVA) did not differ between the groups. 
Secretin, CCK and leptin did not have any effect on the frequency within bursts of SON 
vasopressin neurones. n.s] 
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Fig. 7.1. Illustration showing hypothetical NPY neuronal projections to the SON. NPY is co-
localized with NA in the A1 cell group but co-localization in A2 regions of the brainstem is 
controversial (Sawchenko and Swanson, 1982; Harfstrnd et al., 1987; Simonian and 
Herbison, 1997). NA neurones from the A2 cell group project to the SON oxytocin neurones 
(Onaka et al., 1995). However it is not known whether t ese neurones co-express NPY. ARC 
NPY expression is upregulated prior to feeding or during food deprivation (Kalra and Kalra, 
2003). Although ARC neurones project to the SON (Leng t al., 1988), it is not known 
whether ARC-NPY neurones project to the SON. NPY actions on SON oxytocin neurones 
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Fig. 7.2. Flow chart showing the peripheral and neuro ndocrine events taking place around 
feeding that hypothetically culminate in oxytocin release so as to regulate postprandial 
natriuresis in the rat. Fluid intake accompanies food intake, resulting in blood volume 
expansion. Activation of baroreceptors leads to activ tion of neurones in the brainstem 
which results in the activation of ANP neurones in the hypothalamus. Further activation of 
oxytocin neurones leads to peripheral release of oxytocin. Oxytocin, by its direct action on 
the kidneys or through the release of ANP from the heart, mediates postprandial natriuresis 
(Haanwinckel et al., 1995). In addition to blood volume expansion, oxytocin neurones are 
also activated in response to other peptides that are released around feeding (green arrows), 
as found (or, for CCK, confirmed) in this study. Food intake is followed by transient increase 
in leptin mRNA in the adipose tissue and increased plasma level of leptin  during the 
postprandial period (Saladin et al., 1995; Konturek et al., 2003). The passage of acidic 
chyme from the stomach to the duodenum stimulates th  release of CCK and secretin from 
the duodenum which subsequently act on the exocrine pa creas to increase bicarbonate and 
enzyme rich secretion, respectively, to facilitate digestion (Folsch and Wormsley, 1973). 
Food intake activates brainstem neurones via vagal fferents (Rinaman et al., 1998) which 
might result in NPY release from NA terminals of the axons projecting from the brainstem to 
the SON. This study showed that NPY, leptin and secretin excite SON oxytocin neurones. 
CCK-induced excitation of oxytocin neurones is well established (Renaud et al., 1987). It is 
tempting to propose that NPY, leptin and secretin, along with CCK, also contribute to 
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Fig. 7.3. A flow chart describing the possibility of reciprocal regulation of 
leptin/CCK/secretin by peripheral oxytocin. This study shows that leptin, CCK and secretin 
activate SON oxytocin neurones. As oxytocin receptors are expressed in the adipose tissue, 
gut and enteric nervous system13 (ENS) (Bonne and Cohen, 1975; Egan et al., 1990; Welch 
et al., 2009), it is possible that leptin-, CCK- orsecretin-induced release of oxytocin 
feedback to the sources of these peptides to positively or negatively regulate their 
synthesis/release. Oxytocin might also modulate effcts of secretin indirectly: high doses of 
ANP and CNP attenuate secretin-induced pancreatic secretion via a PLC/PKC pathway 
while lower doses increase this secretion (Sabbatini, 2009).  
 
                                                
13 Enteric nervous system (ENS): It is the intrinsic innervation of the gastro-intestinal tract located 
between the external muscle layers of the gut wall. It is composed of neurones and glial cells arranged 
in interconnecting ganglia. Within the ENS, the neurones vary in their morphology and functions.  
Many neurotransmitters expressed in the CNS are expressed within subclasses of neurones in the 
ENS. The functions of the ENS are: regulating gut motility reflexes, co-ordinating secretion and 
absorption, controlling blood flow and modulating immune and endocrine functions. The ENS is 
capable of mediating reflex activity in the absence of input from the brain or spinal cord. The presence 
of local motor circuits (sensory neurones, intrinsic primary afferent neurones, inter-neurones, and 
excitatory and inhibitory motor neurones) is responsible for this independent activity. [Burns AJ, 
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Fig. 7.4. Flow chart showing the proposed involvement of leptin, secretin and CCK in fluid 
and energy homeostasis directly and via the activation of SON oxytocin neurones. (1) 
Secretin and CCK are synergistic with each other in stimulating exocrine pancreatic 
secretion (Chey et al., 1984); (2) Secretin increases circulating leptin levels (Sobhani et al., 
2000); (3) Leptin is synergistic with CCK in food intake and body weight regulation 
(Barrachina et al., 1997; Wang et al., 1998); (4) This study shows that secretin, leptin and 
CCK excite SON oxytocin neurones [but leptin and CCK did not interact]. Increase in the 
electrical activity of oxytocin neurones results in the peripheral release of oxytocin; (5) 
Secretin, leptin and oxytocin are natriuretic either directly or indirectly (Waldum et al., 
1980a; Waldum et al., 1980b; Waldum et al., 1981; Haanwinckel et al., 1995; Jackson and 
Li, 1997; Villarreal et al., 1998; Jackson and Herzer, 1999); CCK influences postprandial 
natriuresis via oxytocin (Verbalis et al., 1986; Verbalis et al., 1991); (6) CCK increases 
exocrine pancreatic enzyme secretion for digestion of carbohydrates, proteins and fats; CCK 
is also involved in the regulation of food intake and satiety (Gibbs et al., 1973); (7) Leptin 
negatively modulates exocrine pancreatic secretion (Konturek et al., 2003); is directly 
involved in the regulation of food intake, body weight and energy expenditure, i.e. energy 
homeostasis (Friedman, 1998); (8) Oxytocin regulates exocrine pancreatic secretion 
(Bjorkstrand et al., 1996; Ferrer et al., 2000). Central oxytocin is anorectic (Olson et al., 
1991); (9) Secretin increases exocrine pancreatic secretin mainly of bicarbonate and water to 
neutralise the acidity so as to provide a neutral/alkaline medium for the digestive enzymes to 
act on carbohydrates, proteins and fats (Bayliss and Starling, 1902). Secretin has not been 
shown to modify food intake in rats (Lorenz et al.,1979; Garlicki et al., 1990). In summary, 
secretin, CCK and leptin are involved in fluid and energy homeostatic mechanisms either 
directly or indirectly through oxytocin. 
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Fig. 7.5. Thesis conclusions. The study was aimed at testing and comparing the actions of 
well-established or putative appetite regulating peptid s, namely NPY, leptin, secretin and 
CCK, physiologically originating from the brain (NPY) or from the periphery [adipose tissue 
(leptin), sympathetic nervous system (SNS; NPY) andthe gut (CCK and secretin)] on the 
SON oxytocin neurones in anaesthetised female rats (virgin or pregnant, fasted or not). All 

















• Central NPY and systemic leptin, secretin, CCK and NPY: Excited SON 
oxytocin neurones 
• Secretin: Dose-dependent increase in oxytocin neuronal activity and 
peripheral release of oxytocin 
• On oxytocin neurones: Secretin >CCK > leptin 
• Secretin-induced effects in oxytocin and vasopressin neurones: via NA 
pathway  
• Responses in fasted rats: No difference from unfasted rats 
• Pregnancy: Oxytocin neurone response to NPY and leptin did not differ 
from virgins 
• Leptin and CCK Interaction: No potentiation by leptin of CCK-induced 
oxytocin neurone excitation 
• Systemic NPY: Excited SON oxytocin neurones 
• On vasopressin neurones: Variable effects (central NPY: ineffective; 
systemic NPY: inhibition; CCK: predominant inhibiti on; leptin: no 
significant effect; secretin: predominant excitation).  
 
